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NaCl  Sodium  chloride 
NCBI  National  Centre  for  Biotechnology  Information 
NHANES  III  Third  National  Health  and  Nutrition  Examination  Survey 
NO  Nitric  oxide 
NR3C  I  Glucocorticoid  receptor 
OCP  Oral  contraceptive  pill 
xiv OOA  Old  Order  Amish 
PCR  Polyrnerase  chain  reaction 
PDE4D  Phosphodiesterase  4D 
PHA  I  Pseudohypoaldosteronism  type  I 
PHA  11  Pseudohypoaldosteronism  type  Il 
PI  Protease  inhibitor  (also  known  as  SERPINA1,  see  below) 
PKI)l  Polycystin  I 
PKD2  Polycystin  2 
Pp  Pulse  pressure 
PRA  Plasma  renin  activity 
QTL  Quantitative  trait  locus  or  loci 
RFLP  Restriction  fragment  length  polymorphism 
RNA  Ribonucleic  acid 
s  Seconds 
Sabra  H  Sabra  hypertensive  rat 
Sabra  N  Sabra  normotensive  rat 
SAMS  San  Antonio  Family  Heart  Study 
SAH  Subarachnoid  haemorrhage 
SBP  Systolic  blood  pressure 
SD  Standard  deviation 
SERPINAl  Serine  protease  inhibitor  Al 
SHR  Spontaneously  hypertensive  rat 
SHRSP  Spontaneously  hypertensive  rat,  stroke-prone 
SNP  Single  nucleotide  polymorphism 
SOD  Superoxide  dismutase 
SP  Sibpair 
SR  Salt-resistant  Dahl  rat  strain 
SS  Salt-sensitive  Dahl  rat  strain 
S-TDT  Sibling  TDT 
TAL  Thick  ascending  limb 
TDT  Transmission  disequilibrium  test 
TIMP  Tissue  inhibitor  of  metalloproteinase 
VSMC  Vascular  smooth  muscle  cell 
WHO  World  Health  Organisation 
WKY  Wistar  Kyoto  rat 
WNKI  Lysine-deficient  protein  kinase  I 
WNK4  Lysine-deficient  protein  kinase  4 
xv SUMMARY: 
Essential  hypertension  and  familial  intracranial  aneurysm  (FIA)  are  complex 
disorders  which  may  have,  in  common,  features  such  as  gene-gene  and  gene- 
environment  interactions,  small  individual  gene  effects,  genetic  heterogeneity, 
incomplete  penetrance  and  pleiotropy.  Such  features  hamper  efforts  to  discover 
disease  genes  and  have  resulted  in  continuous  evolution  of  complex  genetic 
strategies.  Appropriate  strategies  and  current  thinking  were  applied  to  genetic 
dissection  of  essential  hypertension  and  familial  intracranial  aneurysms. 
Essential  hypertension  is  a  complex  oligogenic  or  polygenic  disorder  with  30% 
to  60%  of  inter-individual  differences  determined  by  genes.  Much  is  known 
from  studies  in  Mendelian  disorders,  rat  and  mouse  models,  and  human 
populations.  The  genetic  basis  of  Mendelian  disorders  has  been  dissected,  but 
susceptibility  genes  have  yet  to  be  confirmed  for  essential  hypertension. 
The  studies  of  hypertension,  described  herein,  combined  complementary 
strategies  to  examine  the  relevance  of  human  chromosome  5q31.1-qter  to  blood 
pressure  as  a  quantitative  trait,  and  hypertension  as  a  qualitative  trait.  This  distal 
region  of  chromosome  5  was  focused  upon  due  to  its  implication  by  other  human 
and  animal  model  studies  and  the  cluster  of  cardiovascular  candidate  genes 
located  there. 
Eleven  microsatellites  across  55  cM  of  5q3l.  I  to  qter  were  genotyped  in  212 
hypertensive  nuclear  families  of  the  Silesian  Hypertension  Study.  Two-point  and 
XVI multipoint  analyses  showed  linkage  of  a7  cM  region  to  both  hypertensive  status 
and  blood  pressure  phenotypes.  A  maximal  multipoint  Z-score  of  2.2  for  systolic 
blood  pressure  (SBP)  was  obtained  proximal  to  the  marker  D5s1480.  In  light  of 
the  debate  regarding  significance  in  linkage  studies,  this  quantitative  trait  locus 
(QTL)  was  confirmed  in  a  second  sample  derived  from  the  Scottish  population. 
Genotyping  of  the  same  markers  was  done  for  1,469  individuals  from  sibships  of 
the  MIDSPAN  Family  Study.  Two-point  and  multipoint  analyses  confirmed  a 
reproducible  7  cM  QTL  with  a  maximum  multipoint  logarithm  of  odds  (LOD) 
score  of  1.8  obtained  for  mean  arterial  pressure. 
Several  putative  candidate  genes  were  located  within  the  QTL  including  the  P2- 
adrenergic  receptor  gene,  ADRB2,  which  is  known  to  have  a  major  role  in 
cardiovascular  physiology.  Three  functional  loci,  Argl6GIy,  Gln27GIu  and 
Thr16411e,  were  genotyped  within  the  ADRB2  gene  using  the  Silesian  sample. 
Single  locus  and  haplotype  analyses  using  transmission  disequilibrium  tests  and 
family-based  association  methods  showed  no  association  to  hypertension  status 
(P>0.05),  effectively  excluding  this  gene  in  the  Silesian  sample. 
The  fibroblast  growth  factor  I  gene,  FGF  I,  is  located  at  the  centre  of  the  QTL. 
This  gene  had  previously  been  cited  as  a  putative  blood  pressure  candidate  gene 
in  the  5q  region  but  not  studied  in  humans.  With  roles  in  endothelial  cell 
proliferation,  possible  oxidative  stress  defence  and  proven  direct  effects  on  blood 
pressure  in  rodent  models,  we  considered  it  a  possible  novel  candidate.  Coding 
regions  and  3'  UTR  were  sequenced  and  family-based  association  analyses 
performed  for  three  polymorphisms  which  were  discovered  in  the  3'  UTR. 
xvil Association  of  SBP  (P=0.045),  pulse  pressure  (P=0.019)  and  hypertension  status 
(P=0.038)  was  demonstrated  to  the  most  proximal  locus.  Association  of 
hypertension  to  a  three-locus  haplotype  was  also  shown  (P=0.020). 
The  work  on  essential  hypertension  demonstrated  the  merit  of  confirming  linkage 
in  independent  populations,  implicating  a7  cM  region  of  5q3l.  l-q33  linked  to 
blood  pressure.  Subsequent  candidate  gene  studies  utilised  the  added  value  of 
haplotype  analyses,  excluding  the  ADRB2  locus  but  showing  interesting  data  to 
implicate  the  novel  FGH  locus  as  a  putative  positional  candidate.  Further  fine 
mapping  strategies  are  now  underway  to  define,  more  clearly,  the  haplotype  tag 
across  the  FGF  I  locus.  Combination  of  genetic  approaches  with  expression  and 
functional  profiling  will  be  required  to  determine  the  importance  of  FGF  I. 
The  work  on  candidate  genes  of  familial  intracranial  aneurysm  (FIA)  considers  a 
complex  disorder  which  has  not  benefited  from  the  detailed  study  directed  at 
essential  hypertension.  Genetic  and  physiological  studies  of  this  disorder  are  in 
their  infancy.  However,  rupture  of  these  lesions  is  often  fatal,  leading  to 
subarachnoid  haemorrhage,  and  contribution  to  all-stroke  mortality  and 
morbidity  is  disproportionate. 
Four  candidate  genes  were  investigated  in  a  small  pilot  study  of  80  individuals 
from  21  Scottish  families  with  a  history  of  FIA.  These  genes  were  collagen  type 
III  (COUAI),  fibrillin  I  (FBNI),  polycystin  I  (PKD1)  and  serine  protease 
inhibitor  I  (SERPINAI).  They  were  selected  based  on  their  importance  to 
arterial  wall  integrity  and  remodelling;  knowledge  from  Mendelian  connective 
xviii tissue  disorders;  and  studies  in  humans  and  animal  models.  A  single  intragenic 
or  proximal  microsatellite  marker  was  genotyped  for  each  gene  and  analysed 
with  intracranial  aneurysm  status  by  linkage  and  association  methods.  A  very 
small  case-control  paradigm  comprising  18  cases  and  carefully  matched  controls 
suggested  association  of  the  marker  proximal  to  SERPINAI  (P=0.028).  Using  a 
family-based  association  test  (FBAT),  aP  value  of  0.062  was  obtained  for  the 
same  marker.  There  was  no  suggestion  that  markers  at  the  CODAI,  FBNI  or 
PKDl  loci  were  linked  or  associated  (P>>0.05). 
To  increase  sample  size,  the  SERPINAI  marker  was  genotyped  in  12  FIA 
families  from  the  south  of  England.  The  combined  dataset  was  analysed. 
Multiallelic  FBAT  and  empirical  variance-FBAT  bordered  on  point-wise 
significance  with  P=0.054  and  0.071,  respectively.  This  was  supported  by  results 
from  biallelic  TDT  analyses  which  implicated  a  157  bp  allele.  Biallelic  FBAT 
analyses  implicated  the  same  allele. 
This  pilot  study  is  very  small  and  a  much  larger  study  will  be  required  to 
determine  whether  these  preliminary  data  are  robust.  However,  the  results  are 
interesting,  being  the  first  known  study  of  this  locus  in  FIA  families.  The 
SERPINAl  gene  fits  neatly  with  pathophysiological  knowledge  of  FIA  and 
further  study  of  this-  gene  is  considered  worthwhile  to  clarify  its  relevance  to  FIA 
aetiology.  However,  to  fully  take  advantage  of  developing  complex  genetic 
strategies,  considerable  work  is  required  on  FIA  to  clarify  important 
pathophysiOlOgical  mechanisms. 
xix CHAPTER  I 
INTRODUCTION 1.1:  HUMAN  ESSENTIAL  HYPERTENSION: 
Blood  pressure  is  a  classic  example  of  a  complex  polygenic  or  oligogenic  trait 
under  the  multifactorial  control  of  genes  and  environment  (Dominiczak  et  al, 
2000)  (Fig.  1.1.1).  The  primary  determinants  of  blood  pressure  (BP)  in  humans 
are  cardiac  output  and  peripheral  resistance  (Brown  &  Haydock,  2000). 
However,  output  and  resistance  are  affected  by  many  complex  systems  including 
the  central  nervous  system;  vasoconstrictor  or  vasodilator  factors;  vascular 
anatomy;  body  fluid  volume  and  renal  function  (Carretero  &  Oparil,  2000b). 
1.1.1:  DEFINITION  AND  EPIDEMIOLOGY  OF  HYPERTENSION: 
Debate  raged  in  the  1960's  regarding  the  population  distribution  of  blood 
pressure  and  the  mode  of  inheritance  of  hypertension  (Pickering,  1967;  Platt, 
1967).  Large  population  studies  have  since  confirmed  the  opinion  of  Pickering, 
showing  that  blood  pressure  is  normally  distributed  with  a  slight  skew  to  the 
right.  The  continuous  unimodal  distribution  implicates  an  oligogenic  or 
polygenic  regulation  (Carretero  &  Oparil,  2000b). 
At  the  individual  level,  blood  pressure  has  a  characteristic  profile  through  life. 
Systolic  blood  pressure  (SBP)  increases  progressively  with  age  as  the  arterial  tree 
loses  its  elasticity.  Women's  SBP  increases  more  steeply.  After  70  years 
women  have  as  high  or  higher  SBP  than  men  (Burt  et  al,  1995).  Diastolic  blood 
pressure  (DBP)  increases  until  age  55  -  60  years  (Carretero  &  Oparil,  2000b). 
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Fig.  1-1-1:  Multifactorial  model  of  hypertensive  disease  demonstrating  the 
potential  influence  of  genes,  environmental  factors,  and  demographic  factors. 
Interactions  are  represented  by  arrows.  Adapted  from  Lifton,  1995. 
3 There  is  a  graded  and  continuous  increase  in  cardiovascular  disease  mortality  and 
morbidity  as  blood  pressure  increases  (Stamler  et  al,  1993).  Hypertension  is  thus 
defined  with  regard  to  disease  risk.  The  World  Health  Organisation  (WHO) 
currently  describes  hypertension  as  "SBP  of  140  mmHg  or  greater  andlor  DBP 
of  90  mmHg  or  greater  in  subjects  who  are  not  taking  antihypertensive 
medication"  (Chalmers  et  al,  1999).  By  these  criteria,  approximately  one  quarter 
to  one  third  of  adults  in  the  Western  economies  are  hypertensive  (Burt  et  al, 
1995;  Mancia  et  al,  1997).  The  third  National  Health  and  Nutrition  Examination 
Study  (NHANES  III)  in  the  US  showed  that  significant  differences  in  prevalence 
exist  between  racial  groups  (Burt  et  al,  1995).  However,  population  blood 
pressures  and  prevalence  of  hypertension  are  decreasing  as  treatment  and 
awareness  improve  (Burt  et  al,  1995).  There  is  also  a  concomitant  reduction  in 
stroke  and  coronary  heart  disease  (CHD).  Despite  the  improvements  it  is 
generally  the  case,  in  Western  economies,  that  about  half  of  hypertensives  are 
treated  and  a  quarter  adequately  controlled  (Burt  et  al,  1995;  Mancia  et  al,  1997). 
Some  suggest  that  this  may  be  an  overestimate.  Treatment  of  hypertension 
therefore  remains  a  major  public  health  challenge  (Brown,  1997). 
A  minority  of  hypertensive  cases  are  due  to  secondary  causes,  for  example 
renovascular  disorders,  phaeochromocytorna  or  aldosteronism  or  rare  single  gene 
disorders.  The  vast  majority  of  hypertensive  disease  is  due  to  primary  or 
essential  hypertension  in  the  absence  of  secondary  causes  and  simple  genetic 
disorders  (Brown  &  Haydock,  2000;  Carretero  &  Oparil,  2000b). 
4 1.1.2:  BLOOD  PRESSURE  AND  DISEASE  RISK: 
Studies  as  early  as  the  1930s  demonstrated  that  blood  pressures  greater  than 
140/90  mmHg  were  associated  with  excess  mortality  and  a  blood  pressure  of 
110/70  mmHg  was  optimal  for  longevity  (Lew,  1973).  This  was  confirmed  by 
large  studies,  for  example  the  Multiple  Risk  Factor  Intervention  (MRFIT)  study 
which  included  300,000  US  middle-aged  men.  Table  1.1.1  shows  the  increasing 
risk  of  CHD  as  SBP  and/or  DBP  increase  in  the  MRFIT  cohort.  Table  1.1.2 
shows  the  striking  relationship  between  adjusted  stroke  risk  and  SBP  (Stamler  et 
al,  1993).  Current  evidence  suggests  disease  risk  increases  above  115/75  mmHg, 
doubling  for  every  20/10  mmHg  increment  thereafter  (Chobanian  et  al,  2003). 
In  the  1970s  the  Framingham  study  showed  that  SBP  rather  than  DBP  was  the 
primary  risk  factor  for  both  CHD  and  stroke  (Kannel  et  al,  1970;  Kannel,  2000). 
1 
These  results  were  later  upheld  in  the  5,000-strong  Framingham  offspring  cohort 
(Wilson  et  al,  1991)  and  studies  such  as  MRFIT  (Stamler  et  al,  1993)  and  the 
Chicago  Heart  Association  Detection  in  Industry  (CHA)  study  (Miura  et  al, 
2001).  Such  studies  confirmed  that  this  is  true  of  all  age/  sex  classes  and 
ethnicities  (Stamler  et  al,  1993).  Other  studies  showed  that  the  risk  was 
reversible  and  that  lowering  of  blood  pressure  was  beneficial  even  in  the  elderly. 
Studies  in  patients  over  60  years  of  age  recorded  reductions  of  one  third  for 
stroke  (Probstfield,  1991),  and  one  quarter  for  myocardial  infarction  (Staessen  et 
al,  1997)  as  a  result  of  anti  -hypertensive  treatment. 
5 TABLE  1.1.1:  Effect  of  baseline  SBP  and  DBP  on  adjusted  coronary  heart 
disease  death  in  the  MR-FIT  study. 
Systolic  Blood 
Pressure,  mmHg  <80 
Diastolic  Blood  Pressure,  mmHg 
80-84  85-89  90-99  >-100 
<120  1.00  1.35t  1.361  0.98  3.23 
120-129  1.19§  1.30t  1.49t  1.49t  1.84 
130-139  1.67t  1.61t  1.67t  1.91  t  2.64-t 
140-159  2.52t  2.22t  2.67t  2.56t  2.99t 
ý!  160  4.19t  3.20t  3.41  t  3.41  t  4.57t 
Adjusted  for  age,  race,  serum  cholesterol,  cigarettes  per  day,  medication  and  income. 
tP<0.001  §P<0.01  JP<0.05.  Taken  from  Stamler  et  al,  1993. 
TABLE  1.1.2:  Deciles  of  SBP  and  adjusted  stroke  mortality  in  the  MRFIT 
study. 
SBPý  No.  of  Rate*  Relative 
Decile  of  SBP  mmHg  deaths  risk 
I  <1  12  19  0.59  1.00 
2  112-117  28  0.77  1.33 
3  118-120  30  0.89  1.56 
4  121-124  59  1.44  2.621 
5  125-128  39  0.97  1.67 
6  129-131  44  1.30  2.251 
7  132-136  78  1.74  3.06§ 
8  137-141  82  2.04  3.60§ 
9  142-150  116  2.53  4.44§ 
10  ý!  151  238  4.76  8.21  § 
*Rate  per  10,000  person-years  adjusted  for  age,  sex,  race,  serum  cholesterol,  cigarettes  per 
day,  diabetes  medication,  and  income.  Average  follow-up  of  11.6  yrs.  TP<0.01;  §P<0.001. 
Taken  from  Stamler  et  al,  1993. 
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r- The  Framingham  study  noted  that  hypertension  must  be  considered  in  the  context 
of  other  cardiovascular  disease  risk  factors  since  the  effects  were  cumulative  as 
shown  in  Fig.  1.1.2.  This  has  been  confinned  by  others  who  show  that  low  risk 
groups  have  only  25%  the  mortality  of  high-risk  groups  (Stamler  et  al,  1999). 
The  Framingham  study  also  noted  that  such  additional  risk  factors  tended  to 
occur  in  hypertensives  more  than  twice  as  often  as  expected  (Kannel,  2000). 
1.1.3:  PATHOPHYSIOLOGY  OF  HYPERTENSION: 
The  variety  of  physiological,  enviromnental  and  genetic  factors  affecting 
regulation  of  blood  pressure  and,  potentially,  development  of  hypertension  is 
immense  (Fig.  1.1.3).  Pathophysiology,  acquired  factors  and  the  evidence  for 
genetic  factors  will  now  be  discussed. 
1.1.3.1.  -  SYMPA  THETIC  NER  VO  US  SYSTEM 
Increased  sympathetic  nervous  system  activation  increases  blood  pressure  and 
maintains  hypertension  via  stimulation  of  heart,  peripheral  vasculature  and 
kidneys.  Population-based  studies  show  positive  correlation  between  increased 
heart  rate  and  development  of  hypertension  (Oparil  et  al,  2003)  and  studies 
demonstrate  that  sympathetic  cardiac  stimulation  is  greater  in  young 
hypertensives  than  controls  (Esler,  2000).  Renal  stimulation,  on  infusion  of  the 
a-adrenergic  antagonist  phentolamine,  is  also  increased  in  hypertensives 
(Hollenberg  et  al,  1975;  Esler  et  al,  1990). 
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0 Arterial  baroceptors,  which  feed  back  to  decrease  sympathetic  outflow,  are  reset 
at  a  higher  pressure  in  hypertensive  patients  and  this  offset  can  be  reversed  by 
normalisation  of  arterial  pressure  (Guo  et  al,  1983;  Chapleau  et  al,  1988;  Me  et 
al,  1990).  Such  resetting  of  the  baroreflex  function  appears  to  be  at  least  partly 
mediated  by  the  central  activity  of  angiotensin  11  (Guo  &  Abboud,  1984).  Small 
molecular  species  such  as  reactive  oxygen  species  and  endothelin  suppress 
baroceptor  activity  and  contribute  to  exaggerated  sympathetic  drive  of 
hypertension  (Chapleau  et  al,  1992;  Li  et  al,  1996).  Chronic  sympathetic 
stimulation  induces  release  of  various  trophic  factors  such  as  transforming 
growth  factor  P,  insulin-like  growth  factor  I  and  fibroblast  growth  factors  (Brook 
&  Julius,  2000).  These  contribute  to  vascular  remodelling  and  left  ventricular 
hypertrophy. 
1.1.3.2:  VASCULAR  REACTIVITY  AND  REMODELLING. 
Hypertensive  patients  show  greater  vasoconstriction  to  noradrenaline  than 
normotensive  controls  (Ziegler  et  al,  1991)  as  do  normotensive  offspring  of 
hypertensive  individuals.  This  suggests  a  genetic  mechanism  rather  than  simply 
an  adaptive  response.  They  also  have  impaired  downregulation  of  adrenergic 
receptors  (Oparil  et  al,  2003).  Antagonists  of  oc  and  P-adrenergic  receptors  are 
effective  anti-hypertensive  treatments  providing  evidence  of  the  role  of 
sympathetic  systems  in  the  maintenance  of  hypertension  (Oparil  et  al,  2003). 
Peripheral  resistance,  determined  at  the  level  of  arterioles  and  small  arteries')  is 
generally  elevated  in  hypertension  due  to  structural  and  mechanical  changes  in 
10 the  vessels  (Oparil  et  al,  2003).  Vascular  remodelling  contributes  to  high  blood 
pressure  and  the  associated  target  organ  damage  (Folkow,  1982;  Mulvany  & 
Aalkjaer,  1990).  Gluteal  skin  biopsies  from  untreated  hypertensives  show 
increased  media-lumen  ratios  due  to  decreased  lumen  area  (Oparil  et  al,  2003). 
Several  classes  of  antihypertensive  treatment  normalise  vessel  structure, 
including  ACE  inhibitors,  angiotensin-receptor  blockers  (ARB)  and  calcium- 
channel  blockers  (Schiffrin,  2001).  P-blocker  therapy  lowers  blood  pressure  but 
does  not  improve  vessel  remodelling.  Also,  hypertension  in  animal  models  can 
be  reversed  by  acute  manipulation  (for  example,  by  unclipping  the  renal  artery  in 
the  Goldblatt  model),  again  without  affecting  vascular  hypertrophy.  This 
suggests  that  resistance  vessel  structure  may  not  be  strictly  secondary  to 
hypertension  (Oparil  et  al,  2003). 
1.1.3.3.  -  ARTERIAL  STIFFNESS: 
Collagen  deposition,  muscle  cell  hypertrophy  and  decreased  integrity  of  elastic 
fibres  are  observed  in  aging  arteries.  These  contribute  to  arteriosclerosis.  In 
conjunction  with  these  structural  abnormalities,  endothelial  dysfunction  develops 
due  to  aging  and  hypertension  in  both  rodent  models  and  humans  (Hamilton  et 
al,  2001).  Thus  arteries  become  stiffer  through  life  (Berry  et  al,  2001).  Reduced 
nitric  oxide  (NO)  synthesis  or  release,  in  this  setting,  contributes  to  increased 
wall  thickness  of  conduit  vessels.  Such  deficiency  appears  to  be  important.  NO 
donors,  such  as  nitrates,  increase  arterial  compliance  and  distensibility,  reducing 
systolic  blood  pressure  without  affecting  diastolic  pressures  (Oparil  et  al,  2003). 
Stiffness  of  arteries  results  in  increased  velocity  of  reflected  pulse  waves.  This, in  turn,  increases  SBP  because  reflected  pulse  waves  reach  the  aortic  valve 
before  closure,  and  may  result  in  decreased  DBP  and  coronary  perfusion 
pressure.  This  phenomenon  explains  the  predictive  value  of  the  SBP-DBP 
derivative,  pulse  pressure,  on  cardiovascular  disease  risk  (Oparil  et  al,  2003). 
1.1.3.4.  -  RENIN-ANGIOTENSIN  SYSTEM 
Angiotensin  11  (Ang  II)  increases  blood  pressure  by  mechanisms  including 
vasoconstriction,  alclosterone  synthesis,  renal  salt  handling,  stimulation  of  thirst 
and  sympathetic  outflow  from  the  brain  (Oparil  et  al,  2003).  Constriction  to  Ang 
II  is  increased  in  hypertensive  individuals.  It  signals  through  two  angiotensin 
receptors,  type  I  (ATIR)  and  type  11  (AT2R).  Via  the  ATIR,  Ang  11  induces 
cardiac  and  vascular  hypertrophy  and  hyperplasia.  It  also  stimulates  release  of 
several  growth  factors  and  cytokines  (McConnaughey  et  al,  1999).  AT2R 
inactivates  the  signalling  pathway  downstream  of  ATIR,  opposing  the  biological 
effects  and  leading  to  vasodilatation,  growth  inhibition  and  cell  differentiation. 
This  is  thought  to  be  important  under  stress  conditions  (Oparil  et  al,  2003). 
Local  renin-angiotensin  systems  are  now  recognised.  These  may  make  an 
important  contribution  to  remodelling  of  resistance  vessels  and  the  development 
of  target  organ  damage  in  hypertensives  (McConnaughey  et  al,  1999). 
1.1.3.5.  -  ANGIOTENSIN  HAND  OXIDATIVE  STRESS: 
Hypertension  associated  with  long-term  infusion  of  Ang  11  is  linked  to 
upregulation  of  vascular  p22phox  mRNA,  a  component  of  the  oxidative  enzyine 
12 NAD(P)H  oxidase  (Fukui  et  al,  1997).  This  results  in  increased  production  of 
superoxide 
(02-) 
which  oxidises  nitric  oxide  to  peroxynitrite  (ONOO-). 
Blockade  of  ATIR  has  beneficial  effects  on  superoxide  levels  in  rat  models  of 
hypertension  and  stroke  (Brosnan  et  al,  2002).  This  reduced  NO  bioavailability 
may  be  part  of  the  reason  for  the  increased  vasoconstriction  to  Ang  Il  in 
hypertensive  individuals.  NAD(P)H  oxiclase  may  also  mediate  the  hypertrophic 
response  to  Ang  11  since  antisense  p22phox  inhibition  in  cultured  vascular 
smooth  muscle  cells  (VSMCs)  inhibits  Ang  II-induced  protein  synthesis  (Zafari 
et  al,  1999). 
1.1.3.6.  -  ENDOTHELIAL  DYSFUNCTION: 
Nitric  oxide  is  a  potent  vasodilator,  inhibitor  of  platelet  adhesion  and 
aggregation,  and  suppressor  of  VSMC  migration  and  proliferation  (Oparil  et  al, 
2003).  The  cardiovascular  system  in  healthy  individuals  is  exposed  to 
continuous  NO-dependent  vasodilator  tone,  but  NO-related  vasodilatation  is 
reduced  in  hypertensive  individuals  (Berry  et  al,  2001;  Oparil  et  al,  2003). 
Superoxide  dismutase  (SOD)  reduces  superoxide  and  in  vivo  delivery  of  SODs 
have  been  shown  to  reduce  blood  pressure  and  increase  NO  bioavailability  in 
hypertensive  models  (Nakazono  et  al,  1991;  Laursen  et  al,  1997;  Fennell  et  al, 
2002).  This  provides  further  evidence  that  oxidative  stress  contributes  to  the 
reduction  of  NO  bioavai  lability,  and  development  of  endothelial  dysfunction  in 
hypertensive  models. 
11) 1.1.4:  ACQUIRED  RISK  FACTORS  FOR  ESSENTIAL  HYPERTENSION: 
The  most  important  modifiable  environmental  risk  factors  are  salt  intake,  alcohol 
consumption  and  obesity  (Kornitzer  et  al,  1999). 
1.1.4.1.  -  SALT  INTAKE 
In  the  1960's,  Dahl  showed  a  heterogeneous  blood  pressure  response  to  salt  in 
rats.  The  trait  was  captured  by  inbreeding,  developing  salt-sensitive  and  resistant 
strains  (Dahl  et  al,  1962a;  Dahl  et  al,  1962b).  This  confirmed  the  influence  of 
both  salt  and  genes  on  blood  pressure.  Effect  of  salt  has  also  been  demonstrated 
in  chimpanzees  (Denton  et  al,  1995)  and  humans. 
The  Intersalt  study  showed  correlation  of  SBP  with  salt  excretion  and  blood 
pressure  increase  over  life  with  salt  intake  in  more  than  10,000  individuals  from 
32  countries  (Stamler  et  al,  1989).  Meta-analyses  have  confirmed  this  between 
populations  (Law  et  al,  1991)  and  within  populations  (Frost  et  al,  1991).  There 
is  also  an  ethnic  component  as  shown  by  73%  prevalence  of  salt-  sensitivity  in 
black  hypertensives  versus  56%  in  white  hypertensives  (Komitzer  et  al,  1999). 
Moderate  salt  reduction  decreases  blood  pressure  in  both  hypertensive  and,  to  a 
lesser  extent,  normotensive  individuals  and  the  effect  is  dose  dependent  (Law  et 
al,  1991;  Cutler  et  al,  1997).  This  applies  to  all  ages  from  new  born  (Geleijnse  et 
al,  1997)  to  elderly  (Whelton  et  al,  1998).  Thus,  many  advocate  a  population- 
wide  reduction  in  salt  intake  (Komitzer  et  al,  1999). 
14 Salt's  effect  on  blood  pressure  could  involve  several  mechanisms.  Salt  intake 
has  been  observed  to  increase  sympathetic  activity  (Koolen  &  Vanbrummelen, 
1984)  and  hyperinsulinaemia  has  been  noted  in  salt-sensitive  individuals 
(Bigazzi  et  al,  1996).  Interaction  with  factors  such  as  stress  has  been  proposed 
(Staessen  et  al,  1994).  Reduced  nitric  oxide  bioavailability,  as  observed  in 
animal  models,  may  enhance  the  pressor  effect  of  sodium  (Weinberger,  1996). 
1.1.4.2.  -  POTASSIUM  INTAKE.  - 
Data  from  NHANES  I  showed  that  increased  blood  pressure  in  the  black 
population  was  partly  attributable  to  a  relatively  low  potassium  intake  (Frisancho 
et  al,  1984).  The  MRFIT  study  showed  an  inverse  relationship  of  potassium 
intake  and  SBP,  and  to  a  lesser  extent  DBP,  in  men  (Stamler  et  al,  1997).  This 
correlation  was  not  observed  in  women  of  the  Nurses  Health  Study  (Komitzer  et 
al,  1999)  but  a  substudy  did  observe  a  significant  2  mmHg  decrease  in  SBP  with 
potassium  supplementation  for  16  weeks  (Sacks  et  al,  1998).  High  potassium 
diets  were  reported  to  reduce  SBP  and  DBP  by  5.5  mmHg  and  3.0  mmHg  in  US 
adults  (Appel  et  al,  1997).  Meta-analysis  of  33  potassium  supplementation  trials 
indicated  a  significant  reduction  in  pressures,  again  of  the  order  of  3  mmHg 
(Whelton  et  al,  1997). 
1.1.4.3.  -  ALCOHOL  CONSUMPTION: 
Studies  in  US,  European  and  Asian  populations  show  a  J-shaped  correlation 
between  alcohol  intake  and  blood  pressure  (MacMahon  et  al,  1990).  The 
15 correlation  of  alcohol  use  and  BP  is  also  dependent  on  age  and  sex  (Fortmann  et 
al,  1983).  The  Intersalt  study  showed  that  high  alcohol  consumption  was 
independently  related  to  the  prevalence  of  hypertension  (Stamler  et  al,  1989)  and 
reduction  of  alcohol  in  hypertensives  has  been  associated  with  decreases  in  SBP 
and  DBP  (Kornitzer  et  al,  1999).  Complete  withdrawal  of  alcohol  in 
normotensive  persons  also  causes  a  reduction  in  blood  pressures  (MacMahon  et 
al,  1990).  7%  to  I  I%  of  male  hypertension  prevalence  may  be  due  to  alcohol 
(MacMahon  et  al,  1990).  Thus,  a  population-wide  limit  of  alcohol  is  advocated. 
Current  recommendations  suggest  daily  limits  of  30  ml  of  alcohol  for  men  and 
15  ml  for  women  (Chobanian  et  al,  2003).  Mechanisms  for  this  relationship  may 
involve  several  pathways,  not  least  increased  catecholarnine  secretion,  disruption 
of  normal  Na+-Li+  countertransport  in  erythrocytes  or  a  decrease  in  insulin 
sensitivity  (Kornitzer  et  al,  1999). 
1.1.4.4.  -  METABOLIC  SYNDROME: 
The  metabolic  syndrome  is  a  clustering  of  disease  risk  factors,  including 
abdominal  obesity,  glucose  intolerance,  dyslipidaemia  and  often  hypertension 
(Isomaa,  2003).  The  link  between  these  features  is  not  clear,  but  it  is  clear  that 
patients  with  hypertension  are  at  greater  risk  of  having  other  features  of  the 
metabolic  syndrome  (Reaven,  2003).  For  example,  insulin  resistance  is  found  in 
45%  of  hypertensives  versus  10%  of  normotensives  (Reaven  et  al,  1996). 
Features  of  the  metabolic  syndrome  are,  themselves,  risk  factors  for  the 
development  of  hypertension.  Body  mass  is  related  to  blood  pressure  and  the 
16 Framingham  study  showed  that  changes  in  weight  were  accompanied  by  changes 
in  blood  pressure  (Kannel  et  al,  1967;  Stamler  et  al,  1975).  Weight  loss  in 
middle-aged,  borderline  hypertensives  has  been  shown  to  reduce  BP  by  3.7/2.7 
mmHg  (Whelton  et  al,  1997).  Intervention  in  the  elderly  also  indicates  a 
beneficial  effect  from  weight  loss  (Whelton  et  al,  1998).  Distribution  of  fat  is 
important.  Abdominal,  visceral  fat  is  metabolically  more  active  and  insulin 
resistant  than  subcutaneous  fat  (Amer,  1995)  and  correlates  with  hypertension 
(Bjomtorp,  1990). 
Insulin  sensitivity  has  been  reported  to  be  inversely  correlated  with  blood 
pressure  in  both  sexes  (Ferrannini  et  al,  1997).  Baseline  fasting  plasma  insulin 
levels  were  shown  to  predict  hypertension  status  a  decade  later  in  2,322  middle- 
aged  men  (Skarfors  et  al,  1991).  Similar  results  have  been  reported  in  women 
with  12  years  follow-up  with  a  threefold  prevalence  of  hypertension  in  the  top 
quartile  compared  with  the  bottom  (Lissner  et  al,  1992). 
Insulin  resistance  is  not  increased  in  patients  with  secondary  hypertension,  but 
there  is  a  higher  prevalence  in  normotensive  relatives  of  hypertensive  individuals 
(Reaven,  2003).  This  suggests  that  hypertension  does  not  cause  the  metabolic 
anomalies.  Some  suggest  that  insulin  resistance  and  hyperinsulinaemia  are 
causally  linked  to  essential  hypertension  (Reaven,  2003).  There  is  evidence  that 
endothelial  damage  may  occur  in  conditions  of  insulin  resistance  and 
hyperglycaemia  (Tooke  &  Hannemann,  2000).  Sympathetic  nervous  system 
stimulation  by  high  plasma  levels  of  insulin  (Julius  &  Jamerson,  1994)  or insulin's  action  on  sodium  retention  by  the  kidney  may  also  be  potential 
mechanisms  (Sechi  &  Bartoli,  1997). 
1.1.4.5.  -  OTHER  FA  CTORS.  - 
Many  studies  show  an  inverse  relationship  between  exercise  and  both  blood 
pressure  and  hypertension  risk  (Komitzer  et  al,  1999).  The  benefit  of  exercise 
and  improved  fitness  in  lowering  blood  pressure  has  been  demonstrated  in 
African  American  men  (Kokkinos  et  al,  1995),  and  Caucasian  men  (Paffenbarger 
et  al,  1983)  and  women  (Kornitzer  et  al,  1999).  Psychosocial  stress  has  also 
been  shown  to  contribute  to  risk.  Work-related  stress  correlates  with  ambulatory 
blood  pressures  in  men  and  women  (Van  Egeren,  1992;  Theorell  et  al,  1993). 
1.1.5:  EVIDENCE  FOR  A  GENETIC  COMPONENT  IN  ESSENTIAL 
HYPERTENSION: 
Evidence  from  human  population  studies,  rat  model  studies  and  Mendelian  blood 
pressure  disorders  demonstrate  a  genetic  component  in  essential  hypertension 
(Rapp  &  Deng,  1995). 
1.1.5.1.  -  EVIDENCE  FROMHUAIMN  POPULATION  STUDIES: 
An  early  study  used  longitudinal  blood  pressures  over  9  years  to  assess 
aggregation  of  blood  pressure  in  families  in  Wales  (Miall  et  al,  1967).  It  showed 
a  correlation  of  BP  in  probands  and  first-degree  relatives  which  was  absent  in 
18 spouses,  despite  their  shared  environment.  Similarly,  the  Framingham  study 
showed  correlation  between  the  BPs  of  parents  and  offspring  but  no  correlation 
between  spouses.  Like  Miall  et  al,  above,  the  conclusion  was  that  genetic  factors 
could  explain  this  (Havlik  et  al,  1979).  Studies  in  Evans  County  in  the  US 
showed  that  blood  pressure  aggregation  was  present  in  both  black  and  white 
populations  and  an  individual's  BP  correlated  with  the  number  of  hypertensive 
parents  (Hayes  et  al,  1971).  Examination  of  related  and  unrelated  individuals 
living  together  or  apart  in  Michigan  was  used  to  quantify  the  genetic  effect. 
Heritability  of  SBP  was  0.42  and  DBP  was  0.30.  Genetic  factors  accounted  for 
25%  of  SBP  variance  (Longini  et  al,  1984).  Comparable  results  have  been 
published  in  populations  lacking  some  of  the  Western  risk  factors,  such  as  urban 
Nigerian  families  with  low  BMI  and  hypertension  prevalence.  Heritability 
estimates  of  0.34  and  0.29  were  obtained  for  SBP  and  DBP  (Adeyemo  et  al, 
2002). 
Twin  studies  support  population  studies.  A  significant  genetic  effect  on  BP  was 
demonstrated  in  500  monozygotic  (MZ)  and  dizygotic  (DZ)  middle-aged  twin 
pairs  by  the  National  Heart,  Lung  and  Blood  Institute  (NHLBI)  (Feinleib  et  al, 
1977).  Resting  blood  pressures  and  response  to  stress,  tested  by  the  cold  pressor 
test,  demonstrated  that  a  genetic  component  was  involved  in  both  cases  in  young 
to  middle-aged  German  twins  (Busjahn  et  al,  1996).  Adoption  studies  support 
the  findings  of  other  study  designs.  One  of  the  most  informative  studies  in 
French-Canadian  families  compared  BP  correlation  between  adoptees,  or  natural 
children,  and  parents.  It  concluded  that  most  of  BP  correlation  was  explained  by 
heredity  (Biron  ef  al,  1976).  Subsequently  the  same  group  estimated  that  up  to 
19 61%  and  58%  of  the  SBP  and  DBP  correlation  could  be  explained  by  shared 
genes.  About  a  third  of  the  phenotypic  variance  in  the  population  was  attributed 
to  genes. 
Overall,  different  study  designs  have  confirmed  that  blood  pressure  is  highly 
heritable.  This  also  applies,  as  one  might  expect,  to  hypertension  (Williams  et  al, 
1989).  The  precise  contribution  of  inherited  genes  has  been  more  difficult  to 
define.  At  best  one  can  say  that  between  30%  and  60%  of  interindividual 
variation  is  attributable  to  genes  (Ward,  1990). 
1.1.5.2.  -  EVIDENCE  FROM  RAT  MODELS: 
In  rodent  models,  it  has  been  shown  very  clearly  that  blood  pressure  must  be 
influenced  by  genetic  variation.  The  20th  century  saw  the  development  of  a 
number  of  inbred  rat  strains.  These  were  produced  by  selectively  breeding  rats 
that  showed  a  propensity  for  high  blood  pressure.  Some  were  developed  from 
outbred  rats,  being  brother-sister  mated  to  fix  the  phenotype  and  the  genomic 
complement  (Smirk  &  Hall,  1958).  Others  were  derived  from  normotensive 
inbred  strains  using  animals  which  displayed  unusually  high  blood  pressures. 
Thus  the  widely  used  spontaneously  hypertensive  rat  (SHR)  was  derived  from 
atypical  Wistar  rats  (Okamoto  &  Aoki,  1963).  Dahl  developed  partially  inbred 
salt  sensitive  and  resistant  strains  (Dahl  et  al,  1962a).  From  these  initial  strains, 
fully  inbred  strains  were  created  later  (Rapp  &  Dene,  1985).  Sabra  H  and  Sabra 
N  rats  were  developed  by  Ben-Ishay,  having  a  marked  BP  response  to  DOCA- 
salt  administration  or  negligible  response,  respectively  (Ben-Ishay  et  al,  1972). 
20 These  rat  strains  develop  spontaneous  hypertension  which  is  relatively 
consistent,  within  a  strain,  in  terms  of  its  severity  and  age  of  onset  (Lee  et  al, 
2000). 
Mating  of  normotensive  and  hypertensive  rats  to  produce  an  F2  generation 
results  in  continuously  distributed  blood  pressures  in  the  progeny.  This  suggests 
that,  as  in  humans,  the  rats  develop  polygenic  forms  of  hypertension 
(Dominiczak  et  al,  1998).  This  has  been  confirmed  by  the  finding  that  multiple 
genetic  loci  contribute  to  the  hypertension  in  each  model  (Rapp,  2000).  Rodent 
models  elegantly  demonstrate  that  high  blood  pressure  levels  are  inherited  from 
generation  to  generation  and  this  phenotype  can  be  captured  by  inbreeding.  Use 
of  congenic  strain  production  provides  definitive  proof  for  the  effect  of  a 
chromosomal  segment  on  blood  pressure  (Rapp  &  Deng,  1995;  Dominiczak  et 
al,  1998).  As  far  as  possible  environment  is  a  constant  so  inbred  rat  strains  allow 
us  to  directly  observe  the  effects  of  genes  on  blood  pressure. 
1.1.5.3.  -  EVIDENCE  FROM  MENDELIAN  HYPERTENSIVE  DISORDERS: 
Whilst  contributing  very  little  to  the  overall  burden  of  hypertensive  disease, 
Mendelian  hypertensive  disorders  have  confirmed  not  only  the  crucial  role  of 
genes  in  human  blood  pressure  control,  but  also  indicated  mechanisms  by  which 
this  control  is  achieved  and  disrupted. 
21 1.1.5.3.1:  Glucocorticoid-remediable  aldosteronism: 
Glucocorticoid-remediable  aldosteronism  (GRA)  is  characterised  by  early  onset 
of  hypertension  with  normal  or  elevated  aldosterone  levels  with  suppressed,  or 
undetectable,  plasma  renin  activity  (PRA)  (Sutherland  et  al,  1966). 
Hypokalaemia  and  metabolic  alkalosis  may  also  feature  (Rich  et  al,  1992). 
Exogenous  glucocorticoids  relieve  symptoms  (Sutherland  et  al,  1966). 
Linkage  analysis  in  multiple  GRA  pedigrees  showed  the  cause  to  be  unequal 
crossing  over  between  two  highly  homologous  genes  on  chromosome  8q  (Lifton 
et  al,  1992a;  Lifton  et  al,  1992b).  CYPIIBI,  normally  regulated  by 
adrenocorticotrophic  hormone  (ACTH),  expresses  steroid  II  P-hydroxylase,  an 
enzyme  involved  in  cortisol  synthesis  in  the  adrenal  fasciculata.  CYP  II  B2, 
normally  regulated  by  angiotensin  11  (AngII),  expresses  aldosterone  synthase,  the 
rate-limiting  enzyme  in  alclosterone  synthesis  in  the  adrenal  glomerulosa.  The 
resulting  chimaeric  gene  expresses  a  protein  with  aldosterone  synthase  activity 
under  the  control  of  ACTH.  Thus,  efforts  to  maintain  normal  levels  of  cortisol 
result  in  ectopic  and  constitutive  production  of  aldosterone  from  the  adrenal 
fasciculata. 
The  hyperaldosteronism  causes  hyperactivation  of  the  mineralocorticoid  receptor 
leading  to  increased  Na+  reabsorption  via  the  epithelial  sodium  channel  (ENaQ 
(Fig.  1.1.4).  Plasma  volume  expansion  and  hypertension  result  (Lifton  et  al, 
2001).  Increased  secretion  of  K'  and  H+  is  driven  by  the  lumen-negative 
potential  from  the  low  Na  2+  concentration. 
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Fig  1.  IA:  Mendelian  hypertensive  disorders  in  humans.  A  schematic  kidney  nephron  is 
shown  in  yellow.  NaCl  reabsorption  pathways  are  shown  with  hypertensive  disorders  in 
red.  PT  =  proximal  tubule;  TAL  =  thick  ascending  limb;  DCT  =  distal  convoluted  tubule; 
CCT  =  cortical  collecting  tubule.  Ang  I=  angiotensinogen  1;  Ang  11  =  angiotensinogen  11. 
PHA  11  =  pseudohypoaldosteronism  type  11.  Adapted  from  Lifton  et  al,  2001. 
23 Conversely,  loss-of-function  mutations  in  the  CYP  11  B2  gene  (Mitsuuchi  et  al, 
1992;  Pascoe  et  al,  1992)  and  the  steroid  21-hydroxylase  gene,  CYP21B, 
(Bongiovanni  &  Root,  1963)  are  known  which  cause  salt-wasting  and 
hypotension. 
1.1.5.3.2:  Syndrome  of  apparent  mineralocorticoid  excess: 
Syndrome  of  apparent  mineralocorticoid  excess  (AME)  is  an  autosomal  recessive 
early  onset  hypertensive  disorder  associated  with  hypokalaemia  and  metabolic 
alkalosis,  accompanied  by  low  PRA  but  virtual  absence  of  circulating 
aldosterone  (New  et  al,  1977).  Administration  of  spironolactone,  a 
mineralocorticoid  receptor  (MR)  antagonist,  or  a  low  sodium  diet  alleviates  the 
symptoms  (New  et  al,  1977;  Mune  et  al,  1995). 
AME  is  caused  by  homozygous  loss-of-function  mutations  in  the  HSDIIB2 
gene,  encoding  the  II  P-hydroxysteroid  dehydrogenase  type  2  kidney  isozyme 
(I  I  PHSD2)  (Mune  et  al,  1995;  Stewart  et  al,  1996).  Cortisol  is  a  potent  agonist 
of  the  MR  (Arriza  et  al,  1987)  which  is  converted  to  inactive  cortisone  by 
II  PHSD  and  so  that  the  MR  is  selective  for  aldosterone  (Fudner  et  al,  1988). 
Removal  of  this  protection  by  mutation  of  the  HSD  II  B2  gene  results  in  a  greater 
half  life  of  cortisol  which  activates  the  MR  (Ulick  et  al,  1979).  This  causes 
hypertension  due  to  increased  sodium  reabsorption  via  the  ENaC  (Fig.  1.1.4). 
Antagonism  of  the  MR  blocks  this. 
High  cortisol  levels  associated  with  heritable  mutations  of  the  glucocorticold 
receptor  or  pituitary  or  adrenal  adenomas  also  result  in  hypertension  (Hurley  et 
24 al,  1991).  Deficiencies  in  steroid  Ilp-hydroxylase  and  17a-hydroxylase  can 
result  in  low  renin  hypertension  due  to  the  accumulation  of  MR-agonist 
precursors  of  cortisol  synthesis  (Kagimoto  et  al,  1988;  White  et  al,  1991). 
1.1.5.3.3:  Pregnancy-accelerated  hypertension: 
Mutation  of  the  mineral  ocorticoid  receptor  causes  an  autosomal  dominant  form 
of  hypertension  which  worsens  during  pregnancy  (Geller  et  al,  2000)  (Fig.  1.1.4). 
The  mutations  disrupt  the  receptor's  specificity  such  that  progesterone  will 
activate  it.  Progesterone  increases  100-fold  in  pregnancy,  and  exacerbates  the 
hypertension  during  this  time  (Lifton  et  al,  2001). 
Conversely,  loss-of-function  mutations  in  the  MR  cause  autosomal  dominant 
pseudohypoaldosteronism  type  I  (AD  PHA  I)  which  is  a  form  of  neonatal  salt 
wasting  associated  with  hypotension  in  the  presence  of  elevated  aldosterone 
levels  and  metabolic  acidosis  (Lifton  et  al,  2001). 
1.1.5.3.4:  Liddle  syndrome: 
Liddle  syndrome  is  characterised  by  autosomal  dominant  transmission  of  early 
onset  hypertension  associated  with  hypokalaemic  alkalosis,  suppressed  plasma 
renin  activity  and  low  Plasma  aldosterone  levels  (Lifton  et  al,  2001). 
The  disease  is  caused  by  mutations  in  either  the  P  or  y  subunit  of  the  epithelial 
sodium  channel  (ENaC).  ENaC  is  a  heterotrimeric  protein  consisting  of  a,  P  and 
y  subunits  (Fig.  1.1.4).  Mutations  result  in  loss  of  the  C  terminus  of  the  affected 
subunit  (Shimkets  et  al,  1994:  Hansson  et  al,  1995).  The  effect  of  mutations  in 
25 either  subunit  is  increased  channel  activity  due  to  increased  numbers  of  ENaC 
molecules  at  the  cell  surface  (Schild  et  al,  1995;  Snyder  et  al,  1995).  All 
mutations  described  affect  a  highly  conserved  PPPXY  motif  in  the  C  terminus 
(Hansson  et  al,  1995;  Inoue  et  al,  1998).  Studies  showed  that  mutation  of  any 
conserved  PPPXY  residues  resulted  in  increased  amiloride-sensitive  Na+ 
conductance  in  X  laevis  oocytes  (Schild  et  al,  1996).  The  PPPXY  motif  was 
subsequently  implicated  in  internalisation  of  channels  or  subsequent  degradation 
hence  the  increased  channel  numbers  at  the  membrane  (Shimkets  et  al,  1997). 
Nedd4-1  (Staub  et  al,  1996),  and  Nedd4-2  (Kamynina  et  al,  2001)  interact  with 
the  PPPXY  motif,  ubiquinating  the  channel  and  targeting  it  for  degradation. 
Loss-of-function  mutations  in  ENaC  cause  recessive  pseudohypoaldosteronism 
type  I  (Chang  et  al,  1996)  which  results  in  neonatal  salt  wasting  with 
hypotension,  elevated  aldosterone  and  metabolic  acidosis.  It  is  more  severe  than 
the  dominant  form  (Strautnieks  et  al,  1996). 
1.1.5.3.5:  Pseudohypoaldosteronism  type  11: 
Pseudohypoaldosteronism  type  11  (PHA  11),  or  Gordon's  syndrome,  is  an 
autosomal  dominant  form  of  hypertension  with  hyperkalaemia,  possible 
metabolic  acidosis  and  suppressed  renin  activity,  despite  otherwise  normal  renal 
function.  It  is  particularly  sensitive  to  thiazide  diuretics  (Lifton  et  al,  2001). 
Genome  wide  scans  identified  linkage  on  chromosomes  I  q3l-42,17p  I1  -q21  and 
12p  13  (Mansfield  et  al,  1997,  Disse-Nicoderne  et  al,  2000).  Subsequently,  two 
serine-threonine  kinases  were  shown  to  underlie  the  linkage  results  on 
26 chromosomes  12  and  17.  Large  deletions  in  the  first  intron  of  lysine-deficient 
protein  kinase  I  (VVNKI)  caused  increased  expression  whilst  missense  mutations 
caused  loss-of-function  of  lysine-deficient  protein  kinase  4  (IANK4)  in  PHA  11 
pedigrees.  Both  proteins  co-localise  to  the  distal  convoluted  tubule  (DCT)  and 
cortical  collecting  duct  (CCD)  of  the  distal  nephron  (Wilson  et  al,  2001).  The 
renal  downstream  target  of  )NNKI  is  not  known  but  may  be  the  Na-K-2CI 
channel,  which  is  known  to  be  regulated  by  a  kinase  dependent  mechanism 
(Choate  et  al,  2003).  WNK4  limits  cell  surface  expression  of  the  diazide- 
sensitive  Na-CI  cotransporter  expressed  in  the  DCT  (Wilson  et  al,  2003). 
Mutations  in  the  Na-K-2CI  channel  cause  the  hypotensive  Bartter  syndrome  type 
I  (Simon  et  al,  1996)  whilst  a  mutant  Na-CI  cotransporter  causes  Gitelman 
syndrome  (Bettinelli  et  al,  1992).  Both  feature  hypotension  with  hypokalaemia 
and  alkalosis  (Simon  et  al,  1996). 
1.1.5.3.6  Hypertension  with  brachydactyly: 
Hypertension  with  brachydactyly  is  an  autosomal  dominant  disorder  showing 
complete  cosegregation  of  severe  early-onset  hypertension  with  abnormal 
skeletal  development  of  the  hand  and  wrist  (Lifton  et  al,  2001).  The  syndrome 
was  mapped  to  12pl2.2-11.2  in  a  Turkish  pedigree  (Schuster  et  al,  1996). 
Deletions  in  this  same  interval  can  result  in  brachydactyly  in  the  absence  of 
hypertension  and  so  the  possibility  that  contiguous  genes  are  altered  has  been 
raised  (Bahring  et  al,  1997). 
27 1.1.6:  THE  ROLE  OF  GENETICS  IN  TREATMENT  OF  HYPERTENSION: 
As  discussed,  despite  advances  in  the  understanding  of  pathophysiology  of 
essential  hypertension,  health  education  and  development  of  novel  medicines, 
essential  hypertension  is  still  not  adequately  controlled  in  the  majority  of  patients 
(Chobanian  et  al,  2003).  Essential  hypertension  has  a  multifactorial  aetiology,  a 
combination  of  environmental  and  genetic  influences  (Lifton  et  al,  2001). 
Therefore,  lifestyle  modifications  have  been  promoted  as  an  important  non- 
pharmacological  approach  to  treatment.  They  effectively  lower  blood  pressure 
and  disease  risk  (Carretero  &  Oparil,  2000a).  However,  in  reality  lifestyle 
targets  are  difficult  to  achieve  and  harder  to  maintain.  Alone  they  cannot  solve 
the  problem  (Chobanian  et  al,  2003). 
What,  then,  can  genetic  studies  contribute  to  the  situation  and  how  would  this 
benefit  patients?  Recent  opinion  dichotomises  the  role  of  genetics.  Essentially, 
there  are  two  distinct  questions.  The  first  concerns  the  genetic  basis  of  essential 
hypertension  -  answered  by  disease  genetics.  The  second  concerns  the  role  of 
genes  in  determining  individual  response  to  therapy  -  answered  by 
pharm  aco  genetics  (Roses,  2000a). 
Disease  genetics  studies,  the  focus  of  this  thesis,  may  lead  to  new  insights  into 
hypertensive  disease  and  could  potentially  inform  future  drug  development 
(Roses,  2000a).  However,  Roses  notes  that,  in  reality,  disease  genes  and  drug 
targets  are  not  the  same  thing.  Most  susceptibility  genes  will  not  be  tractable 
targets  or  amenable  to  high-throughput  screening  methods  to  identify  active 
28 compounds  (Roses,  2000a).  Despite  this,  understanding  of  individual  aetiologies 
at  the  genetic  level  would  allow  mechanism-based  drug  discovery  (McLeod  & 
Evans,  2001).  This  should  ultimately  enable  a  more  customised  treatment 
regimen  based  on  an  individual's  subtype  of  hypertensive  disease.  Another 
possibility,  once  disease  genes  are  known,  would  be  genetic-testing.  However, 
whilst  it  might  be  useful  to  determine  an  individual's  risk,  in  practice  there  is  a 
minefield  of  social,  ethical  and  legal  issues  (Roses,  2000b). 
From  the  pharmacogenetics  standpoint,  an  understanding  of  why  a  given  patient 
fails  to  respond  well  to  a  drug  may  be  of  more  immediate  use  in  treating  the 
individual.  One  of  the  greatest  obstacles  in  treating  patients  is  non-compliance 
with  medication  or  change  in  medication.  Between  50  and  70%  of  hypertensive 
patients  will  change  their  medication  within  6  months  of  commencing  treatment 
(Carretero  &  Oparil,  2000a).  Unpleasant  side  effects  may  result  in  complete 
non-compliance,  and  at  least  will  reduce  the  treatment  options  available.  Even  in 
patients  tolerating  their  medication  it  is  poorly  understood  why  response  to  drugs 
is  so  variable.  The  standard  deviation  of  response  to  medication  is  as  great  as  the 
mean  response.  Ranges  of  response  are  greater  than  the  mean  response.  Ten  to 
twenty  percent  of  patients  have  no  response  at  all  or  a  paradoxical  increase  in  BP 
(Turner  &  Boerwinkle,  2003).  Pharmaco  genetics  could  be  used  to  predict  if  an 
individual  patient  is likely  to  benefit  from  a  medicine  and  be  free  of  serious  side- 
effects  (Roses,  2000a). 
29 1.2:  FAMILIAL  INTRACRANIAL  ANEURYSM  AND  SUBARACHNOID 
HAEMORRHAGE: 
Formation  of  intracranial  saccular  aneurysms  (IA)  is  a  complex  process 
involving  genetic  and  acquired  risk  factors.  Focal  dilatation  of  intracranial 
arterial  walls  results  in  the  formation  of  an  extruded  pouch  -  the  aneurysm  - 
which  compromises  the  integrity  of  the  vessel  and  may  lead  to  rupture  (Zhang  et 
al,  2003).  Within  the  cranium,  rupture  of  aneurysms  on  the  surface  of  the  brain 
results  in  bleeding  into  the  subarachnoid  space,  between  the  pia  mater  and 
arachnoid  membrane.  This  is  termed  'subarachnoid  haemorrhage'  (SAH).  Both 
IA  and  aneurysmal  SAH  exist  as  sporadic  and  familial  disorders  (Zhang  et  al. 
2003). 
1.2.1:  DEFINITION  &  EPIDEMIOLOGY  OF  FAMILIAL  INTRACRANIAL 
ANEURYSM  &  SUBARACHNOID  HAEMORRHAGE: 
The  suggestion  that  IA  formation  may  involve  a  heritable  component  was  first 
raised  by  Chambers  et  al  when  they  described  lAs  in  a  father  and  son  (Chambers 
et  al,,  1954).  Many  families  have  since  been  described  in  the  literature  (Lozano 
&  Leblanc,  1987;  Elshunnar  &  Whittle,  1990;  Schievink  et  al,  1991;  Schievink  et 
al,  1994;  Bromberg  et  al,  1995)  and  the  familial  aggregation  of  lAs  is  now 
accepted.  The  term  'familial  intracranial  aneurysm'  (FIA)  describes  the  disorder 
in  families  having  two  or  more  affected  first  to  third-degree  relatives,  this  being 
distinct  from  'sporadic'  aneurysms  which  have  no  accompanying  family  history 
(Schievink  et  al,  1994;  Bromberg  et  al,  1995). 
30 The  majority  of  aneurysms  remain  asymptomatic  (Schievink  et  al,  1994)  and,  as 
such,  calculation  of  the  population  prevalence  of  sporadic  and  familial 
intracranial  aneurysms  is  very  difficult.  Autopsy  studies  have  been  used  to 
address  this  question.  A  meta-analysis  by  Rinkel  et  al  (Rinkel  et  al,  1998)  of  19 
studies  suggested  a  total  population  prevalence  of  4.3%.  The  proportion  that  are 
familial  aneurysms  is  estimated  to  be  from  4%  in  a  Scottish  population 
(Elshunnar  &  Whittle,  1990)  and  6.7%  in  a  Swedish  study  (Norrgard  et  al,  1987) 
to  29%  in  French-Canadians  (Mathieu  et  al,  1997).  However,  the  latter 
population  may  be  atypical  since  it  is  a  geographically  isolated  population  and 
may  include  founder  effects  (Mathieu  et  al,  1997). 
Whilst  asymptornatic  intracranial  aneurysms  are  not  detrimental  in  themselves, 
should  they  rupture  the  prognosis  for  the  patient  is  very  poor.  About  80%  to 
90%  of  non-traumatic  subarachnoid  haemorrhage  cases  are  attributable  to  a 
ruptured  so-called  saccular  or  'berry'  intracranial  aneurysm  (Alberts,  1999). 
Mortality  is  about  50%  and  more  than  35%  of  those  admitted  to  hospital  die 
within  one  month.  One  third  of  survivors  have  serious  neurological  deficits 
(Gaist  et  al,  2000).  Of  SAH  due  to  saccular  aneurysmal  rupture,  about  5  to  10% 
are  thought  to  be  familial  cases  (Bromberg  et  al,  1995)  although  some  authors 
report  as  high  as  20%  having  a  family  history  (Schievink  et  al,  1995). 
1.2.2:  EVIDENCE  FOR  A  FAMILIAL  DISORDER: 
Most  reported  FIA  families  have  only  two  affected  members  raising  the 
possibility  that  the  observed  aggregation  is  purely  fortuitous.  This  has  been 
31 addressed  by  several  studies.  US  studies  comParing  SAH  incidence  in  first- 
degree  relatives  of  SAH  cases  with  the  population  prevalence  demonstrated 
between  twofold  (Wang  et  al,  1995)  and  fourfold  risk  (Schievink  et  al,  1995). 
Alberts  et  al  (Alberts  et  al,  1994)  showed  fourfold  risk  of  IA  or  SAH  in  siblings 
of  cases  from  large  sibships  in  the  literature.  Comparable  recurrence  risks  of  4 
for  IA  in  Finnish  first-degree  relatives  (Ronkainen  et  al,  1997)  and  3  to  5  for 
SAH  in  Danish  first-degree  relatives  (Gaist  et  al,  2000)  have  been  reported. 
Apparent  differences  between  sporadic  and  familial  IA  or  SAH  also  suggest  two 
separate  entities.  Dutch,  Finnish,  Northern  Irish  and  Canadian  populations 
consistently  show  that  familial  aneurysms  rupture,  on  average,  about  5  years 
earlier  than  sporadic  cases  (Andrews,  1977;  Lozano  &  Leblanc,  1987;  Bailey, 
1993;  Ronkainen  et  al,  1995;  Bromberg  et  al,  1995;  Leblanc  et  al,  1995).  Some 
report  that  ruptures  peak  in  the  4  th  decade  of  life  in  familial  cases  but  in  the  6th 
decade  for  sporadic  (Leblanc  et  al,  1995).  Aneurysms  of  the  anterior 
communicating  artery  are  consistently  twice  as  common  in  sporadic  cases 
(Andrews,  1977;  Lozano  &  Leblanc,  1987;  Bailey,  1993;  Ronkainen  et  al,  1995; 
Bromberg  et  al,  1995;  Leblanc  et  al,  1995). 
FlAs  occur  at  the  same  or  contralateral  site  in  siblings  twice  as  often  as  random 
sporadic  cases  (Andrews,  1977),  (Lozano  &  Leblanc,  1987;  Leblanc  et  al,  1995). 
Of  8  published  monozygotic  twin  pairs,  reviewed  by  Lozano  and  Leblanc,  all  had 
aneurysms  at  the  same  or  contralateral  site.  SAH  also  occurs  in  the  same  decade 
of  life  more  than  twice  as  often  (Andrews,  1977;  Lozano  &  Leblanc,  1987; 
Leblanc  et  al,  1995). 
32 Some  studies  suggest  that  familial  aneurysms  may  rupture  at  a  smaller  size 
(Lozano  &  Leblanc,  1987;  Ronkainen  et  al,  1995).  Some  studies  also  suggest  an 
increased  prevalence  of  multiple  aneurysms  in  familial  cases  (Lozano  &  Leblanc, 
1987;  Bailey,  1993;  Bromberg  et  al,  1995)  although  perhaps  as  many  find  no 
difference  (Schievink  et  al,  1995;  Leblanc  et  al,  1995;  Mathieu  et  al,  1997). 
Prognosis  for  familial  SAH  cases  may  be  worse.  A  Dutch  outcome  study 
showed  that  48%  of  familial  cases  were  able  to  continue  an  independent  life 
following  SAH  compared  with  68%  of  sporadic  cases  at  time  of  discharge.  FIA 
mortality  was  also  higher  (Bromberg  et  al,  1995).  Conversely,  a  Finnish  study 
showed  no  difference  in  outcome,  one  year  after  discharge  (Ronkainen  et  al, 
1999).  However,  Finland  is  exceptional  in  terms  of  its  prevalence  of  IA  and  the 
predominance  of  affected  males.  This  may  indicate  different  aetiology. 
1.2.3:  PATHOLOGY  AND  PATHOPHYSIOLOGY  OF  INTRACRANIAL 
ANEURYSMS: 
A  saccular  intracranial  aneurysm  is  a  berry-shaped  or  multi-lobed  extrusion  of  an 
artery  wall,  usually  associated  with  the  circle  of  Willis  at  the  base  of  the  brain. 
Such  aneurysms  are  distinct  in  their  shape  and  pathogenesis  from  atherosclerotic 
fusiform  aneurysms;  infection-derived  mycotic  aneurysms;  and  dissecting 
arteries,  often  caused  by  trauma  (Alberts,  1999). 
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Fig  1.2.1:  A  schematic  representation  of  processes  which  may  influence  arterial 
integrity  and  the  formation  of  intracranial  aneurysms.  The  complex  aetiology  may 
involve  normal  aging  and  stress  effects  exacerbated  by  an  underlying  vessel  weakness. 
Genetic  susceptibility  may  underlie  aberrant  vessel  remodelling,  artery  wall  turnover 
or  inflammatory  processes.  Acquired  risk  factors  interact  with  some  or  all 
components.  ECM  =  extracellular  matrix 
Aging 
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Fig.  1.2.2:  Schematic  of  the  circle  of  Willis  and  the  commonly  associated  sites  of 
saccular  aneurysm  formation.  Taken  from  Zhang  et  al,  2003. 
35 1.2.3.1.  -  SITE  OF  ANEURYSM  FORMATION., 
Saccular  aneurysms  often  form  at  the  circle  of  Willis  because  of  the  increased 
haemodynamic  forces  in  this  region  (Zhang  et  al,  2003),  particularly  at  arterial 
bifurcations  (Leblanc,  1997)  (Fig.  1.2-2).  Haemodynamic  stress  by  carotid 
ligation  causes  slow  formation  of  experimental  aneurysms,  and  the  process  is 
accelerated  by  induced  hypertension  (Kondo  et  al,  1997).  Mathematical 
modelling  confirms  the  increased  stresses  at  bifurcations  and  the  outside  of 
curves  (Foutrakis  et  al,  1999).  Previously,  haemodynamic  stress  was  thought  by 
some  to  completely  account  for  IA  formation  (Stehbens,  1989).  However,  this 
fails  to  explain  why  IAs  are  still  relatively  rare  in  hypertensive  groups,  and  why 
aggregation  occurs  in  families  and  twins.  Twins,  for  example,  do  not  have 
identical  vasculature  at  the  circle  of  Willis  (Stehbens,  1989). 
1.2.3.2.  -  FEATURES  OF  ANEURYSMAL  VESSEL  WALLS: 
With  aging,  and  probably  due  to  haemodynamic  stress,  layers  of  fibrous  tissue 
develop  between  the  endothelium  and  internal  elastic  lamina  of  the  cerebral 
vessel  wall.  This  decreases  vessel  elasticity  and  causes  further  deposition  of 
fibrous  tissue.  At  arterial  bifurcations  this  further  increases  haernodynamic  stress 
(Zhang  et  al,  2003).  Disruption  of  the  internal  elastic  lamina  (IEL)  is  a  common 
feature  in  both  human  (Stehbens,  1972)  and  experimental  aneurysmal  vessels 
(Yamazoe  et  al,  1990).  IEL  fenestrations  are  known  to  exist  normally,  but  are 
larger  at  aneurysm  sites  (Campbell  &  Roach,  198  1).  In  the  developed  aneurysm, 
the  IEL  and  medial  layer  terminate  abruptly  at  the  neck  of  the  aneurysm 
36 (Abruzzo  et  al,  1998;  Zhang  et  al,  2003).  The  wall  of  the  aneurysm  shows 
evidence  of  depleted  cellular  elements,  being  little  more  than  a  fibrous  layer  with 
remnants  of  IEL  (Stehbens,  1972).  Some  authors  suggest  a  lack  of  fibromuscular 
proliferation  and  neointimal  thickening  is  characteristic  of  such  aneurysms 
(Abruzzo  et  al,  1998).  These  structural  changes  are  more  advanced  in  ruptured 
aneurysms  compared  with  unruptured  aneurysms  (Kataoka  et  al,  1999). 
1.2.3.3.  -  EXTRA  CELL  ULAR  MA  TRIX  REMODELLING: 
Gross  architectural  remodelling  of  extracellular  matrix  (ECM)  has  been  reported 
in  intracranial  aneurysms.  ECM  is  seen  to  be  disorganised  (Skirgaudas  et  al, 
1996).  Quantitatively  and  qualitatively  abnormal  reticular  fibres  have  been 
reported  in  both  aneurysm  tissue  specimens  (Chyatte  et  al,  1990;  Chyatte  & 
Lewis,  1997)  and  normal  cerebral  arteries  of  affected  patients  (Ostergaard  et  al, 
1987).  Skin  biopsies  taken  from  some  IA  patients  indicate  abnormal  collagen 
and  elastic  fibre  morphology  (Grond-Ginsbach  et  al,  2002).  Some  have  reported 
reduced  collagen  type  III  content  in  patients'  fibroblasts  (van  den  Berg  et  al, 
1997;  Gaetani  et  al,  1997)  or  reduced  collagen  fibre  cross-linking  (Gaetani  et  al, 
1996). 
Expression  profiling  suggests  that  intracranial  aneurysms  are  dynamic  lesions 
undergoing  remodelling.  Peters  et  al  examined  an  IA  from  a  3-year  old  girl  and 
showed  increased  expression  of  several  collagen  subtypes,  elastin,  and  the  matrix 
metal  loproteinase  inhibitor  TIMP3  (Peters  et  al,  2001).  Increased  expression  of 
growth  factors  such  as  vascular  endothelial  growth  factor  (VEGF)  and  basic 
37 fibroblast  growth  factor  (bFGF)  has  been  reported  in  adult  lesions  (Skirgaudas  et 
al,  1996).  A  recent  study  reported  decreased  expression  of  bFGF,  TIMP  I  and 
components  of  the  local  renin-angiotensin  system.  It  was  suggested  that  a  lack  of 
vascular  remodelling  may  prevent  arterial  wall  thickening,  in  response  to 
increased  haemodynamic  stress,  leading  to  IA  formation  (Ohkuma  et  al,  2003). 
Increased  expression  of  matrix  metalloproteinases  (MMP)  1,2  and  9  and  plasmin 
has  been  reported  in  unruptured  aneurysms  (Bruno  et  al,  1998).  Increased 
MMP2  activity  and  reduced  procollagens  in  serum  from  IA  patients  suggest  a 
systemic  anomaly  (Chyatte  &  Lewis,  1997).  Such  observations  have  led  to  the 
suggestion  that  an  imbalance  in  ECM  turnover  may  be  a  factor  in  intracranial 
aneurysm  formation. 
1.2.3.4.  -  INFLAMMATORY  PROCESSES: 
Some  studies  have  shown  a  link  between  atherosclerotic  profile  and  ruptured 
aneurysms  (Adamson  et  al,  1994).  Others  have  shown  no  increased  risk 
(Schievink,  1997).  However,  there  is  evidence  to  suggest  that  inflammatory 
processes,  homologous  to  those  resulting  in  atherosclerotic  plaques,  may  be 
involved  in  aneurysm  development  and/or  rupture  (Laursen  et  al,  1997).  Neither 
atherosclerotic  plaques  nor  intramural  inflammation  are  necessary  features  of  lAs 
(Abruzzo  et  al,  1998).  However,  increased  infiltration  of  macrophages  and 
leukocytes  has  been  observed  in  ruptured  compared  with  unruptured  lAs.  It  has 
been  suggested  that  endothelial  damage  encourages  macrophage  invasion  leading 
to  rupture  (Kataoka  et  al,  1999).  A  study  to  assess  markers  of  inflammation  in 
unruptured  lAs  noted  increased  macrophage  and  T  lymphocyte  levels  compared 
38 with  control  arteries  obtained  at  autopsy.  Levels  of  vascular  cell  adhesion 
molecule  I  (VCAM  1)  and  immunoglobulins  IgG  and  IgM  were  also  increased 
(Chyatte  et  al,  1999).  These  cells  and  molecules  are  also  involved  in 
atherosclerosis  and  the  macrophages  are  a  source  of  MMPs. 
1.2.4:  ACQUIRED  RISK  FACTORS  OF  INTRACRANIAL  ANEURYSMS 
AND  SUBARACHNOID  HAEMORRHAGE: 
Familial  IA  and  SAH  are  complex  disorders;  it  is  expected  that  both  acquired 
factors  and  inherited  genetic  susceptibility  underlie  the  increased  risk  in  FIA/ 
SAH  families.  The  majority  of  risk  factor  studies  concentrate  on  SAH,  rather 
than  formation  of  IA,  as  an  endpoint,  partly  due  to  the  fact  that  SAH  patients  are 
more  easily  identified  than  asymptomatic  IA  carriers.  Many  studies  now  suggest 
that  the  primary  acquired  risk  factors  for  FIA  and  SAH  are  smoking  and  female 
sex.  Hypertension  and  alcohol  consumption  have  been  shown  to  be  risk  factors 
for  SAH  only. 
1.2.4.1.  -  SMOKING: 
Smoking  has  been  associated  with  increased  risk  of  IA  formation  and  IA  growth 
in  heterogeneous  series  of  patients  consisting  of  SAH  survivors  with  additional 
unruptured  lAs  and  individuals  with  unruptured  lAs  only  (Juvela  et  al,  2001b). 
Smoking  is  also  a  risk  factor  for  formation  of  multiple  aneurysms,  with  a 
smoking  history  twice  as  likely  in  such  cases  (Qureshi  et  al,  1998;  Ellamushi  et 
al,  2001). 
39 Many  more  studies  have  examined  risk  associated  with  SAH.  Smoking  has  been 
addressed  in  over  20  case-control  and  cohort  studies  alone  and  none  has  yielded 
a  non-significant  association  (Juvela,  2001).  The  association  has  been  confirmed 
in  Finnish,  US,  Australian  and  UK  populations  (Adamson  et  al,  1994;  Teunissen 
et  al,  1996;  Weir  et  al,  1998;  Leppala  et  al,  1999;  Qureshi  et  al,  2001;  Mhurchu 
et  al,  2001;  Pobereskin,  2001;  Kissela  et  al,  2002).  Thus,  smokers  are  up  to  5 
times  more  common  in  SAH  cohorts  compared  with  the  general  population 
(Weir  et  al,  1998;  Qureshi  et  al,  2001);  the  risk  of  SAH  amongst  smokers  is 
increased  between  3  and  9  fold  (Adamson  et  al,  1994;  Teunissen  et  al.  1996; 
Leppala  et  al,  1999;  Qureshi  et  al,  2001;  Kissela  et  al,  2002)  and  smokers,  both 
male  and  female,  suffer  SAH  perhaps  as  much  as  10  years  earlier  than  non- 
smokers  (Weir  et  al,  1998;  Pobereskin,  2001).  The  relationship  is  dose- 
dependent  (Leppala  et  al,  1999;  Juvela,  2001)  and  cessation  reduces  risk. 
However,  any  history  of  smoking  increases  risk  (Teunissen  et  al,  1996;  Qureshi 
et  al,  200  1;  Kissela  et  al,  2002). 
Smoking  may  promote  elastin  degradation  by  inhibition  of  degradation  inhibitors 
such  as  serine  protease  inhibitor  I  which  regulates  extracellular  matrix 
degradation  (Qureshi  et  al,  2001).  Smoking  also  lowers  oestrogen  levels  which 
may  impact  collagen  levels  in  arterial  walls  (Kongable  et  al,  1996). 
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Hypertension  is  considered  neither  sufficient  nor  necessary  for  formation  of  lAs 
(Alberts,  1999).  Indeed,  its  status  as  a  risk  factor  for  IA  fonnation  is  also  in 
doubt.  Smaller  studies  numbering  hundreds  of  individuals  find  no  increased  risk 
of  IA  formation  in  hypertensives  (McCormick  &  Schmalsteig,  1977;  Juvela  et  al, 
2001b).  However,  a  study  in  20,767  individuals  with  unruptured  lAs  found  that 
elderly  unruptured  IA  patients  had  a  slightly  higher  prevalence  of  hypertension 
compared  with  the  control  population  (Taylor  et  al,  1995).  A  UK  study  showed 
that  hypertension  increased  risk  of  multiple  aneurysms  and  that  hypertension 
prevalence  increased  across  groups  having  from  one  to  five  aneurysms 
(Ellamushi  et  al,  2001).  Conversely,  a  similarly  sized  and  designed  US  study 
showed  no  association  (Qureshi  et  al,  1998).  Work  in  animal  models  supports  an 
effect  since  experimental  aneurysm  formation  is  accelerated  if  hypertension  is 
induced  by  renal  artery  ligation  and  salt  administration  (Kondo  et  al,  1997; 
Morimoto  et  al,  2002).  However,  available  evidence  suggest  that  any  increase  in 
IA  risk  from  hypertension  is  small. 
A  history  of  hypertension  is  an  independent  risk  factor  for  SAH  and  indicates  a 
poorer  prognosis  following  SAH  in  both  sporadic  and  familial  cases  (Ronkainen 
et  al,  1999).  First  degree  relatives  of  SAH  patients  are  three  times  more  likely  to 
have  hypertension  than  second  degree  relatives  (Bromberg  et  al,  1996).  There  is 
a  graded  increase  in  risk  with  increase  in  blood  pressure  (Leppala  et  al,  1999). 
Hypertension  and  its  sequelae  are  two  to  threefold  more  common  in  SAH  cohorts 
than  controls  (Teunissen  et  al,  1996,  Kissela  el  al,  2002).  Blood  pressure  spikes, 
41 related  to  normal  circadian  rhythm  and  physical  exertion,  coincide  with  rupture 
of  cerebral  aneurysms  (Kleinpeter  et  al,  1995;  Vermeer  et  al,  1997). 
1.2.4.3:  ALCOHOL  CONSUMPTION: 
Alcohol  consumption  is  not  described  as  a  risk  factor  for  IA  formation 
(Schievink,  1997).  Indeed,  alcohol  has  also  been  reported  to  have  no  significant 
effect  on  risk  of  multiple  aneurysms  (Qureshi  et  al,  1998;  Ellamushi  et  al,  2001) 
although  confounding  of  such  studies  by  smoking  is  always  a  problem. 
With  regard  to  risk  of  SAH,  however,  increased  risk  from  alcohol  consumption  is 
dose-dependent  like  risk  from  smoking  and  hypertension.  Meta-analysis 
estimates  relative  risk  between  2.8  and  4.7  from  longitudinal  studies  and  odds 
ratio  up  to  1.5  for  case-control  studies,  based  on  alcohol  consumption  of  <  150 
g/week  and  ý!  150  g/week  (Teunissen  et  al,  1996).  Kissela  et  al  (Kissela  et  al, 
2002)  reported  that  2  or  more  drinks  per  day  resulted  in  an  SAH  OR  of  8.5  in 
their  US  case-control  study. 
1.2.4.4:  FEMA  LE  SEX.  - 
Female  sex  is  a  prominent  risk  factor  for  both  IA  and  SAH.  Nearly  all  reported 
case  series  show  an  approximate  2:  1  female  to  male  ratio.  This  applies  whether 
ruptured  or  unruptured  lAs  are  considered  (Kongable  et  al,  1996).  Female  sex  is 
also  a  risk  factor  for  multiple  aneurysms  (Qureshi  et  al,  1998;  Ellamushi  et  al, 
42 2001)  independent  of  increased  longevity  (Kongable  et  al,  1996)  and  risk  factors 
such  as  smoking,  hypertension  and  alcohol  (Teunissen  et  al,  1996). 
Hormonal  factors  have  been  investigated  to  explain  this  marked  and  highly 
consistent  sexual  dimorphism  but  the  case  in  favour  is  not  clear-cut.  Most  SAH 
in  women  occurs  post-menopause.  Premenopausal  women  were  reported  to  have 
an  OR  of  0.24  compared  with  age-matched  postmenopausal  women  (Longstreth 
et  al,  1994)  but  other  studies  have  not  found  this  (Mhurchu  et  al,  2001). 
Hormone  replacement  therapy  (HRT)  following  menopause  lowers  SAH  risk  by 
perhaps  a  third  or  a  half  (Longstreth  et  al,  1994;  Mhurchu  et  al,  2001)  although 
this  may  be  dependent  on  smoking  history  (Longstreth  et  al,  1994).  Decreased 
oestrogen  in  the  absence  of  HRT  is  linked  to  decreased  collagen  in  skin  and 
bone;  it  might  be  that  this  also  affects  collagen  levels  in  arterial  walls  (Kongable 
et  al,  1996). 
Other  studies  suggest  oestrogens  are  detrimental  rather  than  protective  based  on 
their  ability  to  stiffen  blood  vessels  and  cause  hypertension  (Okamoto  et  al, 
2001).  Results  from  a  Japanese  case-control  study  suggest  that  conditions 
associated  with  high  oestrogens,  such  as  lower  gravidity  or  parity  and  greater  age 
during  first  pregnancy,  increased  risk  of  SAH  (Okamoto  et  al,  2001).  Contrary 
to  this,  greater  age  at  first  pregnancy  has  also  been  reported  to  lower  risk 
(Mhurchu  et  al,  2001).  A  meta-analysis  concluded  that  use  of  high  oestrogen 
content  oral  contraceptive  pills  (OCPs)  was  associated  with  a  slight  increase  in 
risk  (Johnston  et  al,  1998).  Others  have  not  found  an  effect  (Teunissen  et  al, 
43 1996;  Mhurchu  et  al,  2001)  even  when  oestrogen  dosage  and  duration  of  use  are 
examined  (Schwartz  et  al,  1998). 
1.2.5:  EVIDENCE  FOR  A  GENETIC  COMPONENT  IN  INTRACRANIAL 
ANEURYSM  FORMATION: 
The  nature  of  the  genetic  component  of  familial  intracranial  aneurysm  is,  at 
present,  unknown.  However,  its  existence  is  supported  by  a  number  of  threads  of 
evidence.  Reviewers  often  cite  three:  aggregation  in  families  has  been  discussed. 
Prevalence  in  monozygotic  twins  and  the  association  of  lAs  with  Mendelian 
disorders  are  also  often  noted.  A  fourth,  which  receives  little  attention,  is  the 
evidence  from  animal  studies. 
1.2.5.1.  -  EVIDENCE  FROM  TWIN  CASES: 
A  high  degree  of  phenotypic  concordance  in  monozygotic  twins  is  accepted  as  an 
indicator  of  genetic  predisposition,  particularly  in  the  presence  of  aggregation  in 
other  relatives  (Hrubec  &  Robinette,  1984).  No  large  FIA  twin  studies  have  been 
published  but  a  number  of  individual  cases  have  now  been  described  (Brisman  & 
Abassioun,  1971;  Fairburn,  1973;  Wilson  &  Cast,  1973;  Schon  &  Marshall, 
1984;  Lozano  &  Leblanc,  1987;  Hagen  et  al,  1997;  Nakajima  et  al,  1998;  Sharma 
&  Brown,  2001).  These  are  notable  for  the  similarity  of  age  at  rupture  and  site  of 
IA.  These  features  were  first  described  by  Fairburn,  who  concluded  that  genetic 
factors  should  be  considered  (Fairburn,  1973).  Reports  of  discordant  twin  pairs 
also  exist,  but  authors  suggest  this  may  indicate  reduced  penetrance  or  a  twin 
44 who  will  later  develop  lAs  (Puchner  et  al,  1994;  Astradsson  &  Astrup,  2001). 
The  concordance  in  monozygotic  twins  is  accepted  to  indicate  a  genetic  risk 
factor  (Leblanc,  1997). 
1.2.5.2.  -  EVIDENCE  FROMANIA14L  STUDIES: 
Animals  very  rarely  develop  IAs  and  there  is  a  lack  of  spontaneous  animal 
models  (Dobrin,  1999).  Only  a  single  spontaneous  aneurysm  in  a  Sprague 
Dawley  rat,  with  comparable  histopathology  to  human  aneurysms,  has  been 
reported  (Kim  &  Cervosnavarro,  1991).  Thus,  IA  work  in  animals  relies  on 
intervention  to  induce  aneurysms.  Coutard  and  colleagues  have  attempted  to 
address  this  deficit.  They  reported  age  and  hypertension-dependent  spontaneous 
formation  of  aneurysmal-like  structures  (ALS)  in  the  rat  testicular  artery.  These 
were  regions  of  widened  lumen  lacking  internal  elastic  lamina  and  medial 
smooth  muscle  cells.  They  showed  that  formation  of  ALS  was  strain-dependent 
and  not  entirely  explained  by  blood  pressure  (Coutard  &  OsbornePellegrin,  1992; 
Coutard  &  OsbornePellegrin,  1996).  Later  work  demonstrated  strain  effects  on 
formation  of  induced  aneurysms  in  Brown  Norway  (BN),  Long  Evans  (LE)  and 
Wistar  Kyoto  rats.  The  authors  implicated  a  genetic  predisposition  as  the 
underlying  cause  (Coutard  &  OsbornePellegrin,  1997).  More  recently,  the  same 
group  showed  that,  on  induction  of  hypertension,  LE  rats  were  more  susceptible 
to  lAs  at  the  Circle  of  Willis.  BN  rats  were  prone  to  intracerebral  haemorrhagic 
lesions.  They  crossbred  these  strains  showing  that  FI  animals  did  not  form  lAs. 
However,  FI  rats  backcrossed  to  the  LE  strain  and  rats  of  the  F2  generation 
developed  aneurysms  and  more  ruptured  than  in  the  parental  LE  strain.  The 
45 authors  suggested  that  recessive  genetic  factors  from  the  LE  strain  determined 
formation  of  the  aneurysms,  whilst  arterial  fragility  genes  from  the  BN  strain 
conferred  greater  risk  of  aneurysm  rupture  (Coutard  et  al,  2000). 
1.2.5.3:  EVIDENCE  FROM  MENDELIAN  DISORDERS: 
The  most  widely  discussed  evidence  for  a  genetic  component  in  IA  aetiology  is 
the  association  of  monogenic  connective  tissue  disorders  with  occurrence  of  IA. 
Case  reports  describe  cosegregation  of  lAs  and  several  connective  tissue 
disorders  in  individuals  (Schievink,  1997).  For  most,  there  is  a  shortage  of 
detailed  epidemiological  study.  However,  study  has  been  made  of  autosomal 
dominant  polycystic  kidney  disease,  Marfan  syndrome  and  Ehlers-Danlos 
syndrome  type  IV. 
1.2.5.3.1:  Autosomal  Dominant  Polycystic  Kidney  Disease: 
ADPKD  is  characterised  by  the  development  of  renal  cysts  on  nephrons  and 
collecting  ducts,  typically  leading  to  end-stage  renal  failure  by  late  middle  age 
(Peral  et  al,  1997;  Parnell  et  al,  1998).  It  also  affects  the  liver,  spleen,  pancreas 
and  seminal  vesicles  or  ovaries,  and  features  systemic  arterial  dissections  and 
aneurysms.  Thus,  it  is  considered  a  connective  tissue  disorder  (Schievink,  1997; 
Schievink,  1998).  ADPKD  is  the  only  connective  tissue  disorder  which  has  been 
conclusively  linked  to  lAs,  to  date  (Leblanc,  1997).  Intracranial  aneurysms  are 
found  in  approximately  one  quarter  of  ADPKD  patients  at  autopsy  and 
aneurysmal  rupture  is  the  cause  of  death  in  the  majority  of  these  patients. 
46 Conversely,  ADPKD  accounts  for  only  2%  to  7%  of  intracranial  aneurysms 
(Schievink,  1998). 
The  vast  majority  of  ADPKD  cases,  perhaps  85-90%,  are  due  to  mutations  in  the 
polycystin-I  (PKDI)  gene  on  l6pI3.3  (Parnell  et  al,  1998;  Torra  et  al,  1999). 
Most  remaining  cases  are  due  to  the  PKD2  locus  on  chromosome  4q2l  -q22 
(Torra  et  al,  1999).  Nonsense  and  frameshift  mutations  have  been  described 
throughout  the  PKD  I  (Roelfsema  et  al,  1997)  and  PKD2  genes  (Peral  et  al, 
1997;  Aguiari  et  al,  1999).  PKDI  encodes  polycystin-I  which  is  a  membrane- 
associated  glycoprotein  thought  to  act  as  a  G-protein  coupled  receptor  (Pamell  et 
al,  1998).  The  product  of  PKD2  is  polycystin-2.  It  is  thought  to  be  a  cation 
channel  subunit,  based  on  sequence  homology  with  a  family  of  voltage-gated 
cation  channels  (Parnell  et  al,  1998)  including  the  PCL  gene,  which  is  a  channel 
for  Ca  2+ 
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K+  and  Na+  when  expressed  in  oocytes  (Chen  et  al,  1999). 
Polycystin-I  and  polycystin-2  interact  via  coiled-coil  domains  and  PKDI  may 
regulate  PKD2  function  (Qian  et  al,  1997).  Studies  of  the  C.  elegans 
homologues,  lov-1  andpkd-2,  show  that  they  are  involved  in  the  same  signalling 
events  during  mating  (Barr  &  Sternberg,  1999).  This  implies  interactions 
between  them  but  how  this  leads  to  cyst  and  aneurysm  formation  is  not  clear. 
1.2.5.3.2:  Marfan  syndrome: 
Marfan.  syndrome  is  an  autosomal  dominant  disorder  characterised  by 
abnormalities  of  the  skeleton,  cardiovascular  system,  eye  and  spinal  meninges 
(Schievink,  1997).  Spontaneous  aortic  rupture  and  dissection  are  the  most 
47 common  causes  of  mortality  in  adults  (Schievink,  1997).  Marfan  syndrome  is, 
clinically,  highly  variable  (Pereira  et  al,  1994). 
Marfan  syndrome's  association  with  intracranial  aneurysms  is  a  vigorously 
contested  issue.  More  than  10  case  reports  describe  Marfan  syndrome  patients 
with  lAs  (for  example:  (Higashida  et  al,  1988;  Hainsworth  &  Mendelow,  1991; 
Rose  &  Pretorius,  1991).  Association  has  been  suggested  based  on  lAs  in  two  of 
seven  patients  with  Marfan  syndrome  at  autopsy  (Schievink,  1997).  However, 
no  evidence  of  symptomatic  lAs  was  found  in  135  Dutch  patients  with  Marfan 
syndrome  after  4.5  year  follow-up  (van  den  Berg  et  al,  1996)  and  a  US  review  of 
25  Marfan  autopsies  found  no  evidence  of  associated  lAs  (Conway  et  al,  1999). 
In  addition,  no  cases  of  Marfan  syndrome  were  found  in  case  series  of  826  (van 
den  Berg  et  al,  1996)  and  710  individuals  undergoing  surgery  for  lAs  (Conway  et 
al.  1999). 
Marfan  is  caused,  possibly  exclusively,  by  mutations  in  the  FBNI  gene  on 
chromosome  15q21.1  encoding  the  extracellular  matrix  protein  fibrillin.  Fibrillin 
is  an  integral  component  of  microfibrils  in  both  elastic  and  non-elastic  tissues 
(Alberts,  1999).  Missense  mutations  were  first  described  by  Dietz  et  al  (Dietz  et 
al,  1991)  and  it  is  now  known  that  mutations  tend  to  be  specific  to  one  family 
(Nijbroek  et  al,  1995). 
Site  of  mutation  within  the  FBNI  gene  may  explain  some  of  the  clinical 
heterogeneity  since  a  number  of  studies  have  noted  that  neonatal  and  severe 
cases  arise  from  mutation  of  the  central  domains  of  the  gene  (Kainulainen  et  al, 
48 1994),  (Nijbroek  et  al,  1995).  This  determines  whether  variant  fibrillin-  I  fibres 
incorporate  into  a  microfibril  and  exert  a  dominant-negative  effect.  Until  the 
relationship  between  mutation  and  phenotype  is  fully  understood,  it  will  be 
difficult  to  clarify  the  involvement  of  IAs  in  Marfan  syndrome. 
1.2.5.3.3:  Ehlers-Danlos  Syndrome  type  IV: 
Ehlers-Danlos  Syndrome  type  IV  (EDS  IV)  is  an  autosomal  dominant  connective 
tissue  disorder  characterised  by  the  spontaneous  dissection,  rupture  or  aneurysm 
formation  of  large  and  medium-sized  arteries.  The  association  of  EDS  IV  with 
intracranial  aneurysms  is  controversial.  Case  reports  of  cosegregation  do  exist 
(Dewazieres  et  al,  1995;  DeWitte  et  al,  1997)  although  these  are  rare  (Leblanc  et 
al,  1990).  Carotid-cavernous  fistulae,  derived  from  aneurysms,  are  described  as 
common  complications  of  EDS  IV  by  some  (Schievink  et  al,  1994)  but  should  be 
considered  as  distinct  from  saccular  aneurysms  according  to  others  (Leblanc  et 
al,  1990).  There  appears  to  be  no  debate,  however,  that  EDS  IV  does  result  in 
fragile  cerebral  arteries  (Pope  et  al,  1991).  However,  a  study  in  the  US  of  202 
patients  with  EDS  IV  showed  no  increase  in  IAs  compared  with  the  general 
population  (North  et  al,  1995). 
Ehlers-Danlos  syndrome  type  IV  arises  from  mutations  in  the  COUAI  gene 
encoding  collagen  type  III  which  is  a  structural  protein  widely  distributed  in 
blood  vessels  (Pope  et  al,  1996).  Much  of  the  CODAI  gene  encodes  a  triple 
helix  consisting  of  an  uninterrupted  sequence  of  Gly-X-Y  amino  acid  cassettes. 
'X'  and  'Y'  are  frequently  proline  or  lysine  (Pope  et  al,  1996).  Mutations 
include  point  mutations,  which  alter  Gly  residues,  small  deletions,  mutations 
49 activating  cryptic  splice  sites  and  exon-skipping  mutations  (Chiodo  et  al,  1995; 
Byers,  1995;  Schwarze  et  al,  1997). 
Mutations  disrupting  the  triple  helix  affect  folding  and  secretion  of  the  protein 
(Narcisi  et  al,  1993).  Those  closest  to  the  C  terminal  have  the  greatest  effect 
(Mackay  et  al,  1996)  and  correlation  between  site  of  mutation  and  clinical 
features  has  been  noted.  For  example,  the  region  between  amino  acids  910  and 
1021  is  implicated  in  lethal  arterial  complications  (Pope  et  al,  1996).  It  is  the 
opinion  of  many  that  rarer  type  III  collagen  genetic  mutants  are  associated  with 
cerebrovascular  abnormalities  (Pope  et  al,  1990).  Whether  there  is  a  firm  link  to 
lAs  remains  to  be  answered. 
1.2.6:  ROLE  OF  GENETICS  IN  TREATMENT  OF  INTRACRANIAL 
ANEURYSMS: 
Overall,  detection  and  elective  surgery  of  lAs  is  preferable  to  emergency  surgery 
after  SAH.  Meta-analysis  of  case  series  from  around  the  world  showed  mortality 
of  I%  and  morbidity  of  about  4%  for  elective  surgery  (King  et  al,  1994).  The 
international  ISUIA  study,  considering  the  outcome  of  over  1,400  IA  patients, 
estimated  combined  surgical  morbidity  and  mortality  at  13  to  17%.  However, 
this  still  compares  well  with  50%  and  35%  respectively,  post-SAH  (Gaist  et  al, 
2000).  However,  as  already  stated,  many  lAs  remain  asymptomatic  (Schievink 
et  al,  1994)  and  only  a  minority  rupture.  It  is  important  to  establish  whether 
subgroups  of  high-risk  patients  are  identifiable,  and  what  the  rupture  risk  of  a 
particular  aneurysm  is  (White  &  Wardlaw,  2003).  Identifying  candidates  for 
50 surgery  is  not  trivial,  requiring  expensive  screening  which  itself  may  carry  a  risk 
of  complications.  For  example,  conventional  catheter  angiography  may  be 
complicated  in  1.8%  and  fatal  in  1%  of  cases  (van  Gijn  &  Rinkel,  2001). 
Current  management  guidelines  of  FIA  families  issued  by  the  American  Heart 
Association  Stroke  Council  suggest  screening  on  an  'individual  basis'  (Bederson 
et  al,  2000).  This  essentially  admits  that  no  cohesive  strategy  exists.  Several 
studies  have  attempted  to  model  the  benefits  and  risks  of  screening.  Findings 
have  suggested  that  screening  can  extend  life  expectancy  (Leblanc  et  al,  1994), 
but  is  not  beneficial  in  families  with  less  than  three  affected  individuals 
(Crawley  et  al,  1999).  Modelling  of  various  incidences  and  rupture  rates  led 
Obuchowski  et  al  to  recommend  a  compromise  of  one  screening  at  age  30  or 
younger.  However,  it  was  noted  that  any  screening  protocol  is  ineffective  in 
cases  where  lAs  form  and  rupture  rapidly,  or  form  then  stabilise.  This  will  only 
identify  low  risk  cases  (Obuchowski  et  al,  1995).  Wiebers  et  al  observed  that 
lAs  over  10  mm  ruptured  in  a  series  of  160  IA  patients,  but  the  average  size  at 
rupture  at  their  institution  was  7.5  mm.  They  concluded  that  lAs  form  and 
rupture  at  small  sizes  or  stabilise  depending  on  vessel  wall  elasticity.  If  they 
stabilise,  they  rupture  when  larger  than  10  mm  (Wiebers  et  al,  1987).  The  size 
dependency  of  rupture  has  been  noted  by  others  (Rinkel  et  al,  1998;  Raaymakers 
et  al,  1999;  Wiebers  et  al,  2003). 
Many  authors  recommended  screening  in  families  with  a  strong  history,  based  on 
their  clinical  experience  (Schievink  et  al,  1991;  Alberts  et  al,  1994;  Ronkainen  et 
al.  1994).  Ronkainen  et  al  advocated  a  dynamic  individual  approach  based  on 
ýI the  history  of  the  family,  for  example  screening  at  the  same  age  as  a  patient's 
sibling  or  relative  ruptured  (Ronkainen  et  al,  1996).  However,  retrospective  data 
from  the  ISUIA  study  suggested  that  annual  rupture  rates  of  lAs  are  lower  than 
was  previously  believed;  0.05%  for  lAs  less  than  10  mm  and  0.5%  for  lAs  over 
10  mm.  Risk  of  rupture  was  dependent  on  personal  history  of  SAH,  location  and 
size  of  IA  (Wiebers  et  al,  1998).  The  same  study  recently  published  the  first 
prospective  data  on  lAs  which  supported  the  retrospective  findings  (Wiebers  et 
al,  2003).  Overall,  many  now  argue  that  there  is  a  strong  case  against  screening 
for  IAs  (Kirkpatrick  &  McConnell,  1999;  Crawley  et  al,  1999;  White  et  al, 
1999).  This  is  based  on  low  rupture  rates,  the  fact  that  screening  is  expensive 
and  will  identify  low-risk  lesions,  and  that  risks  of  surgical  intervention  in  such 
low-risk  cases  outweigh  the  reduction  of  rupture  risk. 
One  way  forward  from  this  conundrum  is  to  identify  which  individuals  are  most 
at  risk.  More  information  is  needed  on  the  genetic  basis  and  inheritance  patterns 
of  IA  and  SAH  (White  et  al,  1999).  An  understanding  of  the  genetics  of  FIA 
formation  and  rupture  may  open  the  door  to  cheap  and  simple  testing,  and 
prophylactic  treatment.  This  would  reduce  the  risk  and  expense  of  screening 
and,  importantly,  surgical  intervention.  The  knowledge  might  also  be 
extrapolated  to  sporadic  IA  and  SAH  treatment. 
52 1.3:  STRATEGIES  FOR  THE  DISSECTION  OF  COMPLEX  TRAITS: 
The  challenge  of  dissecting  complex  disorders  is  immense  due  to  small 
individual  gene  effects,  gene-gene  interactions  and  gene-environment 
interactions,  genetic  heterogeneity,  phenocopy  and  incomplete  penetrance 
(Lander  &  Schork,  1994;  Tabor  et  al,  2002).  The  underlying  gene  variants  may 
be  common  -  the  'common  disease,  common  variant'  hypothesis  -  as  seen  for 
the  ApoE4  allele  in  Alzheimer's  disease  and  the  insulin  gene  minisatellite  in  type 
I  diabetes.  Others  argue  a  larger  pool  of  less  common  variants  may  be  more 
likely.  The  truth  may  lie  somewhere  between  these  extremes  (Johnson  &  Todd, 
2000).  Genetic  strategies  evolve  continually  in  the  face  of  this  challenge.  In 
humans,  these  include  study  of  rare  Mendelian  disorders,  genome-wide  scanning 
strategies  and  candidate  gene  approaches  (O'Shaughnessy,  2001).  In  animal 
models,  genome-wide  scans  have  been  confirmed  by  congenic  strain  production 
leading  to  target  genomic  regions  (Stoll  et  al,  1999;  Dominiczak  et  al,  2000). 
Mendelian  disorders  relevant  to  hypertension  and  intracranial  aneurysms  are 
described  in  Sections  1.1  and  1.2.  The  other  strategies  will  now  be  discussed. 
1.3.1:  GENOME-WIDE  SCANS: 
Genome-wide  scans  (GWS)  allow  screening  of  the  entire  genome  in  the  absence 
of  any  a  priori  hypothesis  regarding  location  or  function  of  causative  genes. 
Traditionally,  GWS  studies  have  involved  linkage  analysis  which  detects 
cosegregation  of  a  marker  and  phenotype  in  relatives.  Such  studies  reveal 
regions  of  linkage  which  provide  targets  for  ffirther  detailed  study  (Dominiczak 
53 et  al,  1998).  In  studies  examining  continuous  traits,  these  regions  of  linkage  are 
known  as  quantitative  trait  loci  (QTL).  Linkage  studies  originally  used  single 
restriction  fragment  length  polymorphisms  (RFLPs)  in  Mendelian  diseases 
(Botstein  et  al,  1980).  This  expanded  to  encompass  heterogeneous  disorders. 
then  the  entire  human  genome  (Lander  &  Botstein,  1986),  before  adaptation  to 
experimental  models  (Lander  &  Botstein,  1989).  RFLPs  were  soon  replaced  by 
microsatellite  markers  which  are  more  common  and  more  suitable  to  high 
throughput  systems. 
There  are  now  many  reported  genome-wide  scans  of  complex  traits  (Altmuller  et 
al,  2001)  and  it  is  well  recognised  that  agreement  between  them  is  limited.  Their 
widespread  use  has  resulted  in  great  debate  regarding  interpretation  of  results  and 
issues  of  statistical  significance.  Lander  and  Kruglyak  were  the  first  to  suggest 
guidelines  for  reporting  linkage  (Lander  &  Kruglyak,  1995).  They  set  stringent 
thresholds  of  significance,  dependent  on  study  design.  For  sib  pair  studies,  for 
example,  these  were  logarithm  of  odds  (LOD)  ý!  3.6;  Z  ý!  4.1;  P  :! ý  2xl  0-55 
equating  to  a  corrected  95%  confidence  level.  Others  argued  for  lower 
stringency,  used  a  less  demanding  model  to  reduce  false  negatives,  and  suggested 
P:!  ý  0.0023  as  significant  (Rao  &  Province,  2000).  What  has  become  clear  is  that 
reproduction  in  different  studies  is  key  (Krushkal  et  al,  1999). 
1.3.1.1.  -  GENOME-  WIDE  SCANS  FOR  ESSENTIAL  HYPER  TENSION: 
At  present,  there  are  more  than  25  genome-wide  scan  studies  relating  to  blood 
pressure  (Table  1.3.1).  Most  report  nominal  or  suggestive  linkages  with  only  4 
54 (Levy  et  al,  2000;  Allayee  et  al,  2001;  Kristjansson  et  al,  2002;  Angius  et  al, 
2002)  reaching  the  stringent  genome-wide  significance  levels  of  Lander  and 
Kruglyak  (Lander  &  Kruglyak,  1995).  It  is  notable  that  two  of  these  studies  were 
in  relatively  isolated  populations  (Kristjansson  et  al,  2002;  Angius  et  al,  2002), 
although  Angius  et  al  only  reached  genome-wide  significance  on  increasing 
marker  density  across  a  suggestive  locus.  The  Framingham  study  is  unique  in  its 
use  of  a  longitudinal  blood  pressure  phenotype  (Levy  et  al,  2000). 
The  diversity  of  the  studies  is  emphasised  by  Table  1.3.1.  The  first  reported 
GWS  (Krushkal  et  al,  1999)  analysed  SBP  using  a  discordant  sib  pair  design, 
sampling  individuals  from  the  top  and  bottom  quintiles  of  blood  pressure 
distribution  in  the  US.  Since  then,  studies  in  unselected  sib  pairs,  affected  sib 
pairs,  nuclear  families,  extended  families  and  large  single  pedigrees  have  also 
been  reported.  These  have  been  selected  from  families  ascertained  by  blood 
pressure  alone,  or  with  diabetes  (Hsueh  et  al,  2000),  obesity  (Rice  et  al,  2000),, 
familial  hyperlipidaernia  (Allayee  et  al,  2001),  early-onset  hypertension  (von 
Wowern  et  al,  2003)  or  early-onset  cardiovascular  disease  (Camp  et  al,  2003). 
South  East  Asian,  Northern  European,  Southern  European,  African,  and  Hispanic 
ethnic  groups  are  represented.  Outbred  populations  predominate,  but  isolated 
communities  such  as  the  Old  Order  Amish  (Hsueh  et  al,  2000),  Sardinian 
villagers  (Angius  et  al,  2002)  and  rural  Chinese  individuals  (Gong  et  al,  2003) 
have  been  studied.  Phenotypes  tested  encompass  hypertension  status  and 
quantitative  phenotypes  for  SBP,  postural  SBP,  DBP  and  pulse  pressure  (PP) 
Some  studies  also  examined  effects  of  fitness  training  (Rankinen  et  al,  2001; 
Rice  et  al,  2002). 
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as Wl The  major  QTL  from  each  study  are  shown  in  Figure  1.3.1.  There  is  clearly  no 
single,  major  locus  across  all  populations.  Areas  of  linkage  have  been  found  on 
the  majority  of  human  chromosomes.  This  probably  reflects  genetic 
heterogeneity  of  blood  pressure  control  and  hypertension  (Samani,  2003),  the 
propensity  for  false  positives  in  genome-wide  scans  (Lander  &  Kruglyak,  1995) 
and/or  the  variability  of  study  design  (Munroe  &  Caulfield,  2000). 
Some  QTL  have  been  detected  in  multiple  studies.  Primary  among  these  is  the 
locus  on  2pI  1.2  which  has  been  linked  to  SBP  in  Canadian  whites  (Rice  et  al, 
2000)  and  DBP  in  Mexican  Americans  (Atwood  et  al,  2001)  and  Nigerians 
(Cooper  et  al,  2002).  In  all  three  studies,  linkage  peaked  at  the  same  marker, 
D2s  1790.  Proximal  QTL  on  2p  have  also  been  reported  for  SBP  in  US  blacks 
(Rice  et  al,  2002;  Rao  et  al,  2003)  and  whites  (Krushkal  et  al,  1999),  whilst 
genome  scans  for  preeclampsia,  a  pregnancy-associated  hypertensive  disorder, 
have  reported  linkage  to  2p13  (Amgrimsson  et  al,  1999;  Moses  et  al,  2000). 
Recent  work  has  suggested  the  sodium  bicarbonate  gene,  SLC4A5,  as  a 
positional  candidate  in  the  2p  QTL  following  analysis  of  multiple,  intragenic 
single  nucleotide  polymorphisms  (Barkley  et  al,  2004).  Other  QTL  seen  in 
multiple  independent  studies  also  exist  on  lp,  lq,  3p,  6q,  7q,  8q,  1  lq,  l5q,  18q 
and  19p  (Fig.  1.3.1). 
Some  QTL  have  been  reproduced,  in  independent  samples,  by  the  reporting 
authors  thus  strengthening  the  case  for  their  existence.  Linkage  of  DBP  to  15q25 
was  shown  in  Chinese  siblings  (Xu  et  al,  1999).  Confirmation  was  shown  in  a 
second  independent  cohort  of  low  DBP  siblings,  with  the  LOD  score  increasing 
60 from  2.7  to  3.2  at  the  same  marker,  D15s657.  Increasing  the  marker  density  in 
this  locus  from  an  average  spacing  of  10  cM  to  2  cM  resulted  in  a  LOD  score  of 
3.77  (Xu  et  al,  1999).  Zhu  et  al  (Zhu  et  al,  2001)  also  used  a  fine  mapping 
approach  in  an  independent  sample  of  Han  Chinese.  A  marker  spacing  of  2  cM 
resulted  in  a  multipoint  Z  score  of  3,  confirming  linkage  of  hypertension  to  2q2l. 
The  heterogeneity  of  hypertension  and  blood  pressure  control  is  a  major  hurdle 
for  GWS  studies.  The  lack  of  agreement  between  studies  has  led  some  to 
suggest,  retrospectively,  that  analysis  of  subgroups  may  improve  this.  It  is 
argued  that  a  more  homogeneous  study  sample  may  improve  power,  where 
simply  increasing  numbers  of  subjects  has  failed  (Samani,  2003;  Lalouel,  2003; 
Harrap,  2003).  This  notion  is  strengthened  by  data  from  the  Family  Blood 
Pressure  Program  (FBPP)  meta-analysis  (Province  et  al,  2003).  Analysis  of  over 
6,000  individuals  pooled  from  black,  white,  Hispanic  and  Asian  cohorts  failed  to 
improve  on  LOD  scores  obtained  in  the  individual  groups  (Province  et  al,  2003; 
Lalouel,  2003). 
Some  studies  have  already  attempted  to  address  the  issue  of  heterogeneity  by 
stringent  recruitment  policies.  The  best  example  is  the  BRIGHT  Study  from  the 
UK  which  is  also  the  largest  single  hypertension  GWS  to  date  (Caulfield  et  al. 
2003).  BRIGHT  recruited  phenotypically-extreme  affected  sib  pairs  in  the  top 
5%  of  blood  pressure  distribution  from  the  Caucasian  population.  Thus,  subjects 
had  blood  pressures  over  1501100  mmHg  as  determined  at  a  single  screening.  In 
addition,  age  at  onset  of  hypertension  was  below  60  years.  The  study  aimed  to 
-2 
recruit  individuals  with  BMI  less  than  30  kg  M,  and  was  80%  successful  in  this. 
61 Those  with  high  alcohol  consumption,  diabetes  or  renal  disease  were  excluded. 
This  stringent  recruitment  enriched  the  sample  for  linkage  information  to 
hypertension  loci,  reduced  heterogeneity  and  maximised  power  for  the  2,010  sib 
pairs  analysed.  With  this  rigorous  design  and  large  size,  the  maximum  LOD 
score  obtained  was  3.21  at  6q27  (Caulfield  et  al,  2003). 
1.3.1.2.  -  GENOME-WIDE  SCANS  FOR  FAMILIAL  INTRACRANIAL 
ANEURYSMAND  SUBARACHNOID  HAEMORRHAGE.  - 
There  are  inherent  problems  in  performing  GWS  studies  of  familial  IA  or  SAH 
due  to  the  high  mortality,  difficulties  of  determining  affection  status  and  potential 
for  misclassification.  Thus,  any  GWS  in  FIA  or  SAH  is  a  major  undertaking  and 
must  rely  on  an  affected  patient  strategy.  At  present  two  GWS  have  been 
reported.  Onda  et  al  (Onda  et  al,  2001)  used  a  suitably  focused  strategy  in  an, 
inevitably,  small  study  of  104  Japanese  affected  sib  pairs,  most  of  whom  had 
suffered  IA  ruptures.  Two-point  linkage  highlighted  three  regions  on  5q22,7ql  I 
and  14q22  for  fine  mapping.  Multipoint  analysis  gave  LOD  scores  of  2.24,3.22 
and  2.31  respectively.  Yamada  et  al  aimed,  but  failed,  to  reproduce  the  results  of 
Onda  (Yamada  et  al,  2003).  However,  with  mostly  unruptured  cases  and 
different  markers  this  is  difficult  to  interpret.  A  recent  US  study  showed  linkage 
to  7ql  I  in  13  extended  Utah  families  with  39  IA  cases.  Multipoint  analysis  of 
three  markers  across  the  region  gave  LOD  =  2.34  (Farnham  et  al,  2004). 
Olson  et  al  (Olson  et  al,  2002)  used  48  Finnish  affected  sib  pairs  for  their  GWS. 
They  also  focused  fine  mapping  efforts  by  initial  linkage  analyses.  Of  seven 
62 regions,  which  were  fine  mapped,  the  most  promising  multipoint  LOD  score  of 
2.6  was  obtained  for  chromosome  l9q.  No  QTL  overlay  those  of  the  Japanese 
study.  However,  the  two  studies  were  performed  in  distinct  ethnic  groups  and 
Finnish  IA  cases  may  be  particularly  atypical.  SAH  history  in  the  Finnish 
patients  was  also  disregarded. 
1.3.2:  CANDIDATE  GENE  STUDIES: 
1.3.2.1.  -  EVIDENCE-BASED  CANDIDATE  GENE  SELECTION: 
In  contrast  to  the  genome-wide  approach,  candidate  genes  studies  are  entirely 
based  on  a  priori  hypotheses.  Lack  of  reproducibility  of  candidate  gene  studies 
in  complex  traits  has  led  to  recommendations  for  a  multifaceted  selection 
strategy.  Thus,  type  of  phenotype  and  risk  factors;  heritability;  mode  of 
inheritance;  penetrance;  tissue-specific  expression  studies  and  animal  model 
evidence  may  be  used  when  assessing  the  potential  pathophysiological  role  of  a 
gene  (Tabor  et  al,  2002). 
Useful  leads  can  be  derived  from  many  sources.  Study  of  Mendelian  disease 
suggests  physiological  pathways  involved  in  the  regulation  of  complex  traits 
(Dominiczak  et  al,,  1998).  Study  of  complex  traits  and  intermediate  phenotypes 
increases  knowledge  of  interacting  systems  and  possible  pathophysiological 
processes  (Dominiczak  et  al,  1998).  Genome-wide  scans  implicate  genomic 
regions  and  the  positional  candidate  genes  within  them.  QTL  may  be  large  (Lee 
et  al,  2000),  and  contain  many  genes,  but  narrow  the  field  considerably.  Rodent 
63 QTL  can  be  transferred  to  the  equivalent  'syntenic'  chromosomal  region(s)  in 
humans  -  so-called  'comparative  mapping'  (Gauguier  et  al,  1999;  Stoll  et  al, 
2000).  Candidate  gene  and  biochemical  studies  in  animals,  and  knock-out  or 
knock-in  mouse  models,  implicate  homologous  genes  in  humans  (Dominiczak  et 
al,  1998).  Increasingly,  microarray  technology  is  being  used  to  provide  genome- 
wide  gene  expression  data  (Aitman  et  al,  1999;  McBride  et  al,  2003). 
1.3.2.2.  -  ASSOCIATION,  LlNK,  4GE  DISEQUILIBRIUM  &  HAPLOTYPE  TAGS: 
A  candidate  gene  study  most  often  tests  for  association  of  polymorphic  markers 
with  trait,  although  linkage  analysis  may  also  be  used.  Association  to  a  trait  is 
demonstrated  by  allele-specific  frequency  differences  between  affected  and 
unaffected  samples.  This  is  distinct  from  linkage  which  compares  the  inheritance 
of  a  marker  and  a  trait  amongst  relatives  and  is  not  allele-specific.  Association  is 
strongest  when  the  polymorphism  being  tested  is  the  causative  locus  underlying 
the  trait  (Risch  &  Merikangas,  1996).  Otherwise,  any  marker  tested  is  a 
surrogate  for  the  disease  locus  and  must  be  in  linkage  disequilibrium  (LD)  with 
the  disease  locus. 
LD  is  a  short-range  effect  compared  to  linkage  (Kruglyak,  1999).  It  is  a  non- 
random  association  of  alleles  at  adjacent  loci  (Ardlie  et  al,  2002),  for  example  a 
marker  locus,  M,  and  a  disease  mutation  locus,  D.  LD  is  proportional  to  distance 
between  loci  at  distances  over  60kb;  below  this  the  relationship  is  non-linear 
(Wright  ei  al,  1999;  Drysdale  et  al,  2000).  LD  is  said  to  be  high  if  the  allele  at  M 
predicts  the  allele  at  D.  If  there  is little  or  no  relationship  between  M  and  D,  LD 
64 is  low  (Remm  &  Metspalu,  2002).  LD  is  affected  by  recombination,  the  number 
of  original  founder  mutations,  natural  selection,  population  structure  and  allele 
frequency  (Weiss  &  Clark,  2001;  Zondervan  &  Cardon,  2004). 
Simulations  by  Risch  and  Merikangas  showed  that  the  power  of  association  to 
detect  small  gene  effects  exceeds  that  of  linkage  (Risch  &  Merikangas,  1996). 
Therefore,  association  methods  have  been  applied  to  microsatellite  markers  and, 
more  commonly,  single  nucleotide  polymorphisms  (SNPs)  to  interrogate 
candidate  genes.  SNPs  are  now  more  commonly  used  because  they  are  the  most 
common  genomic  variation  in  species  (Jordan  et  al,  2002;  Gabriel  et  al,  2002), 
may  affect  gene  function  and  are  well  suited  to  high-throughput  genotyping 
(Syvanen,  2001). 
As  a  rule,  SNPs  within  candidate  genes  have  been  studied  as  individual  loci 
(Sharma  &  Jeunemaitre,  2000).  However,  haplotype  tagging  approaches  have 
recently  been  developed  (Johnson  et  al,  2001).  These  make  use  of  the  fact  that 
small  blocks  of  the  genome  appear  to  undergo  relatively  little  recombination,  and 
SNPs  within  these  regions  segregate  into  distinct  haplotypes.  These  'haplotype 
blocks'  of  I  Kb  to  100  Kb  have  been  reported  by  a  number  of  studies  (Daly  et  al, 
2001;  Dawson  et  al,  2002;  Gabriel  et  al,  2002)  and  are  separated  by  'hot  spots' 
of  recombination  (Maniatis  et  al,  2002).  Common  haplotypes  can  be  determined 
by  genotyping  specific  haplotype  tag  SNPs  and  can  allow  interrogation  of 
regions  with  the  minimum  of  genotYPing.  However,  this  requires  prior 
knowledge  of  LD  within  the  local  region  (Johnson  et  al,  2001)  and  detailed 
haplotype  and  LD  map  construction  is  underway  (Gibbs  et  al,  2003).  Such 
65 haplotype  tagging  methods  have  been  used  recently  in  common  disorders  to 
investigate  small  regions  and  specific  candidate  genes  (Drysdale  et  al,  2000; 
Rioux  et  al,  2001;  Gretarsdottir  et  al,  2003). 
1.3.2.3:  CANDIDATE  GENE  STUDIES  FOR  ESSENTIAL  HYPERTENSION 
AND  BLOOD  PRESSURE  PHENOTYPES: 
Many  genes,  to  a  greater  or  lesser  extent,  have  been  investigated  as  hypertension 
candidates.  In  general,  lack  of  reproducible  evidence  means  that  most  are  still 
candidates  but  no  more.  Some  examples  are  discussed  below. 
1.3.2.3.1:  Angiotensinogen: 
Angiotensinogen  (AGT)  is  the  precursor  of  angiotensin  I  and,  ultimately, 
angiotensin  Il  (Ang  II).  Ang  11  regulates  aldosterone  production  by  aldosterone 
synthase  which  determines  sodium  reabsorption  via  ENaC  in  the  distal  tubule 
(Morgan  et  al,  1996)  (See  Fig.  1.1.4).  Jeunemaitre  et  al  (Jeunemaitre  et  al, 
1992b)  demonstrated  linkage  of  a  microsatellite  in  the  3'  region  of  the  AGT  gene 
to  hypertension,  association  of  the  M235T  polymorphism  to  hypertension,  and 
variation  of  circulating  AGT  levels  with  M235T  genotype  in  French  and  US 
sibling  pairs.  Caulfield  et  al  (Caulfield  et  al,  1994)  examined  a  proximal 
dinucleotide  repeat  and  the  intragenic  M235T  and  T174M  polymorphisms  in  63 
white,  European  families.  Linkage  and  association  of  hypertension  to  the 
dinucleotide  repeat,  but  not  the  other  polymorphisms,  was  shown.  Later  work  in 
African  Caribbean  sib  pairs  similarly  showed  linkage  and  association  to  the 
dinucleotide  repeat  only  (Caulfield  et  al,  1995). 
66 Subsequent  studies  of  AGT  polymorphisms  have  found  no  association  with 
hypertension  (Corvol  et  al,  1999),  nor  linkage  to  hypertension  even  in  the 
phenotypically  extreme  resource  of  the  BRIGHT  Study  (Munroe  et  al,  2000). 
However,  meta-analyses  of  the  M235T  polymorphism  across  multiple  ethnicities 
(Staessen  et  al,  1999),  Japanese  studies  (Kato  et  al,  1999)  and  Caucasian  studies 
(Kunz  et  al,  1997)  all  demonstrate  a  weak,  but  significant,  association  of  the  T 
allele  with  hypertension.  It  is  possible  that  the  effect  of  the  AGT  locus  is  more 
pronounced  in  white  and  younger  individuals  (Staessen  et  al,  1999).  The  M235T 
locus  is  in  linkage  disequilibrium  with  a  promoter  substitution,  A(-6)G,  known  to 
enhance  gene  transcription  (Inoue  et  al,  1997).  Elegant  observations  in  mice 
show  that  blood  pressure  increases  as  AGT  gene  copy  number,  and  expression, 
increase  (Kim  et  al,  1995). 
1.3.2.3.2:  Angiotensin  converting  enzyme: 
The  angiotensin  converting  enzyme  (ACE)  locus  has  been  the  target  of  intense 
study.  It  catalyses  the  conversion  of  Ang  I  to  Ang  11  (Morgan  et  al,  1996)  (See 
Fig.  1.1.4),  affects  vascular  reactivity  and  morphology  (Lee  et  al,  2000),  and  is 
the  target  of  ACE  inhibitor  anti-hypertensive  therapy  (Black  et  al,  1997).  Studies 
in  Europeans  initially  suggested  no  linkage  of  the  ACE  locus  to  essential 
hypertension  (Jeunemaitre  et  al,  1992a).  However,  the  Rochester  Family  Heart 
study  later  showed  linkage  (Fomage  et  al,  1998)  and  the  Framingham  study 
showed  linkage  and  association  to  blood  pressure  (O'Donnell  et  al,  1998)  in 
white,  male  US  population  samples.  Framingham  found  that  the  D  allele  of  the 
I/D  polymorphism  in  intron  16  of  the  ACE  gene  increased  hypertension  risk  in 
men  only  (O'Donnell  et  al,  1998).  The  D  allele  also  associated  with  hypertension 
67 in  Japanese  men  (Higaki  et  al,  2000).  These  significant  results  contrast  with  an 
earlier  meta-analysis  of  23  I/D  studies  which  comprised  nearly  7,000  pooled 
subjects  for  hypertension  (Staessen  et  al,  1997)  and  showed  no  association  to  the 
D  allele.  Meta-analysis  of  quantitative  BP  traits  in  over  12,000  individuals  from 
46  studies  also  showed  no  association  (Staessen  et  al,  1997).  The  variability  of 
results  from  studies  of  the  AGT  and  ACE  loci  suggests,  then,  that  any  effect  on 
hypertension  risk  and  blood  pressure  variation  is  probably  small,  and  in  the  case 
of  ACE,  may  be  more  influential  in  men. 
1.3.2.3.3:  Epithelial  sodium  channel  subunits: 
AGT  and  ACE  have  been  studied  ad  infinitum,  but  systematic  assessment  of 
Mendelian  blood  pressure  genes,  for  example  the  epithelial  sodium  channel 
subunits,  is  less  common  (Lifton  et  al,  200  1).  Linkage  analyses  of  P  and  y-ENaC 
subunit  loci,  implicated  by  their  role  in  Liddle  syndrome  (Hansson  et  al,  1995; 
Hansson  et  al,  1995),  have  proved  non-significant  in  Chinese  hypertensive  sib 
pairs  (Niu  et  al,  1999),  but  positive  in  white  Australian  families  (Wong  et  al. 
1999).  A  case-control  study  of  206  hypertensives  and  142  controls  suggested 
association  of  a  T594M  variant  in  the  P-subunit  with  hypertension  in  UK  blacks 
(Baker  et  al,  1998)  who  are  also  more  prone  to  salt-sensitive  hypertension 
(Komitzer  et  al,  1999).  However,  coding  regions  of  the  P  subunit  gene  were 
sequenced  in  whites  and  blacks  but  functional  effects  of  the  seven 
polymorphisms  found  were  small  and  non-significant  in  Xenopus  oocytes.  There 
was  also  no  evidence  of  association  of  a  G589S  variant,  which  had  the  greatest 
effect  on  ENaC  activity,  and  hypertension  in  a  single  large  family  (Persu  et  al, 
1998). 
68 1.3.2.3.4:  Lysine  -deficient  protein  kinase  4: 
Another  direct  consequence  of  findings  in  Mendelian  disorders  is  the  recent 
interest  in  the  role  of  lysine-deficient  protein  kinase  4  (WNK4)  in  essential 
hypertension.  This  follows  its  implication  in  PHA  II  (Wilson  et  al,  2001)  (See 
Section  1.1).  Recently,  a  case-control  study  showed  association  of  hypertension 
with  a  single  SNP  in  intron  10  of  WNK4  in  whites  but  not  blacks  (Erlich  et  al, 
2003).  Linkage  studies  of  the  genomic  region  have  also  been  positive  in  whites 
but  not  blacks  (Julier  et  al,  1997;  Baima  et  al,  1999).  The  primary  finding  of  the 
Framingham  GWS  study  was  a  QTL  for  longitudinal  SBP  on  chromosome 
17q2  1,  the  location  of  WNK4  (Levy  et  al,  2000).  To  complete  the  picture, 
linkage  in  the  stroke-prone  spontaneously  hypertensive  rat  model  to  chromosome 
10  has  also  been  demonstrated  (Jacob  et  al,  1991),  although  recent  sequencing 
and  transcription  studies  of  rat  Wnk4  have  not  supported  its  role  (Monti  et  al, 
2003). 
1.3.2.4:  CANDIDATE  GENE  STUDIES  FOR  FAMILIAL  INTRACRANIAL 
ANE  UR  YSMS  AND  SUBARA  CHNOID  HAEMORRHA  GE.  - 
The  cosegregation  of  lAs  and  connective  tissue  disorders,  and  expression 
profiling  in  IA  patients,  have  concentrated  candidate  gene  studies  on  components 
of  vessel  structure  and  remodelling. 
1.3.2.4.1:  Elastin: 
Elastin  and  its  primary  protease,  elastase,  are  key  to  the  elastic  properties  of  the 
artery.  Reduced  elastin  in  aortic  aneurysms  has  been  reported  (Minion  et  al. 
69 1994).  Aortic  or  intracranial  aneurysms  develop  in  transgenic  mice  with 
compromised  elastin  genes  or  lysyl  oxidase,  the  latter  being  required  for  correct 
elastin  synthesis  (Sechler  et  al,  1995;  Coutard,  1999).  Inhibition  of  elastin 
crosslinking  by  P-aminopropionitrile  leads  to  experimental  IA  formation 
(Yamazoe  et  al,  1990). 
The  Japanese  GWS  by  Onda  et  al  implicated  the  elastin  locus  at  7ql  I  (Onda  et 
al,  2001).  They  followed  this  with  haplotype  analysis  of  SNPs  in  the  gene, 
finding  a  strong  association  of  a  2-locus  haplotype  with  intracranial  aneurysms. 
This  equated  to  an  odds  ratio  of  4.39  for  homozygous  carriers  of  this  haplotype. 
A  European  study  was  unable  to  demonstrate  a  similar  association  in  a  case- 
control  study  using  IA  patients  with  mostly  unknown  family  history  (Hofer  et  al, 
2003).  Further  clarification  of  the  role  of  elastin  in  aneurysm  development  is 
needed  (Zhang  et  al,  2003). 
1.3.2.4.2:  Collagen  type  1  u2: 
The  COLIA2  gene  is  located  on  7q22.1  and  encodes  collagen  type  I  a2,  one  of 
the  most  abundant  structural  proteins  in  vertebrate  connective  tissue. 
Overexpression  in  IA  tissue  has  been  reported  (Peters  et  al,  2001).  On  the 
strength  of  this  and  its  location,  the  COLIA2  gene  was  investigated  by  the 
Japanese  GWS  group  as  a  second  positional  candidate  near  7ql  1  (Yoneyama  et 
al,  2004).  Association  was  seen  to  an  Ala  --+  Pro  polymorphism  in  exon  28  in 
260  cases  and  293  controls.  Functional  studies  suggested  that  this  affected  the 
melting  temperature  of  the  triple  helix.  However,  with  an  8%  frequency  in 
familial  IA  cases  it  may  only  account  for  a  proportion  of  IA  (Yoneyama  et  al, 
70 2004).  Confirmation  of  this  is  needed  but  there  is,  at  present,  no  other  study  for 
IA  and  only  one  in  aortic  aneurysmal  disease  which  showed  no  linkage  to  the 
locus  in  sib  pairs  (van  Vlijmen-van  Keulen  et  al,  2003). 
1.3.2.4.3:  Matrix  metalloproteinases  and  their  inhibitors: 
Matrix  metal  loproteinase  s  (MMPs)  have  wide-ranging  roles  in  protease 
activation,  structural  protein  degradation  and  tissue  remodelling  (Nagase,  1997). 
Their  increased  expression  in  IAs  has  been  shown  in  several  studies  (Chyatte  & 
Lewis,  1997).  Peters  et  al  (Peters  et  al,  1999)  showed  association  of  a 
dinucleotide  repeat  in  the  promoter  of  MMP9  in  a  US  case-control  study. 
Interestingly,  the  polymorphism  affected  gene  expression  in  fibroblasts. 
However,  only  10%  of  cases  had  a  confirmed  family  history  of  IA.  A  Finnish 
study  using  57  familial  cases  (Yoon  et  al,  1999),  and  a  UK  study  with  92  mixed 
cases  (Zhang  et  al,  2001),  were  also  negative.  Promoter  polymorphisms  of 
MMP  1,3  and  12  also  showed  no  association  in  the  latter  study. 
Tissue  inhibitors  of  metalloproteinases  (TIMPs)  regulate  the  activity  of  MMPs 
(Nagase,  1997).  Their  elevated  expression  has  also  been  demonstrated  in  IA 
tissue  (Kim  et  al,  1997).  Krex  et  al  (Krex  et  al,  2003)  studied  TIMPS  1,2  and  3 
in  44  cases  and  controls.  Polymorphisms  were  discovered  by  sequencing  of  the 
coding  and  promoter  regions  of  the  three  genes,  but  there  was  no  association  to 
any  of  the  loci.  This  agreed  with  earlier  work  on  TIMP  I  and  2.  A  SNP  in  each 
gene,  discovered  by  sequencing,  showed  no  association  in  a  small  number  of  IA 
patients,  although  an  nt573  polymorphism  in  TIMP2  was  more  common  in  aortic 
aneurysm  patients  (Wang  et  al.  1999). 
71 1.3.3:  REDUCING  THE  COMPLEXITY:  USE  OF  EXPERIMENTAL 
MODELS: 
Use  of  animal  models  in  complex  disease  genetics  allows  tight  control  of 
environmental  factors,  rapid  breeding  and  large  litters.  Late  onset  disorders, 
taking  decades  in  humans,  present  within  weeks  in  animal  models.  Mating  pairs 
can  be  selected  for  informativeness  and  inbred  strains  simplify  the  genetics  of  the 
experimental  trait  under  investigation  (Dominiczak  et  al,  2000). 
1.3.3.1.  -  RA  T  MODELS  OF  GENETIC  HYPER  TENSION: 
Traditionally,  the  rat  has  been  the  model  of  choice  in  essential  hypertension 
research.  Multiple  inbred  strains  now  exist  which  were  selectively  bred  for 
blood  pressure  phenotypes  (Table  1.3.2).  It  is  important  to  note  that  these 
experimental  strains  develop  a  continuously  distributed,  complex  hypertensive 
trait  under  Oli9O-  or  polygenic  control  (Rapp,  2000). 
1.3.3.1.1:  Genome-wide  scans  in  rat  models  of  hypertension: 
Genome-wide  scans  have  been  widely  published  in  rat  models  (Jacob  et  al,  1991; 
Schork  et  al,  1995;  Clark  et  al,  1996;  Kovacs  et  al,  1997).  The  concept  is  very 
similar  to  that  in  human  populations.  Essentially,  two  inbred  strains  discordant 
for  the  trait  of  interest  are  bred  together  to  generate  an  F1  population  which  is 
then  brother  x  sister  mated  to  produce  an  F2  population.  In  the  case  of  a 
quantitative  trait,  like  blood  pressure,  this  F2  population  will  represent  the  full 
distribution  of  that  trait  between  the  normotensive  and  hypertensive  rat  strains 
72 used  (Lee  et  al,  2000).  Linkage  analysis  of  microsatellites  across  the  genome 
leads  to  the  identification  of  QTL  as  in  the  human  paradigm.  QTL  for  blood 
pressure  phenotypes  of  20-30  cM  (Dominiczak  et  al,  2000)  have  been  reported 
on  the  majority  of  rat  chromosomes  through  use  of  different  inbred  crosses  (Lee 
et  al,  2000)  (Table  1.3.3).  Since  all  rats  of  an  inbred  strain  are,  by  definition, 
genetic  clones,  modelling  of  the  genetic  heterogeneity  inherent  in  human 
populations  is  achieved  by  use  of  various  crosses. 
1.3.3.1.2:  Congenic  rat  strains: 
It  is  once  the  GWS  has  been  completed  and  thus  when  QTL  need  to  be 
confirmed,  and  genes  positionally  cloned,  that  rat  models  come  into  their  own. 
The  effect  of  a  QTL  can  be  directly  proved  by  the  production  of  congenic  strains 
achieved  by  breeding  parental  strains  together  and  then  selectively  back-crossing 
the  offspring  to  one  or  other  of  the  parental  strains.  The  resultant  congenic 
strains  are  homozygous  for  a  specified  chromosomal  segment  from  strain  A  in  a 
genome  otherwise  derived  from  strain  B.  Two  lines  can  be  made,  one  in  which 
the  QTL  from  the  hypertensive  strain  is  introgressed  into  the  normotensive 
background  and  a  reciprocal  strain  in  which  the  converse  is  true.  If  the  QTL  is 
genuine,  BPs  of  these  two  congenic  strains  should  be  higher  than  the 
normotensive  strain  and  lower  than  the  hypertensive  strain,  respectively.  This 
provides  proof-positive  of  the  existence  of  relevant  genes  in  the  QTL  (Rapp, 
2000),  an  option  not  available  in  human  studies. 
By  breeding  of  substrains,  congenic  regions  can  be  narrowed,  ultimately 
allowing  more  precise  positioning  of  causative  genes.  Theoretically,  the 
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-0 Table  1.3.3:  Quantitative  trait  loci  for  blood  pressure  in  rat  genome-wide  scans 
Chr 
2 
3 
4 
5 
10 
13 
16 
17 
18 
19 
20 
x 
y 
WKY  =  Wistar-Kyoto;  SHRSP  =  stroke-prone  spontaneously  hypertensive;  izm  =  Izumo; 
Hd  =  Heidelberg;  gla  =  Glasgow;  Dahl  SS  =  Dahl  salt-sensitive;  Sabra  HR  =  Sabra 
hype  rtens  i  on-res  i  stant;  Sabra  HP  =  Sabra  hypertension-prone,  Lyon-N  =  Lyon  normotensive, 
Lyon-H  =  Lyon  hypertensive;  BN  =  Brown  Norway;  MNS  =  Milan  normotensive: 
RI(BNxSHR)  =  recombinant  inbred  strain  from  BN  x  spontaneously  hypertensive.  N/A 
LOD  score  not  quoted.  Taken  from  Lee  et  al,  2000. 
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Rat  strains 
WKYHdx  SHRSPHd 
Lewis  x  Dahl  SS 
Lewis  x  Dahl  SS 
WKY  x  SHR 
WKY  x  SHR 
Sabra  HR  x  Sabra  HP 
Sabra  FIR  x  Sabra  HP 
WKYgIa 
XSHRSPgIa 
WKY  x  Dahl  SS 
MNS  x  Dahl  SS 
Lyon  Nx  Lyon  H 
BN  x  SHR 
BN  x  SHR 
BN  x  SHR 
WKYgIa  XSHRSPg]a 
WKYi,, 
n  x  SHRSPi,.,, 
RI(BN  x  SHR) 
WKY  x  SHR 
LEW  x  Dahl  SS 
WKY  x  SHR 
WKY  x  SHRSP 
WKY  x  SHRSPHd 
MNS  x  Dahl  SS 
MNS  x  Dahl  SS 
Lyon-N  x  Lyon-H 
WKY  x  SHR 
BN  x  SHR 
Sabra  HR  x  Sabra  HP 
WKY  x  SHRSPHd 
RI(BNxSHR) 
RI(BNxSHR) 
WKY  x  SHRSPHd 
WKY  x  SHR 
Phenotype 
SBP  after  salt 
SBP 
SBP 
SBP,  DBP 
SBP 
SBP  after  salt 
SBP  after  salt 
SBP,  DBP  after  salt 
SBP  after  salt 
SBP  after  salt 
pp 
SBP 
SBP 
SBP 
SBP  after  salt 
SBP 
MAP 
SBP,  DBP,  MAP 
SBP  after  salt 
SBP 
SBP,  DBP  after  salt 
SBP  after  salt 
SBP  after  salt 
SBP  after  salt 
DBP 
SBP,  DBP 
SBP 
SBP  after  salt 
SBP 
SBP 
SBP 
SBP 
SBP 
Central  Marker/  gene  LOD  score 
Sa 
DIMcol,  Cytp450 
Sa 
Sa 
Mtlpa 
DIMit2,  Sa 
DIMitl,  Cytp450 
D2Mit6,  D2Mit  14 
Nakal 
Camk 
Cpb 
Mtlpb 
Gca 
R598 
D3Mghl6 
D3Mghl2 
116 
Npy,  Spr 
Glutb,  Et-2 
Mitrl678,,  Anf,  Bnf 
Ace 
Ace 
Nos2 
Ace 
Ren 
D13Mit2 
R220 
DI  7Mgh5 
Rr  1094 
D19Mit7 
Hsp70 
Per-ha2,  Per-ha7 
N/A 
N/A 
3.5 
2.5 
4.5,3.8 
3.0 
4.9 
4.7 
3.3,3.1 
3.4 
2.6 
7.0 
3.0 
6.3 
3.0 
5.6 
6.2 
N/A 
N/A 
N/A 
4.2 
N/A 
5.1 
6.3 
4.8 
5.6 
5.7 
4.3 
3.4 
3.2 
N/A 
N/A 
N/A 
N/A congenic  strategy  was  thought  to  allow  QTL  mapping  to  aI  cM  segment,  small 
enough  to  allow  sequencing.  In  reality,  it  seems  that  even  greater  resolution  is 
possible  with  the  report  of  a  Dahl  Sx  Dahl  R  congenic  having  an  introgressed 
segment  <  177  kb  in  size  on  chromosome  7  (Garrett  &  Rapp,  2003).  Many  other 
congenic  strains  have  confirmed  QTL  found  by  GWS  on  most  rat  chromosomes 
(St.  Lezin  et  al,  1999;  Jeffs  et  al,  2000;  Frantz  et  al,  2001;  Yagil  et  al,  2003). 
Locus-locus  interactions  have  also  been  demonstrated  by  so-called  'double' 
congenics  having  two  introgressed  regions.  Rapp  et  al  (Rapp  et  al,  1998) 
showed  an  interactive  effect  on  blood  pressure  of  QTL  on  chromosomes  2  and  10 
in  a  Dahl  RxS  cross  by  this  method. 
1.3.3.1.3:  Comparative  mapping:  the  application  of  animal  data  in  humans: 
Observations  in  animal  models  are  only  useful  if  they  can  be  translated  to 
humans.  There  are  limited  examples  of  this,  at  present  (Corvol  et  al,  1999),  but 
the  following  two  examples  demonstrate  the  potential. 
1.3.3.1.3.1.  -  Comparative  mapping  of  a  rat  bloodpressure  QTL  to  human: 
The  rat  chromosome  10  blood  pressure  QTL  has  already  been  mentioned  in  the 
context  of  ACE  and  WNK4  studies.  It  is  also  the  only  example  of  prospective 
mapping  of  a  common  rat  blood  pressure  QTL  to  human.  The  rat  chromosome 
10  QTL  was  first  reported  in  SHRSP  x  WKY  experimental  crosses  (Hilbert  et  al, 
1991;  Jacob  et  al,  1991),  confirmed  in  other  strains  and  proven  by  congenic 
strain  production  (Rapp,  2000).  On  the  strength  of  the  evidence  in  rat,  Julier  et  al 
(Julier  et  al.  1997)  investigated  the  syntenic  region  on  human  chromosome  17 
and  showed  linkage  to  hypertension  in  French  and  UK  sib  pairs.  Baima  et  al 
76 (Baima  et  al,  1999)  offered  some  confirmation  in  a  US  sample.  However. 
studies  of  Afro-Caribbeans  (Knight  et  al,  2000)  and  African  Americans  (Baima 
et  al,  1999)  have  proved  negative  as  have  studies  in  Caucasian  populations 
excluding  diabetics  (Knight  et  al,  2001;  Rutherford  et  al,  2001).  The 
chromosome  17  locus  may,  therefore,  be  relevant  only  in  a  subset  of 
hypertensives  (Knight  et  al,  2003).  However,  the  study  by  Julier  et  al  illustrates 
the  application  of  comparative  mapping  to  complex  disease. 
1.3.3.1.3.2.  -  a-Adducin.  - 
Adducin  is  a  heterodimeric  protein  consisting  of  combinations  of  a,  0  or 
subunits.  It  regulates  cell-signal  transduction  by  changes  in  the  actin  skeleton 
(Cusi  et  al,  1997).  The  membrane  skeleton  was  implicated  in  membrane  Na+ 
transport  differences  in  Milan  hypertensive  (MHS)  and  norynotensive  (NfNS) 
rats.  Adducin  was  identified  as  a  potential  candidate  and  non-synonymous  Tyr 
to  Phe  and  Gln  to  Arg  polymorphisms  were  found  a  and  P  subunits,  respectively 
(Tripodi  et  al,  1991).  These  affected  protein  phosphorylation,  and  genotypes  at 
the  loci  correlated  with  blood  pressure  in  an  NINS  x  MHS  FI  cross,  accounting 
for  43%  of  SBP  difference  between  strains  (Bianchi  et  al,  1994).  The  same 
group  translated  these  findings  to  humans,  with  case-control  evidence  of 
association  of  hypertension  to  markers  around  the  a-adducin  locus  in  Italians 
(Casari  et  al,  1995),  and  confirmation  in  independent  Italian  and  French  samples 
(Tripodi  et  al,  1991).  Study  of  a  Gly460Trp  polymorphism  showed  that  the  Trp 
allele  was  associated  with  hypertension,  greater  sensitivity  to  body  sodium 
levels,  and  greater  response  to  diuretic  treatment  (Cusi  et  al,  1997).  Association 
of  the  Trp  allele  to  hypertension  was  supported  by  the  US  HyperGEN  study  in 
77 whites.  However,  their  findings  in  blacks  suggested  no  effect  of  the  a-adducin 
locus  (Province  et  al,  2000).  Ethnic  differences  may  be  important,  given  other 
negative  case-control  studies  in  Japanese  (Kato  et  al,  1998;  Ishikawa  et  al,  1998; 
Ranade  et  al,  2000)  and  mixed  South  East  Asian  samples  (Ranade  et  al,  2000). 
The  involvement  in  whites  may  also  be  complex  since  studies  of  blood  pressure 
in  white  US  populations  report  no  association  of  Gly460Trp  (Schork  et  al,  2000; 
Bray  et  al,  2000a). 
1.3.3.1.4:  Mouse  models  in  hypertension  research: 
The  ability  to  produce  knock-in  and  knock-out  mouse  genetic  models  has 
enabled  functional  studies  of  genes  in  blood  pressure  regulation.  The  study  of 
Kim  et  al  (Kim  et  al,  1995)  has  already  been  mentioned  in  the  context  of 
angiotensinogen.  This  very  elegant  work  demonstrated  an  almost  linear 
relationship  between  blood  pressure  and  0  to  4  functional  copies  of  the  murine 
"gt  gene  expressing  in  mice.  The  interaction  of  renin  and  angiotensinogen  has 
also  been  demonstrated  in  mice  expressing  the  human  homologues.  Both  human 
AGT  and  REN  were  required  for  an  effect  on  blood  pressure  because  murine 
renin  is  ineffective  against  human  angiotensinogen  (Murakami  &  Fukamizu, 
1999).  Transgenic  approaches  have  proved  informative  in  the  study  of  many 
components  of  blood  pressure  control  including  enzymes,  vasoactive  peptides, 
receptors  and  ion  channels  (Cvetkovic  &  Sigmund,  2000). 
The  genome-wide  approaches  used  in  rat  are  not  as  widespread  in  mouse,  partly 
due  to  difficulties  of  phenotyping  such  small  animals  (Fitzgerald  et  al,  2003). 
However,  at  least  two  GWS  have  now  been  reported  using  F2  crosses  of  different 
78 hypertensive  and  normotensive  mouse  strains  (Wright  et  al,  1999;  Sugiyama  et 
al.  2001).  Both  report  a  number  of  significant  loci  although  none  are  present  in 
both  studies.  However,  the  latter  noted  that,  of  six  QTL,  five  were  concordant 
with  rat  QTL,  and  four  were  concordant  with  human  QTL  (Sugiyama  et  al. 
2001). 
1.3.3.2.  -  EXPERIMENTAL  MODELS  FOR  INTRACRANIAL  ANEURYSMS: 
1.3.3.2.1:  Rat  models: 
The  dearth  of  genetic  rat  models  of  aneurysm  formation  has  been  discussed  in 
Section  1.2.  As  noted,  with  the  exception  of  the  work  by  Coutard  and 
colleagues,  there  has  been  no  genetic  study  of  lAs  in  rats  due,  quite  simply,  to  the 
fact  that  they  do  not  occur  spontaneously  (Coutard  et  al,  2000).  Induction  of 
aneurysms  by  renal  hypertension  and  carotid  ligation  is  common,  and  has  been 
used  to  show,  for  example,  changes  in  vessel  wall  structure  (Kondo  et  al,  1998). 
Aneurysms  have  been  induced  in  animals  by  infusion  of  large  doses  of  elastase 
which  underlines  the  importance  of  the  extracellular  matrix,  and  elastase  itself 
(Miskolczi  et  al,  1998;  Short  et  al,  2001).  However,  these  models  are  intended 
for  evaluation  of  surgical  devices  and  are  not  physiological. 
1.3.3.2.2:  Mouse  models: 
As  with  hypertension,  mouse  models  can  provide  useful  data  on  gene  function. 
Knockout  mice,  which  develop  arterial  aneurysms  and  ruptures,  may  suggest 
candidate  genes  for  IA  formation.  For  example,  expression  of  truncated  rat 
elastin  genes  in  mice  resulted  in  an  emphysematous  phenotype  for  genes  lacking 
79 exon  33,  but  aortic  rupture  in  mice  lacking  exons  19-31  (Sechler  et  al,  1995). 
This  suggests  potential  for  considerable  variety  in  effects  of  elastin  mutations, 
including  haemorrhagic  arteriopathies.  Mice  null  for  the  lysyl  oxidase  gene, 
which  initiates  crosslinking  of  collagen  and  elastin  fibres,  also  develop  aortic 
aneurysms  (Maki  et  al,  2002).  The  Blotchy  mouse,  which  has  a  defective  lysyl 
oxidase  gene,  develops  cerebral  and  peripheral  aneurysms  with  greater  ease  than 
controls  following  carotid  artery  ligation  (Coutard,  1999).  In  mice  it  has  also 
been  shown  that  knockout  of  matrix  metalloproteinase  9  reduces  aortic  aneurysm 
formation  by  elastase  infusion  or  application  of  CaC12  (Pyo  et  al,  2000;  Longo  et 
al,  2002).  Conversely,  disruption  of  TIMP  I  function  increases  aortic  aneurysm 
formation  in  mice  (Silence  et  al,  2002).  As  has  been  described,  genetic  studies  to 
follow  up  such  leads  have  been  performed  in  humans.  Unfortunately,  this  is  the 
only  option  with  the  present  lack  of  genetic  models. 
80 1.4:  AIMS  OF  THE  STUDY: 
The  overall  aim  of  this  work  was  to  apply  current  genetic  thinking  and  strategies 
to  the  dissection  of  two  complex  disorders,  essential  hypertension  and  familial 
intracranial  aneurysm,  in  human  study  samples.  Linkage  and  association 
mapping  methods  were  used  to  accomplish  this,  taking  into  account  current 
opinions  on  best  practice.  There  were  three  specific  aims: 
1.  To  examine  two-point  and  multipoint  linkage  of  a  discrete  region  on  the  distal 
arm  of  chromosome  5  to  blood  pressure  and  essential  hypertension  in  the  Silesian 
Hypertension  Study  resource,  with  confirmation  in  a  Scottish  population  sample 
from  the  MIDSPAN  Family  Study. 
2.  To  follow  up  linkage  evidence  by  studying  cardiovascular  candidate  genes 
within  the  5q  linkage  region.  This  was  achieved  by  linkage  and  association  study 
of  known  functional  polymorphisms  within  the  P2-adrenergic  receptor  gene,  and 
sequencing  and  study  of  polymorphic  loci  in  the  fibroblast  growth  factor  I  gene. 
3.  To  perform  a  pilot  study  of  candidate  genes  of  familial  intracranial  aneurysm, 
concentrating  on  collagen  type  III,  polycystin  I,  fibrillin  I  and  serine  protease 
inhibitor  AI-  Linkage  and  association  analyses  were  applied  to  a  small  sample  of 
Scottish  families.  Studies  of  the  serine  protease  inhibitor  Al  locus  were 
expanded  to  a  combined  group  including  a  small  number  of  families  from  the 
south  of  England. 
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MATERIALS  &  METHODS 
82 2.1:  GENERAL  LABORATORY  PRACTICE: 
The  procedures  detailed  herein  were  conducted  with  appropriate  regard  for 
safety.  Routinely,  lab  coat  and  powder-free  latex  gloves  were  used  as  a 
minimum.  Laboratory  spectacles,  facemasks  and  fume  hoods  (Holliday,  Fielding 
&  Hocking,  UK)  were  used  as  required  when  suggested  by  hazard  labelling  on 
reagents. 
Instrumentation  was  used  following  appropriate  training.  Instruments  were 
maintained  under  contract  and  calibrated,  in  line  with  manufacturer's  guidelines, 
where  necessary.  Software  used  for  collecting  and  processing  data  was  as 
supplied  by  manufacturers  for  the  requisite  instrument  and  application. 
Computing  equipment  was  sourced  from  reputable  manufacturers  and  data 
backed  up  to  appropriate  extemal  storage  media. 
Reagents  were  of  the  highest  quality  available  and  sourced  from  specialist 
suppliers.  Aqueous  solutions  were  made  using  autoclaved,  deionised  water. 
Plasticware  was  disposable  and  either  sterilised  by  irradiation  or  autoclaving. 
Glassware  was  washed  in  Decon  75  detergent,  rinsed  with  distilled  water  and 
dried  in  an  oven  at  37'C.  Manual  liquid  handling  of  volumes  from  0.1-5,000  ýtl 
was  performed  using  calibrated  Finnpipettes  (Life  Sciences  International,  UK) 
and  autoclaved  tips  (Alpha  Labs,  UK).  Automated  liquid  handling  of  5-1,000  ýtl 
volumes  was  performed  by  a  TECAN  Genesis  RSP  500  workstation  JECAN., 
UK)  using  supplied  conductive  tips. 
83 2.2:  STUDY  RECRUITMENT  AND  PHENOTYPING: 
The  work  detailed  in  Chapters  3  to  6  used  DNA  resources  collected  for  three 
separate  studies.  The  studies  described  were  conducted  with  the  approval  of  the 
appropriate  local  ethics  committees.  All  recruitment  to  the  studies  was  with  the 
informed  consent  of  the  participants.  All  data  collected  were  anonymised  before 
being  made  available  to  laboratory  staff. 
2.2.1:  SILESIAN  HYPERTENSION  STUDY: 
The  Silesian  Hypertension  Study  was  based  on  recruitment  of  probands  with 
diagnosed  essential  hypertension  and  their  available  parents  and  siblings. 
Recruitment  strategies  for  the  study  were  designed  by  Dr  Maciej  Tomaszewski, 
clinical  researcher  at  the  Silesian  School  of  Medicine,  Poland.  Participants  were 
recruited  through  probands  attending  hypertension  clinics  in  the  Silesian  region 
of  southern  Poland  by  Drs  Tomaszewski  and  Lacka  during  1999  to  2000.  In 
2001,  Dr  Tomaszewski  received  the  International  Society  of  Hypertension 
Fellowship  based  in  Professor  Dominiczak's  laboratory  at  the  University  of 
Glasgow  in  order  to  learn  genetic  techniques  and  apply  these  to  the  Silesian 
Hypertension  Study.  He  brought  with  him  to  Glasgow  all  DNA  samples.  I  have 
set  up  the  relevant  laboratory  techniques  and  trained  Dr  Tomaszewski  in  all 
relevant  genotyping  methods.  Subsequently,  he  and  I  analysed  all  samples.  This 
involved  638  DNA  samples  tested  for  II  microsatellite  markers  and  6  SNPs  and 
required  several  months  of  set-up  work  and  genotyping  from  both  of  us.  it  is 
routine,  in  our  laboratory,  that  genotyping  of  large  clinical  studies  is  performed 
84 by  several  research  and  technical  personnel  working  together.  The  data  have 
been  analysed  and  written  up  (Tomaszewski  et  al,  2001;  Charchar  et  al,  2002)  as 
a  joint  effort  under  overall  supervision  of  Professor  Dominiczak. 
In  the  Silesian  Hypertension  Study,  hypertension  was  defined  as  systolic  blood 
pressure  greater  than  140  mmHg  and/or  diastolic  blood  pressure  greater  than  90 
mmHg  on  three  separate  occasions  and/or  anti-hypertensive  treatment.  Clinical 
history,  anthropometric  data  and  cardiovascular  phenotypes  were  recorded. 
Subjects  with  secondary  hypertension  were  excluded.  All  other  individuals  with 
essential  hypertension  and  their  relatives  were  included.  Clinical  histories 
indicated  only  two  cases  of  type  11  diabetes  in  parents. 
Height  and  weight  were  measured  under  standard  conditions  to  allow  calculation 
of  body  mass  index  (BMI).  Blood  pressures  were  measured  by  mercury 
sphygmomanometer  with  subjects  seated  and  rested  for  20  minutes.  Systolic 
blood  pressure  (SBP)  was  recorded  at  the  return  of  arterial  sounds  (Korotkoff 
phase  1)  and  diastolic  blood  pressure  (DBP)  at  the  disappearance  of  arterial 
sounds  (Korotkoff  phase  V).  Three  consecutive  readings  were  averaged  for  both 
SBP  and  DBP.  Blood  samples  were  collected  for  DNA  extraction  and  to  provide 
serum  samples  for  freezer  storage.  Biochemistry  and  electrolyte  assays  were  not 
routinely  performed. 
For  subjects  receiving  hypertensive  treatment,  the  recorded  blood  pressures  are 
right-censored  values.  With  such  a  high  percentage  of  treated  hypertensives  in 
the  sample,  a  correction  for  this  was  necessary.  We  employed  a  non-parametric 
85 method  developed  by  the  Framingham  Study  (Levy  et  al,  2000).  Separate 
adjustments  were  conducted  for  men  and  women.  Cubic  regression  models  were 
fitted  to  account  for  age  effects.  Residuals  were  then  sorted  from  highest  to 
lowest  within  age  groups  (<35,35  to  44,45  to  54,55  to  64,65  to  74,  and  75+) 
and  a  correction  applied  within  each  age  group.  For  treated  individuals,  the 
algorithm  used  the  expected  value  of  the  untreated  residual  conditioned  on  the 
distribution  of  other  residuals  of  greater  or  equal  magnitude,  as  the  adjusted 
residual  for  a  treated  measurement.  The  adjusted  residual  equals  the  average  of 
that  individual's  residual  and  all  larger  residuals.  Adjusted  BP  equals  the 
measured  BP  plus  the  difference  between  the  adjusted  residual  and  the  initial 
residual.  This  approach  takes  into  account  an  individual's  position  within  the 
distribution  of  BP  for  his  age/  sex  group.  This  is  perhaps  a  more  individualised 
approach  than  an  adjustment  using  an  estimated  age-specific  treatment  effect 
derived  from  a  regression  on  age  and  treatment.  The  latter  would  result  in  a 
standard  adjustment  for  all  treated  persons.  The  Framingham  approach  tailors 
the  adjustment  to  the  individual  by  using  residuals  from  untreated  individuals  of 
the  same  sex  and  similar  age  to  derive  an  expected  untreated  blood  pressure. 
Thus,  patients  who  have  had  their  blood  pressure  lowered  considerably  by 
intervention  will  be  corrected  upwards  to  a  greater  extent  than  individuals  who 
are  treated  but  still  remain  hypertensive.  It  should  be  noted,  however,  that  all 
such  adjustments  are  inexact  since  the  magnitude  of  response  of  an  individual  to 
a  specific  treatment  regime  is  impossible  to  detennine  using  the  available  data. 
86 2.2.2:  MIDSPAN  FAMILY  STUDY: 
The  MIDSPAN  Family  Study  was  implemented  and  recruited  by  clinical  staff  of 
the  Department  of  General  Practice,  University  of  Glasgow.  Between  1972  and 
1976,  all  residents  aged  45-64  living  in  the  large  burghs  of  Renfrew  and  Paisley 
situated  in  the  west  of  Scotland  were  invited  to  participate.  Those  willing  were 
asked  to  complete  a  questionnaire  and  invited  to  attend  for  screening 
examination  at  clinics  set  up  nearby.  At  screening,  detailed  data  were  collected 
on  seated  blood  pressures  and  other  clinical,  anthropometric  and  socio-economic 
characteristics.  In  1993-1994,  the  offspring  of  the  original  cohort  were  traced 
and  those  aged  30-59  years  were  invited  to  join  the  study.  A  total  of  2,338 
offspring  participated  consisting  of  869  singletons  and  1,469  individuals  derived 
from  608  sibships  ranging  in  size  from  2  to  8  members.  Data  collected  on  the 
offspring  cohort  included  blood  pressures,  history  of  cardiovascular  events  and 
diabetes,  smoking  history  and  details  of  medication.  Blood  samples  were  taken 
for  DNA  extraction  and  measurement  of  serum  levels  of  potassium,  sodium,  urea 
and  creatinine.  Glucose  and  total  cholesterol  were  also  measured  although  most 
subjects  were  not  fasted.  All  data  were  stored  in  a  Microsoft  Access  database. 
2.2.3:  FAMILIAL  INTRACRANIAL  ANEURYSM  PILOT  STUDY: 
Recruitment  of  the  FIA  pilot  study  was  funded  by  the  McFeat  Bequest 
administered  by  North  Glasgow  University  Hospitals  NHS  Trust.  Recruitment 
was  carried  out  during  1998  to  1999  by  a  research  nurse,  Sister  Mairi  McDade,  in 
Glasgow.  The  study  was  originally  conceived  as  an  affected  sib-pair  study,  a 
87 design  since  used  by  genome-wide  scans  of  FIA.  All  families  were  under  the 
care  of  Mr  Ken  Lindsay,  a  neurosurgeon  at  Glasgow's  Southern  General 
Hospital.  Initial  contact  was  made  with  a  proband  by  the  nurse.  Further 
recruitment  within  a  family  was  via  the  proband.  After  6  months  of  recruitment, 
it  was  clear  that  affected  sib-pairs  were  not  easily  available.  I  then  focused 
recruitment  on  obtaining  as  many  affected  relatives  as  possible  and  on 
recruitment  of  parents  of  affected  individuals,  or  unaffected  siblings  if  two 
parents  were  not  available.  Relatives  not  known  to  be  affected  were  recruited 
when  possible.  This  rationale  was  based  on  the  requirements  of  the  increasingly 
popular  transmission-disequilibrium  statistical  approaches  of  the  time  (discussed 
further  in  Chapter  5),  the  classic  approach  for  which  required  clinical  phenotype 
to  be  known  for  an  affected  child  only.  This  was  an  advantage  given  the 
difficulties  of  establishing  a  genuine  unaffected  status  in  individuals  (discussed 
further  in  Chapter  5). 
No  distinction  was  made  between  individuals  with  unruptured  IA  or  those  who 
had  survived  aneurysmal  SAH.  The  scale  of  this  single  centre  study  combined 
with  the  relative  paucity  of  IA/  SAH  patients  did  not  allow  us  the  luxury  of 
studying  subgroups.  For  the  same  reason,  phenotypes  were  not  differentiated  in 
analyses.  Presently,  the  largest  published  studies  of  FIA  genetics  also  face  this 
problem.  For  example,  a  recently  published  genome-wide  scan  in  104  Japanese 
sib-pairs  also  combined  ruptured  with  unruptured  patients  (Onda  et  al,  200  1). 
Autosomal  dominant  polycystic  kidney  disease  (ADPKD)  is  a  rare  disorder 
which  is  firmly  linked  with  occurrence  of  intracranial  aneurysms.  We  therefore 
88 wished  to  exclude  cases  of  ADPKD  from  the  study.  To  this  end,  renal 
ultrasound  (RUS)  can  be  used  to  detect  the  characteristic  renal  cysts.  RUS  was 
offered  to  all  participants  and  accepted  by  58  individuals.  Family  history  and 
individual  serum  creatinine  levels  were  also  examined.  Of  80  study  participants, 
RUS  and  family  history  eliminated  ADPKD  in  58  individuals.  RUS  was  refused 
by  22  individuals  but  family  history  and  serum  creatinine  levels  did  not  indicate 
ADPKD. 
Participating  subjects  visited  the  hospital  where  the  nurse  administered  a 
standard  questionnaire.  This  included  history  of  hypertension,  smoking, 
medication,  personal  and  family  history  of  intracranial  aneurysms  and 
subarachnoid  haemorrhages,  and  angiography.  Blood  pressure  was  measured  in 
a  seated  position  and  blood  samples  for  DNA  extraction  and  blood  chemistry 
assays  were  collected.  Affected  status  was  confirmed  by  reference  to  case  notes. 
Data  were  transcribed  into  a  Microsoft  Access  database.  Transcription  of  the 
data  was  checked  by  a  second  person  to  ensure  accuracy. 
2.3:  DNA  EXTRACTION,  QUANTITATION  AND  DILUTION: 
Extraction  methods  for  obtaining  genomic  DNA  from  whole  blood  varied  by 
study.  Extraction  of  DNA  from  Silesian  blood  samples  was  performed  by 
technical  staff  at  the  Silesian  School  of  Medicine.  Extractions  were  performed 
using  MasterPure  DNA  purification  kits  (Epicentre  Technologies,  US)  following 
the  manufacturer's  protocol. 
89 MIDSPAN  Study  DNA  samples  were  extracted  by  technical  staff  at  the 
University  of  Glasgow  under  the  direction  of  Dr.  Gordon  Inglis  using  a  standard 
phenol-chloroform  method  adapted  from  Miller  et  al  (Miller  et  al,  1988). 
Briefly,  cells  were  lysed  with  buffer  containing  0.32  M  sucrose,  10  mM  Tris,  5 
MM  MgCl2,  and  1%  Triton  X-100,  pH  7.5.  Samples  were  mixed  by  inverting 
and  centrifuged  at  1,500g  for  10  min.  Nuclei  were  lysed  by  suspension  of  pellets 
in  3  ml  of  buffer  containing  10  mM  Tris,  0.4  M  NaCl,  2  mM  EDTA,  pH  8.2. 
Addition  of  0.6%  (v/v)  SDS  and  200  ýtl  of  Proteinase  K  (Sigma,  UK)  was 
followed  by  18  hr  incubation  at  37'C.  I  ml  of  saturated  NaCI  and  5  ml  of 
phenol/chloroform  solution  were  added  followed  by  centrifugation  at  1,200g  for 
10  min.  The  aqueous  layer  was  washed  with  99%  ethanol.  Precipitated  DNA 
was  resuspended  in  400  ýd  of  autoclaved,  deionised  water.  Samples  were  stored 
at  -70'C  until  use. 
Extraction  of  DNA  samples  for  the  FIA  study  was  performed  by  technical  staff  at 
the  University  of  Glasgow  using  Wizard  Genomic  DNA  Purification  kits 
(Promega,  UK).  Extractions  were  performed  using  the  manufacturer's 
recommended  protocol. 
Quantitation  of  all  Silesian  and  MIDSPAN  DNA  was  by  Picogreen  dsDNA 
Quantitation  kit  (Molecular  Probes,  Netherlands).  Genomic  DNA  was  diluted 
1000  fold  by  two  serial  dilutions  of  1:  10  followed  by  1:  100.  The  manufacturer's 
protocol  using  a  high  concentration  standard  curve  was  followed.  Samples  were 
read  in  black  96-well  plates  on  a  Wallac  Victor  2  microplate  reader  (Perkin  Elmerq 
UK). 
90 Quantitation  of  DNA  for  the  FIA  study  was  performed  using  a  Biotech  Ultraspec 
2000  spectrophotometer  (Amersham  Biosciences,  UK).  5  gl  of  genomic  DNA 
was  added  to  995  [tI  of  deionised  water  in  a  quartz  cell  and  mixed.  Absorbance 
at  260  and  280  nm,  and  concentration  in  ng/ýtl,  were  recorded.  The  reading  was 
then  repeated  and  the  results  averaged. 
Following  quantitation,  genomic  DNA  samples  were  diluted  into  deep  well 
plates  (Beckman  Coulter,  UK)  at  the  appropriate  concentration  for  the 
downstream  application.  Water  blanks  and  control  DNA  were  included  on  all 
plates.  Control  DNA  was  obtained  from  Coriell  Cell  Repositories. 
2.4:  MICROSATELLITE  MARKER  GENOTYPING: 
2.4.1:  POLYMERASE  CHAIN  REACTION  AMPLIFICATION: 
Primer  sequences  for  PCR  amplification  of  microsatellite  markers  were  obtained 
from  the  Genome  Database  (GDB,  http:  //gdbwww.  gdb.  org/),  National  Centre  for 
Biotechnology  Information  (NCBI,  http:  //www.  ncbi.  nlm.  nih.  gov/),  Applied 
Biosystems  Linkage  Marker  Set  2  (Applied  Biosystems,  UK)  or  the  literature  as 
specified.  Primer  sequences  are  given  in  Appendix  3. 
Primers  were  manufactured  by  either  MWG  Biotech  or  Applied  Biosystems.  To 
enable  fluorescent  genotyping,  forward  primers  were  synthesised  with  5' 
fluorescent  dyes.  To  improve  electrophoretic  resolution  and  peak  morphology 
91 reverse  primers  were  synthesised  with  a7  base  tail  at  the  5'  end,  the  sequence  of 
which  was  GTTTCTT.  This  has  been  shown  to  improve  peak  morphology  which 
gives  cleaner  data  and  more  accurate  genotyping  (Magnuson  et  al,  1996). 
PCR  was  performed  using  HotStar  Taq  (Qiagen,  UK)  with  25  ng  DNA;  2  ýtl  of 
1  Ox  buffer  with  I 
5MM  M9CI2;  200  mM  of  each  dNTP;  20  pmol  primers  and  0.2 
U  of  enzyme  in  a  total  volume  of  20  ýtl.  Reactions  were  set  up  in  96-well 
microplates  (ABgene,  UK)  and  cycled  on  PCT-225  thermal  cyclers  (MJ 
Research,  US).  A  PCR  program  was  used  which  maximised  addition  of  'plus-A' 
bases  at  the  3'  end  of  amplification  products  to  facilitate  genotyping.  This  was 
as  follows: 
1)  95'C  for  15  min 
2)  94'C  for  I  min 
3)  x'C  for  1  min  where  x=  annealing  temperature 
4)  72'C  for  I  min 
5)  Steps  2-4  repeated  34  times 
6)  60'C  for  30  min 
7)  Cool  to  12'C 
Cycled  PCR  reactions  were  stored  at  -20'C  until  used. 
2.4.2:  MICROSATELLITE  MARKER  GENOTYPING: 
2.4.2.1.  -  AB1377  SEMI-AUTOMATED  DNA  ANALYSER.  - 
Genotyping  of  microsatellites  for  the  Silesian  Study,  the  MIDSPAN  Study  and 
the  FIA  pilot  study  was  performed  on  an  ABI  377  (Applied  Biosystems,  UK). 
The  process  of  genotyping  on  the  ABI  377  is  presented  in  schematic  format  in 
Figure  2.4.1.  Electrophoresis  was  performed  '  through  5%  denaturing 
92 polyacrylamide  gels.  Gels  were  cast  by  hand  using  50  ml  of  Long  Ranger  5% 
acrylamide  gel  solution  (FMC  Bioproducts,  US)  containing  6M  urea,  250  gl  of 
10%  APS  (Amresco,  US)  and  25  ýtl  of  TEMED  (Arnresco,  US).  They  were 
allowed  to  polymerise  for  a  minimum  of  one  hour  and  a  maximum  of  overnight. 
Microsatellite  PCR  products  were  pooled  together  and  combined  with  a  loading 
cocktail  containing  ultrapure  deionised  formamide  (Amresco,  US), 
GS350TAMRA  or  GS350ROX  size  standard  (Applied  Biosystems,  UK)  and 
Dextran-EDTA  loading  buffer  (Applied  Biosystems,  UK).  Samples  were 
denatured  for  2  min  at  95'C  and  resolved  on  the  ABI  377  (AppliedBiosystems, 
UK)  using  the  manufacturer's  recommended  protocol.  On  completion  of 
electrophoresis,  raw  data  were  extracted  with  GeneScan  v3.1  and  genotyped  with 
Genotyper  v2.1  or  v2.5  (Applied  Biosystems,  UK).  All  gentotypes  were  checked 
by  two  individuals  who  were  unaware  of  phenotypes.  Positive  control  DNA  was 
included  on  all  plates  of  samples  to  ensure  consistency  from  run  to  run.  This  was 
obtained  commercially  (Coriell  Cell  Repositories,  US)  and  derived  from  a  stable 
cell  line  from  an  individual  of  the  CEPH  resource. 
For  samples  where  one  or  more  genotypes  were  not  retrieved,  due  to  failure  or 
ambiguity,  the  entire  pool  containing  the  problem  marker  was  re-amplified  by 
PCR  and  re-genotyped.  Potentially  the  greatest  source  of  genotyping  error 
comes  from  the  compilation  of  plates  of  the  various  DNA  samples  to  be  re- 
genotyped.  This  has  to  be  done  manually  and  there  is  potential  for  human  error. 
By  following  the  rigorous  approach  of  re-genotyping  an  entire  pool  of  markers, 
rather  than  just  those  that  were  lacking,  we  were  able  to  monitor  two  t  ings. 
Firstly,  we  could  confirm  that  the  correct  DNA  sample  was  being  re-genotyped  . 
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Fig.  2.4.1:  A  schematic  representation  of  the  microsatellite  marker  genotyping 
process  using  the  ABI  377  semi-automated  DNA  analyser.  Steps  requiring  human 
intervention  are  shown. 
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Fig.  2.4.2:  A  schematic  representation  of  the  microsatellite  marker  genotyping 
process  using  the  ABI  3730  automated  DNA  analyser.  Considerably  less  intervention 
is  required  and  run  times  are  shorter. 
95 by  comparing  genotypes  obtained  in  the  original  run  with  those  in  the  re-run. 
Secondly,  I  was  able  to  estimate  genotyping  error  rates  based  on  disagreement 
between  genotypes  obtained  in  two  or  more  runs.  It  is  likely  that  this  over- 
estimates  error  rates  since,  inevitably,  estimates  tend  to  be  based  on  re-runs  of 
poor  quality  samples  where  genotyping  is  perhaps  more  difficult,  ambiguous  and 
error-Prone.  In  all  cases,  estimates  of  error  rates  were  approximately  0.3-0.5%. 
2.4.2.2.  -  ABI  3  73  0  CAPILLARY  DNA  ANAL  YSER.  - 
Genotyping  of  microsatellites  for  the  Southampton  FIA  samples  was  performed 
on  an  ABI  3730  (Applied  Biosystems,  UK).  This  process  is  shown  in  schematic 
form  in  Figure  2.4.2.  PCR  products  were  pooled  together  and  combined  with  a 
loading  cocktail  containing  fluorescent  size  standard  and  Hi-Di  formamide 
(Applied  Biosystems,  UK).  Samples  were  denatured  for  2  min  at  95'C  and 
resolved  through  POP-7  polymer  on  the  ABI  3730  using  the  manufacturer's 
recommended  microsatellite  fragment  analysis  protocol.  Data  were  genotyped 
using  GeneMapper  0  (Applied  Biosystems,  UK).  Genotypic  data  were  then 
checked  by  a  second  independent  person.  Genotyping  was  blind  to  phenotypic 
status.  Positive  control  DNA  was  included  on  all  plates  of  samples  to  ensure 
consistency  from  run  to  run.  Where  data  from  377  and  3730  runs  were  to  be 
combined,  parity  between  these  data  sets  was  confirmed  by  running  some  DNA 
samples  on  both  platforms.  Genotypes  from  both  instruments  were  compared 
using  an  Excel  spreadsheet  macro  to  ensure  that  binning  was  identical.  Samples 
that  required  re-running  to  obtain  missing  genotypes  were  handled  in  exactly  the 
same  Nvay  as  ABI  377  genotyping.  Error  rates  were  similarly  low. 
96 2.5:  P2-ADRENERGIC  RECEPTOR  GENE  SNP  GENOTYPING: 
2.5.1:  PCR  OF  P2-ADRENERGIC  RECEPTOR  SNPs: 
Three  polymorphisms  within  the  ADRB2  gene  were  chosen  for  genotyping  due 
to  their  reported  functional  significance.  These  were  Argl6GIy,  Gln27GIu  and 
Thr16411e.  Amplification  of  fragments  containing  the  single  nucleotide 
polymorphisms  (SNPs)  of  interest  was  accomplished  by  PCR  with  HotStar  Taq 
(Qiagen,  UK).  Primer  sequences  are  given  in  Appendix  3.  Total  reaction 
volume  was  20  ýtl  and  included:  25  ng  genomic  DNA,  2  [tl  lOx  PCR  buffer 
containing  15  MM  MgC12,200  ýM  each  dNTP,  20  pmol  of  primers  and  0.2  U  of 
enzyme.  Reactions  were  set  up  in  96-well  microplates  (ABgene,  UK)  and  cycled 
on  PCT-225  thermal  cyclers  (MJ  Research,  US).  The  following  program  was 
used: 
1)  95'C  for  15  min 
2)  94'C  for  I  min 
3)  x'C  for  I  min  where  x=  annealing  temperature 
4)  72'C  for  I  min 
5)  Steps  2-4  repeated  34  times 
6)  60'C  for  30  min 
7)  Cool  to  12'C 
Cycled  PCR  reactions  were  stored  at  -20'C  until  used. 
2.5.2:  GENOTYPING  OFP2-ADRENERGIC  RECEPTOR  SNPs: 
Each  of  the  three  polymorphisms  introduces  a  restriction  site  into  the  genomic 
sequence.  Therefore,  genotyping  was  performed  by  restriction  digest  and  gel 
resolution.  The  Arg  I  6Gly  SNP  was  genotyped  by  digestion  of  the  PCR  products 
97 with  2U  of  BsrDI  enzyme  (New  England  Biolabs,  UK)  at  60'C  for  6  hours.  The 
restriction  products  were  resolved  on  3%  Agarose-1000  (Life  Technologies,  UK) 
gel  containing  ethidium  bromide.  Bands  were  visualised  using  a  Fluor-S  Multi- 
Imager  (Biorad  Laboratories,  UK).  Gels  were  scored,  by  eye,  by  two 
individuals. 
The  Gln27GIu  SNP  was  genotyped  by  digestion  of  PCR  products  with  1.5  U  of 
Ital  restriction  enzyme  (Roche,  Switzerland)  at  37'C  for  20  hours.  Digestion 
products  were  resolved  on  2.5%  Agarose-1000  gels  containing  ethidium 
bromide.  Visualisation  was  performed  on  the  Fluor-S  Multi-Imager.  Gels  were 
scored,  by  eye,  by  two  individuals. 
The  PCR  fragments  containing  the  Thr1641le  SNP  were  digested  with  2U  of 
Mn1l  restriction  enzyme  (New  England  Biolabs,  UK)  at  37'C  for  5  hours. 
Resolution  on  2%  Ultra  Pure  agarose  (Life  Technologies,  UK)  gels  containing 
ethidiurn  bromide  was  followed  by  visualisation  on  the  Fluor-S  Multi-Imager. 
Genotypes  were  scored  by  two  individuals. 
Accuracy  of  genotyping  and  reliability  of  the  restriction  digests  were  verified  by 
direct  sequencing  of  15  unrelated  individuals  performed  on  the  ABI  377  using  a 
standard  BigDye  Terminator  protocol  (Applied  Biosystems).  All  genotypes  were 
found  to  agree  with  the  sequence  data. 
98 2-6:  FIBROBLAST  GROWTH  FACTOR  1  SNP  IDENTIFICATION  AND 
GENOTYPING: 
Within  the  FGF  I  gene,  no  known  coding  region  polymorphisms  were  found  in 
the  literature  or  on-line  SNP  databases  such  as  NCBI  (www.  ncbi.  nlm.  nih.  gov) 
and  Ensembl  (www.  ensembl.  org).  To  confirm  the  presence  or  absence  of  coding 
region  polymorphisms,  in  the  Silesian  population,  the  coding  exons,  flanking 
intronic  regions  and  3'  UTR  of  FGF  I  were  amplified  by  PCR  and  sequenced. 
2.6.1:  FIBROBLAST  GROWTH  FACTOR  I  PCR  AMPLIFICATION: 
Twenty  unrelated  individuals  from  the  Silesian  Hypertension  Study  group  were 
selected  for  sequencing.  Our  rationale  was  to  select  a  heterogeneous  group  of 
male  and  female  hypertensives  and  normotensives.  Thus,  of  20  selected,  ten 
individuals  were  hypertensive  and  ten  individuals  were  normotensive.  Within 
these  subgroups,  half  were  male  and  half  female.  Sequencing  of  these  40 
chromosomes  was  expected  to  give  99%  probability  of  detecting  polymorphisms 
with  minor  allele  frequency  of  10%  and  nearly  90%  power  to  detect 
polymorphisms  with  5%  minor  frequency. 
PCR  primers  were  designed  to  flanking  intronic  sequences  to  allow  amplification 
of  exons  and  exon/intron  boundaries.  Primers  for  amplification  of  the  3'  UTR 
were  also  designed.  Sequences  of  these  primers  are  given  in  Appendix  3.  The 
target  genomic  sequence  was  taken  from  the  National  Centre  for  Biotechnology 
Information  (NCBI,  Accession  no:  NT_029289)  and  exon  sequences  were  taken 
99 from  published  cDNA  sequences  from  NCBI  and  the  literature  (Payson  et  al, 
1993).  PCR  was  performed  using  HotStar  Taq  (Qiagen,  UK)  to  amplify  template 
DNA  for  sequencing.  Reaction  volume  was  20  ýtl  and  consisted  of:  2  ýtl  of  I  Ox 
PCR  buffer  containing  15  MM  MgC12,200  mM  of  each  dNTP,  20  pmol  of 
primers,  25  ng  genomic  DNA  and  autoclaved  deionised  water  to  volume. 
Reactions  were  set  up  in  96-well  microplates  (ABgene,  UK)  and  cycled  on  PCT- 
225  thermal  cyclers  (MJ  Research,  US).  The  following  program  was  used: 
1)  95'C  for  15  min 
2)  94'C  for  I  min 
3)  x'C  for  I  min  where  x=  annealing  temperature 
4)  72'C  for  1  min 
5)  Steps  2-4  repeated  34  times 
6)  60'C  for  30  min 
7)  Cool  to  12'C 
Cycled  PCR  reactions  were  stored  at  -20'C  until  used. 
2.6.2:  FIBROBLAST  GROWTH  FACTOR  I  SEQUENCING: 
PCR  products  were  purified  prior  to  sequencing  to  remove  unincorporated 
dNTPs  and  primers.  Nucleofast-96  plates  (Macherey-Nagel,  Germany)  were 
used  which  work  on  the  principal  of  size  exclusion.  PCR  products  are  retained 
but  small  primers  and  dNTPs  pass  through  a  porous  membrane  to  waste.  The 
manufacturer's  protocol  for  centrifuge  filtration  was  followed  with  products 
being  re-suspended  in  50  ýd  of  autoclaved  water. 
Purified  PCR  products  were  sent  to  MWG  Biotech  for  direct  sequencing. 
Forward  sequences  were  obtained  using  the  forward  PCR  primers.  Sequence 
100 data  obtained  were  aligned  to  a  reference  sequence  using  Vector  NTI  v8 
(Informax,  US).  Potential  polymorphic  sites  were  identified  following  alignment 
and  confirmed  by  reference  to  electrophero  grams  from  the  MWG  sequencing 
runs. 
2.6.3:  FIBROBLAST  GROWTH  FACTOR  I  SNP  GENOTYPING: 
Genotyping  of  polymorphisms  within  the  FGFI  gene  was  done  by  the  MRC 
Gene  Service  (Cambridge,  UK).  Genomic  DNA  at  5  ng/ýtl  was  provided.  PCR 
primers  were  identical  to  those  used  during  sequencing  of  the  FGF  I  gene. 
Genotyping  was  performed  on  an  ABI  7900HT  (TaqMan)  instrument  platform 
(Applied  Biosystems,  UK).  Allelic  recognition  probes  were  labelled  with  the 
fluorescent  dyes  VIC  or  FAM.  Their  sequences  are  provided  in  Appendix  3. 
2.7:  STATISTICAL  ANALYSES: 
All  genotypic  data  were  checked  with  PEDCHECK  (O'Connell  &  Weeks,  1998) 
to  detect  genotyping  errors  and  misspecification  of  relationships.  Inconsistencies 
were  corrected,  if  possible,  or  individuals  were  removed  from  the  dataset. 
2.7.1:  LINKAGE  ANALYSES: 
Linkage  analyses  were  conducted  on  genotype  data  derived  from  the  Silesian  and 
MIDSPAN  study  groups.  All  genotyped  samples,  which  were  passed  by 
PEDCHECK,  were  included  in  analyses.  Whilst  this,  potentially,  leads  to 
101 analysis  of  a  more  heterogeneous  sample,  neither  resource  was  large  enough  to 
sensibly  address  hypertensive  subgroups.  Different  statistical  approaches  were 
used  in  each  study  sample  owing  to  the  differing  ascertainment  criteria  and 
family  structures. 
Multiple  methods  were  employed  for  analysis  of  the  Silesian  data  as  consistency 
between  different  methods  provides  confidence  in  the  result.  Haseman-Elston 
(H-E)  regression  as  implemented  in  SIBPAIR  was  used  for  identity  by  descent 
(IBD)  two-point  linkage  analyses  of  hypertension  status  and  systolic  and 
diastolic  blood  pressures  (Duffy,  1999).  The  merit  of  this  test  lies  in  its 
applicability  to  both  quantitative  and  qualitative  traits.  Analysis  of  both  is 
preferable  to  give  confidence  in  results  and  allows  direct  comparison  of  them. 
The  H-E  non-parametric  method  regresses  a  function  of  squared  trait  sums  and 
differences  between  siblings  on  the  proportion  of  alleles  identical  by  descent. 
The  test  essentially  determines  whether  siblings,  who  are  phenotypically  alike, 
are  also  more  genotypically  alike  than  would  be  expected  at  a  given  locus.  The 
identity-by-de  scent  of  siblings  reflects  the  sharing  of  0,1  or  2  alleles  which 
derive  from  a  common  ancestral  chromosome.  IBD  was  estimated  within  SIB- 
PAIR  based  on  sib  pair  and  parental  genotypes.  Parental  genotypes  were  not 
available  in  30%  of  families  and  in  these  cases  IBD  was  estimated  using  the  sum 
of  sharing  for  each  possible  set  of  parental  genotypes  weighted  by  their 
likelihood  based  on  all  children  in  the  sibship.  Allele  frequencies  were 
calculated  within  SIB-PAIR  using  founders  of  pedigrees. 
102 SPLINK  vl.  08  was  used  to  run  a  second  confirmatory  IBD  two-point  analysis  of 
hypertension  status  (Clayton,  2000).  This  is  an  affected  sib  pair  analysis  which 
uses  a  maxmimum  likelihood  approach  to  estimate  the  probability  that  two 
affected  sibs  share  0,1  or  2  autosomal  marker  alleles  IBD.  Allele  frequencies 
are  also  estimated  by  a  maximum  likelihood  method  for  use  in  IBD  estimation  in 
absence  of  informative  parental  genotypes.  SPUNK  has  the  advantage  that  it 
does  not  use  the  unaffected  siblings  other  than  to  assist  IBD  estimation.  Given 
that  some  of  the  normotensive  siblings  may,  later,  develop  hypertension,  and 
therefore  are  misclassified,  an  affected  sib  pair  analysis  provides  useful 
confirmation  in  a  sample  with  unambiguous  disease  status. 
A  two-point  X2  identity  by  state  (IBS)  affected  sibpair  method  in  SIB-PAIR  was 
also  used  to  test  linkage  to  hypertension  as  confirmation  of  the  H-E  results. 
Whilst  of  lower  power  than  IBD  analyses,  the  IBS  approach  does  not  rely  on 
estimation  of  IBD  and  therefore  circumvents  any  bias  arising  from  such 
estimation.  Identity-by-  state  is  determined  by  the  number  of  alleles  shared, 
regardless  of  their  ancestral  origin.  Observed  IBS  statistics  are  compared,  by  y,  2 
test,  with  expected  IBS  which  are  derived  from  allele  frequencies  in  the  whole 
sample.  Missing  parental  genotypes  have  no  effect  on  the  test. 
MAPMAKER/SIBS  was  used  for  non-parametric  multipoint  analyses  of 
quantitative  traits  since  these  are  expected  to  be  more  informative  than  analysis 
of  arbitrarily  defined  qualitative  traits  such  as  hypertension.  For  this  reason, 
multipoint  SPLINK  analysis  was  not  performed.  MAPMAKERJSIBS  calculates 
the  ftill  IBD  probability  distribution  by  a  maximum  likelihood  method.  The  non- 
103 parametric  test  ranks  sib  pairs  by  their  absolute  value  of  phenotypic  difference. 
For  each  location  across  the  region  under  investigation,  a  statistic  is  defined  to 
relate  the  rank  to  number  of  alleles  shared  IBD  and  thus  linkage  may  be 
demonstrated  or  refuted.  Of  the  available  tests  in  MAPMAKER/SIBS,  the  non- 
parametric  option  was  preferred  since  it  may  be  more  powerful  than  other 
available  options  such  as  multipoint  Haseman-Elston.  It  also  makes  no 
assumptions  about  distribution  of  phenotypic  noise  and  therefore  provides  a 
robust  confirmation  of  two-point  results  (Kruglyak  and  Lander,  1995).  Allele 
frequencies  for  use  in  the  multipoint  analysis  were  taken  from  SIB-PAIR  which 
calculates  frequencies  based  on  founders  of  pedigrees  only. 
Both  two-point  and  multipoint  analyses  in  the  MIDSPAN  Study  used  the 
variance  components  methodology  of  SOLAR  (Almasy  &  Blangero,  1998). 
SOLAR  was  selected  following  the  example  of  other  studies  in  population 
samples,  for  example  the  Framingham  Study  genome-wide  scan  (Levy  et  al, 
2000).  Unlike  the  Silesian  Study  sample,  which  consists  of  small  family  units  of 
consistent  size,  the  MIDSPAN  sample  contains  sibships  ranging  between  2  and  8 
individuals.  An  advantage  of  the  variance  components  approach  is  that  it  treats 
each  family  as  a  unit,  explicitly  allowing  for  non-  independence  among  sibs.  This 
pedigree  approach  is  more  powerful  and  less  liable  to  type  I  error,  when  using 
larger  sibships,  than  are  statistics  based  on  pairs  of  relatives  (Levy  et  al,  2000; 
Marlow,  2002).  This  made  SOLAR  a  more  appropriate  choice  than  the  sib-pair 
approach  of  MAPMAKER/SIBS.  Variance  components  methods  assume 
normally  distributed  phenotypes  and  so  logIO-based  transformations  of  SBP. 
DBP  and  MAP,  and  the  BMI  covariate,  were  perfonned.  Nonnal  distribution 
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Inc.  ).  In  the  absence  of  parents  in  the  MIDSPAN  sample,  IBD  was  calculated  by 
SOLAR  using  a  maximum  likelihood  method.  This  was  based  on  allele 
frequencies  which  were  also  calculated  internally  by  the  program,  again  using 
maximum  likelihood.  To  improve  these  estimates,  singletons  from  the 
MIDSPAN  sample  were  genotyped  and  included  in  the  input.  Two-point 
analysis  was  also  repeated  with  all  treated  individuals  omitted  from  the  data  set 
to  ensure  that  inclusion  of  treated  blood  pressures  did  not  adversely  skew  the 
analysis.  The  correction  used  in  the  Silesian  sample  was  not  applied  as  this,  of 
course,  cannot  accurately  derive  untreated  BP.  Since  the  percentage  of  treated 
individuals  in  the  MIDSPAN  sample  was  so  small,  exclusion  of  these  was  more 
appropriate,  rather  than  replacing  treated  blood  pressures  with  estimates. 
2.7.2:  BLOOD  PRESSURE  CANDIDATE  GENE  ANALYSES: 
2.7.2.1.  -  fl2-ADRENERGIC  RECEPTOR  ANALYSES: 
Analysis  of  the  ADRB2  SNPs  was  conducted  in  line  with  analyses  by  Bray  et  al, 
whose  study  provided  the  initial  motivation  to  examine  the  chromosome  5q 
region  and  the  ADRB2  gene  (Bray  et  al,  2000).  They  used  TDT  analysis  in  their 
families,  and  logistic  regression  in  the  parental  generation  of  their  sample.  We 
therefore  did  likewise  to  make  our  findings  as  comparable  as  possible. 
Transmission  disequilibrium  testing  (TDT)  was  employed  to  test  for  linkage  in 
the  presence  of  association  (Spielman  et  al,  1993)  using  two  parent-one  child 
105 trios.  TDT  detects  preferential  transmission  of  an  allele  (greater  than  50%)  from 
parents  to  affected  offspring  compared  with  untransmitted  alleles  which 
effectively  provide  the  control  genotype.  Thus,  TDT  examines  both  linkage  and 
association  at  once.  At  least  one  heterozygous  parent  is  required  for  a  family  trio 
to  be  informative.  TDT  and  similar  family-based  tests  were  devised  to  avoid  the 
problem  of  population  stratification  which  may  give  false  positive  results  in  case- 
control  association  studies. 
The  results  of  TDT  were  confirmed  by  the  empirical  variance  family-based 
association  test  (EV-FBAT),  a  method  which  was  unavailable  to  Bray  et  al.  EV- 
FBAT  tests  the  null  hypothesis  that  linkage  is  present  but  there  is  no  association 
(Lake  et  al,  2000).  This  was  appropriate  because  we  were  testing  SNPs  within  a 
region  already  showing  evidence  of  linkage  to  the  trait.  Unlike  TDT,  EV-FBAT 
does  not  require  parental  genotypes  as  it  is  not  based  on  treating  non-transmitted 
alleles  as  controls.  Rather,  the  distribution  of  offspring  genotypes  is  important 
and  this  can  be  calculated  from  genotypic  data  for  all  offspring  within  the  family, 
in  the  absence  of  parents.  Thus,  it  does  not  suffer  from  the  costly  reduction  in 
sample  size  caused  by  missing  parental  data  that  is  inherent  with  approaches  that 
condition  on  sibling  IBD  patterns.  EV-FBAT  determines  the  expected  value  of 
an  association  test  statistic  by  conditioning  on  the  minimal  sufficient  statistic 
under  the  null  hypothesis  and  uses  an  empirical  variance-covariance  estimator 
which  is  unaffected  by  correlation  of  sibling  genotypes.  At  the  time  of  the 
ADR132  analyses,  EV-FBAT  was  a  relatively  unknown  method,  and  we  therefore 
preferred  the  widely  reported  and  validated  TDT  method  as  a  primary  approach, 
as  used  by  Bray  et  al.  However,  in  its  favour  EV-FBAT  allowed  us  to  make 
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was  designed  to  handle  more  complex  families,  and  decomposes  such  families 
into  nuclear  units  for  analysis.  TDT,  however,  is  completely  restricted  in  its  use 
of  trios  and  makes  no  use  of  genotyping  in  extra  siblings. 
In  concordance  with  Bray  et  al,  binary  logistic  regression  analysis  was  performed 
in  the  parental  generation  to  test  for  increased  risk  of  hypertension  associated 
with  each  tested  genetic  variant  of  ADRB2.  Correction  was  made  for  age,  sex 
and  body  mass  index.  Finally,  SNP  haplotypes  were  assessed  using  a  modified 
TDT  method  implemented  in  TRANSMIT.  This  is  a  likelihood  method  which 
allows  for  missing  parental  data  and  haplotype  phase  uncertainty  and  uses 
genotype  data  from  available  parents  and  offspring  to  efficiently  determine 
phase.  A  score  vector  is  generated  which  is  averaged  for  all  possible 
configurations  of  haplotypes  and  transmissions  from  parents  to  offspring 
consistent  with  the  observed  data.  Additional  offspring  who  are  of  unaffected  or 
unknown  status  are  used  to  narrow  the  options  for  parental  haplotypes.  The 
method  is  robust  against  population  stratification.  Again,  this  was  a 
methodology  not  available  to  Bray  et  al,  but  haplotype  analyses  are  expected  to 
be  more  informative  than  single  locus  anlyses.  This  is  particularly  true  where  the 
combined  effect  of  functional  loci  can  be  considered  rather  than  examining  each 
without  regard  to  positive  or  negative  influences  from  others.  We  felt  this  would 
be  a  more  categorical  analysis  to  confirin  or  refute  the  previous  findings  of 
ADRB2  studies. 
107 2.7.2.2.  -  FIBROBLAST  GROWTHFACTOR  I  ANALYSES: 
Analysis  of  FGF  I  SNPs  was  conducted  using  EV-FBAT  (Lake  et  al,  2000)  and 
the  recent  extension  of  this  methodology,  Haplotype  FBAT.  TDT  was  not  used 
for  FGF  I  analyses  since,  by  this  point,  EV-FBAT  was  more  widely  reported  and 
considered  reliable.  EV-FBAT  was  felt  to  be  a  more  useful  analysis  since  it  is 
appropriate  for  both  qualitative  and  quantitiative  traits,  unlike  classical  TDT-  In 
addition,  as  explained  above,  it  extracts  all  possible  information  from  complex 
families  regardless  of  missing  parents  and  multiple  offspring.  This  was  more 
appropriate  for  a  study  group  that  contained  genotypes  in  additional  siblings.  As 
stated,  classical  TDT  is  totally  restricted  to  trios  and  dichotomous  traits.  At  the 
time  of  the  ADRB2  analyses,  Haplotype-FBAT  had  not  been  developed. 
However,  its  availability  for  analysis  of  FGFI  allowed  consistency  between  the 
single  locus  and  haplotype  analyses  of  this  gene  and  made  it  the  preferred 
approach  rather  than  TRANSMIT.  It  allowed  analysis  of  the  three  locus 
haplotype  across  all  SNPs  gemotyped  in  FGFL  This  is  discussed  further  in 
Chapter  4. 
2.7.3:  FAMILIAL  INTRACRANIAL  ANEURYSM  CANDIDATE  GENE 
ANALYSES: 
The  variable  structure  of  the  families  recruited  to  the  FIA  pilot  study  and 
difficulties  of  defining  individuals  as  unaffected  meant  that  no  single  analysis 
method  used  the  study  sample  to  its  full  extent.  I  therefore  applied  multiple 
methods  in  an  effort  to  detect  linkage  and/or  association,  with  the  aim  of  using  as 
108 many  of  the  families  as  possible.  Given  the  small  size  of  the  study,  my  primary 
aim  of  analysis  was  to  identify  trends  across  different  analytical  methods. 
IBS  linkage  between  disease  status  and  markers  was  assessed  by  the  Affected 
Pedigree  Member  (APM)  method  (Weeks  &  Lange,  1988).  IBS  methods  test  for 
sharing  of  alleles  between  relatives.  However,  this  is  done  in  such  a  way  as  to 
disregard  whether  these  shared  alleles  originated  from  the  same  ancestral 
chromosome.  This  makes  IBS  methods  less  powerful  than  IBD  methods  which 
are  based  on  estimation  of  allele  sharing  where  such  alleles  are  derived  from  the 
same  founder  chromosome.  Not  all  parents  were  available  in  families  suitable 
for  the  affected  pedigree  member  analysis.  In  the  absence  of  parents,  IBD 
statistics  are  estimated  by  a  likelihood  approach.  However,  the  very  small 
number  of  individuals  suitable  for  the  APM  analysis  would  have  made  such 
estimates  highly  speculative  and  unreliable.  The  more  simplistic  IBS  approach  is 
therefore  more  appropriate,  although  a  larger  study  would  have  benefited  from 
IBD  analysis. 
Linkage  and  association  were  assessed  using  the  combined  Transmission 
Disequilibrium  Test  JDT)  (Spielman  et  al,  1993)  and  sibling  TDT  (S-TDT) 
(Spielman  &  Ewens,  1998)  which  was  described  in  Section  2.7.2.1.  Tests  of 
association  and  linkage  within  extended  families  were  done  with  FBAT  and  EV- 
FBAT  (Horvath  et  al,  2001).  FBAT  tests  the  null  hypothesis  of  no  linkage  and 
no  association.  It  is  also  based  on  calculation  of  the  expected  value  of  an 
association  test  statistic  conditioned  on  the  minimal  sufficient  statistic,  and  again 
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siblings.  EV-FBAT  was  previously  described  in  Section  2.7.2.1. 
A  case-control  paradigm  was  also  used.  The  existence  of  Hardy-Weinberg 
equilibrium  in  controls  was  first  confirmed  by  Fisher's  exact  test  using  GDA 
vl.  O  (Lewis,  P.  0.,  and  Zaykin,  D.  2001;  http:  //lewis.  eeb.  uconn.  edu/lewishome 
/software.  html).  Frequencies  of  genotype  in  case  and  control  groups  were 
compared  by  an  exact  X2  test  using  STATXACT-TURBO  v2.1  (Cytel  Software 
Corporation,  USA).  Genotype  frequencies  were  compared  since  they  do  not 
make  the  assumption  of  an  additive  affect,  which  underlies  the  commonly  used 
comparison  of  allele  frequencies. 
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LINKAGE  OF  BLOOD  PRESSURE  AND  HYPERTENSION  TO 
HUMAN  CHROMOSOME  5q3l.  l-q33  IN  TWO  POPULATIONS 3-1:  INTRODUCTION: 
Essential  hypertension  is  an  important  risk  factor  for  cardiovascular  disease 
(Lifton  et  al,  2001).  It  is  a  multifactorial,  complex  polygenic  or  oligogenic  trait 
and,  as  such,  has  seen  the  application  of  various  complementary  genetic 
strategies  to  clarify  the  underlying  genes.  Work  has  been  conducted  along  three 
lines.  Firstly,  study  of  Mendelian  hypertensive  diseases  has  resulted  in 
elucidation  of  a  number  of  disorders,  such  as  Liddle  syndrome  (Shimkets  et  al, 
1994),  glucocorticoid-remediable  aldosteronism  (GRA)  (Lifton  et  al,  1992a)  and 
syndrome  of  apparent  mineralocorticoid  excess  (AME)  (Mune  et  al,  1995).  Such 
advances  have  clarified  the  role  of  various  pathways  in  blood  pressure  regulation 
but  not  contributed  greatly  to  the  public  health  impact  of  hypertensive  disease. 
Secondly,  genome-wide  scan  (GWS)  linkage  approaches  have  implicated 
quantitative  trait  loci  (QTL)  in  essential  hypertension,  but  have  not  definitively 
implicated  a  common  QTL  or,  therefore,  causative  genes  (Samani,  2003). 
Thirdly,  candidate  gene  approaches  have  been  used  to  examine  genes  implicated 
by  Mendelian  disorders,  genes  in  QTL  and  other  plausible  biological  candidate 
genes.  Whilst  a  potentially  powerful  approach,  results  have  been  conflicting  and, 
as  such,  difficult  to  interpret  (Risch,  2000;  Tabor  et  al,  2002). 
A  targeted  chromosomal  region  approach  to  complex  genetics,  essentially 
amalgamating  the  genome-wide  and  candidate  gene  rationales,  has  also  been 
postulated  (Krushkal  et  al,  1998).  A  small  chromosomal  region,  selection  of 
which  is  based  on  genome-wide  evidence  and  the  presence  of  suitable 
112 physiological  candidate  genes,  allows  denser  saturation  with  markers  and 
evidence  of  linkage  can  be  followed  by  positional  analysis.  The  5q3  I  -qter  region 
of  human  chromosome  5  is  an  excellent  target  region  for  such  a  study.  A  number 
of  genes,  known  to  be  important  regulators  of  blood  pressure  or  implicated  in 
cardiovascular  phenotypes,  cluster  here  (Fig.  3.1.1).  These  include  the  P2-  and 
(XIB-adrenergic  receptors;  the  dopamine  receptor  type  I  A;  glucocorticoid  receptor 
and  glutathione  peroxidase.  Owing  to  the  presence  of  such  genes,  the  5q3  I  -qter 
region  has  been  focused  on  before. 
Evidence  of  linkage  in  the  5q3  I  -qter  region  to  systolic  blood  pressure  (SBP)  was 
reported  in  young,  discordant  US  sib  pairs  (Krushkal  et  al,  1998).  Multipoint 
linkage  was  maximal  at  172  cM  from  the  pter,  following  genotyping  of  8 
microsatellite  markers  across  the  region  at  an  average  density  of  4.5  cM. 
Transmission  disequilibrium  testing  (TDT)  also  showed  greatest  linkage  and 
association  at  this  locus.  Maximal  linkage  at  this  same  marker  was  later  reported 
in  a  genome-wide  scan  of  the  same  sibships  using  a  10  cM  marker  set  (Krushkal 
et  al.  1999).  More  recent  genome-wide  scans  have  also  reported  multipoint 
linkage  peaks  in  the  region  at  189  cM  (Hunt  et  al,  2002)  and  160  cM 
(Kristjansson  et  al,  2002)  when  investigating  hypertension,  and  proximal  to  the 
ADRB2  locus  for  exercise-induced  change  in  diastolic  blood  pressure  (Rankinen 
et  al,,  2001).  These  have  all  been  in  Caucasian  populations. 
With  the  exception  of  Krushkal's  studies,  the  evidence  of  5q  linkage  in  the 
genome-wide  scans  has  largely  been  overlooked.  In  all  cases,  greater  logarithm 
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Fig.  3.1.1:  An  ideogram  of  chromosome  5  showing  the  region  of 
interest,  5q3l-qter.  There  are  multiple  candidate  genes  for 
cardiovascular  disease,  some  of  which  are  noted. 
114 of  odds  (LOD)  scores  were  obtained  on  other  chromosomes  and  emphasis  was 
placed  on  these.  This  is  due,  to  a  large  extent,  to  the  importance  placed  on 
1.41 absolute  magnitude  of  LOD  scores  by  Lander  and  Kruglyak  (Lander  & 
Kruglyak,  1995).  However,  the  majority  of  genome-wide  scans  for  complex 
traits  have  failed  to  satisfy  these  standards  leading  to  calls  for  less  stringent 
levels  of  significance  (Rao  &  Province,  2000).  Lander  and  Kruglyak  did, 
however,  stress  that  linkage  falling  short  of  their  genome-wide  threshold  may, 
nonetheless,  be  genuine. 
Such  ambiguity  has  led  to  the  suggestion  that  combination  of  evidence  from 
several  studies  may  be  needed  to  localise  genes  with  modest  effect  (Altmuller  et 
al,  2001).  To  this  end,  linkage  studies  in  two  independently  ascertained  human 
populations  are  described  here.  The  Silesian  Hypertension  Study  is  a  sample  of 
Polish  nuclear  families  with  aggregation  of  hypertension.  Linkage  of 
quantitative  and  qualitative  blood  pressure  traits  to  the  5q3l-qter  region  was 
assessed  in  this  resource.  The  MIDSPAN  Family  Study,  a  large,  general 
population  sample  from  Scotland,  was  used  to  determine  whether  findings  in  the 
Silesian  Study  were  applicable  outwith  this  hypertensive  sample. 
115 3.2:  METHODS: 
3.2.1:  STUDY  DESIGN  AND  RECRUITMENT: 
3.2.1.1.  -  SILESIAN  HYPERTENSION  STUDY.  - 
The  Silesian  Hypertension  Study  recruited  hypertensive  nuclear  families  from 
the  region  of  Silesia  in  southern  Poland  as  detailed  in  Section  2.2.1  using 
probands  in  hypertension  clinics  as  a  first  contact.  Subjects  with  secondary 
hypertension  were  excluded.  A  total  of  638  individuals  was  recruited  from  212 
families  with  clustering  of  essential  hypertension.  Hypertension  was  defined  as 
systolic  and/or  diastolic  blood  pressure  over  140/90  mmHg,  respectively,  on  3 
separate  occasions  and/or  treatment  for  hypertension.  Clinical  history, 
anthropomorphic  data  and  cardiovascular  phenotypes  were  recorded  for  a  total  of 
635  individuals  from  210  families.  Blood  samples  for  DNA  extraction  were 
taken. 
3.2.1.2.  -  MIDSPAN  FAMILY  STUDY.  - 
The  MIDSPAN  Family  study  represents  a  sample  of  the  general  population  from 
the  west  of  Scotland  consisting  of  sibships  ranging,  in  size,  from  singletons  to 
octets.  These  individuals  were  recruited  in  a  second  phase  of  the  MIDSPAN 
Study  as  detailed  in  Section  2.2.2.  A  total  of  2,338  individuals  were  recruited 
from  1,477  pedigrees.  This  comprised  869  singletons  and  1,469  individuals  from 
608  sibships.  These  individuals  completed  questionnaires  on  diverse  lifestyle 
116 and  clinical  parameters  and  were  phenotyped  for  blood  pressure  as  well  as 
anthropornetric  and  other  data.  Blood  samples  for  DNA  extraction  and  serum 
assays  were  taken. 
3.2.2:  MICROSATELLITE,  MARKER  STUDIES: 
3.2.2.1:  SELECTION  OFMICROSATELLITEMARKERS.  - 
Initially,  8  microsatellite  markers  spanning  the  36  cM  from  5q31.1  to  qter  were 
genotyped.  These  were  taken  from  the  original  study  of  this  region  (Krushkal  et 
al,  1998).  Following  initial  analyses,  3  additional  markers  spanning  19  cM 
proximal  to  the  original  markers  were  added  to  further  define  the  linkage  region. 
These  were  selected  for  their  high  reported  heterozygosity  and  inter-marker 
spacing.  Thus  a  total  of  55  cM  was  investigated  with  II  markers  at  an  average 
distance  of  5  cM  (2.67  to  7.94  cM).  Map  distances  were  taken  from  the 
Marshfield  sex-averaged  genetic  map  as  quoted  by  the  National  Center  for 
Biotechnology  Information  (NCBI,  www.  ncbi.  nlm.  nih.  gov).  The  Marshfield 
genetic  map  was  compared  with  the  physical  genomic  sequence  map  to  confirm 
that  marker  order  was  correct. 
3.2.2.2.  -  MICROSA  TELLITE  MARKER  GENOTYPING.  - 
Genomic  DNA  was  extracted  from  whole  blood  samples  as  described  in  Section 
2.3.  DNA  for  both  Silesian  and  MIDSPAN  studies  was  diluted  to  5  ng/[tl  in 
sterile  deep  well  microplates  (Beckman  Coulter  UK  Ltd,  UK).  25  ng  DNA  per 
117 PCR  reaction  was  used.  PCR  was  performed  as  detailed  in  Section  2.4.1  using 
Qiagen  HotStar  Taq  (Qiagen  Ltd,  UK).  Forward  primers  used  were  5'-Iabelled 
with  either  the  fluorescer  6-carboxyfluorescein  (FAM)  or  its  analogues  TET  or 
HEX.  The  size  range  of  marker  alleles  and  pooling  considerations  dictated  the 
specific  label  used.  PCR  products  for  an  individual's  II  markers  were  combined 
into  3  pre-determined  pools  for  resolution  on  the  ABI  377  DNA  Analyser. 
Resolution  and  genotyping  proceeded  as  per  Section  2.4.2.1.  Genotypes  were 
scored  by  two  independent  observers  blinded  to  phenotype. 
3.2.3:  STATISTICAL  ANALYSES: 
Genotypes  from  both  Silesian  and  MIDSPAN  studies  were  checked  for 
Mendelian  inconsistencies  using  the  PEDCHECK  program  (OConnell  &  Weeks, 
1998).  Genotypes  were  confirmed  for  individuals  flagged  by  the  software, 
corrected  if  appropriate  or  individuals  removed  from  the  dataset. 
Blood  pressures  of  the  Silesian  Hypertension  Study  sample  were  corrected  for 
anti  -hypertensive  treatment  effect  as  described  in  Section  2.2.1.  Multiple 
methods  were  then  used  for  linkage  analyses  of  the  Silesian  Hypertension  Study 
clataset.  Haseman-Elston  regression  analysis  was  used  to  assess  two-point 
identity  by  descent  (IBD)  linkage  of  markers  to  quantitative  blood  pressure 
phenotypes.  A  function  of  squared  trait  sums  and  differences  between  siblings' 
blood  pressures  was  regressed  on  number  of  alleles  shared  IBD.  Two-point 
linkage  of  markers  to  hypertension  status  was  assessed  by  an  IBD  approach 
implemented  in  SPLINK  vl.  08  (Clayton,  2000).  Two-point  linkage  to 
118 hypertension  was  confirmed  by  an  identity  by  state  (IBS)  X2  test,  with  alleles 
shared  IBS  compared  with  a  random  distribution.  Both  the  IBD  Haseman-Elston 
test  and  IBS  Z  test  were  implemented  in  the  SIB-PAIR  software  package  (Duffy, 
1999).  Multipoint  non-parametric  IBD  linkage  analysis  was  performed  using 
MAPMAKER/SIBS  for  quantitative  blood  pressure  phenotypes.  Analyses  are 
discussed  in  detail  in  Section  2.7.1. 
The  MIDSPAN  dataset  was  analysed  for  both  two-point  and  multipoint  IBD 
linkage  to  quantitative  blood  pressure  phenotypes  using  the  variance-components 
methodology  of  SOLAR  (Almasy  &  Blangero,  1998).  SOLAR  is  particularly 
suitable  given  the  variable  size  of  sibships  within  the  MIDSPAN  cohort,  as  it 
intrinsically  corrects  for  dependence  of  multiple  sib  pairs  derived  from  the  same 
pedigree  (Marlow,  2002).  This  pedigree-based  approach  of  SOLAR  is  also  more 
powerful  than  sib  pair  analysis  when  data  on  larger  sibships  are  available.  For 
this  reason  it  has  been  the  method  of  choice  for  other  large  linkage  studies  of 
general  population  samples  (Levy  et  al,  2000).  Traits  were  transformed  to  a 
normal  distribution  by  a  log  10  transformation,  and  this  distribution  cofirmed  by 
Kolmogorov-Smimov  test.  With  only  5%  of  individuals  treated,  a  correction 
was  not  done  since  this  would  only  estimate  untreated  pressures.  However,  a 
second  twopoint  analysis  was  also  performed  with  all  treated  individuals  omitted 
from  the  dataset  to  confirm  that  these  did  not  skew  the  result.  Analytical 
methods  are  discussed  in  detail  in  Section  2.7.1. 
Since  IBD  estimation  in  the  absence  of  parental  genotypes  is  reliant  upon 
estimated  allele  frequencies,  the  868  singletons  were  included  in  analysis.  This 
119 improves  both  allele  frequency  and  phenotypic  distribution  estimates.  Allele 
frequencies  were  calculated  internally  by  SOLAR  using  an  maximum  likelihood 
estimation.  SOLAR  also  modelled  the  contribution  of  age,  sex  and  normalised 
BMI  within  the  MIDSPAN  cohort.  These  were  retained  by  the  model  and  thus 
included  as  covariates. 
3.3:  RESULTS: 
3.3.1:  STUDY  SAMPLES: 
In  the  Silesian  Hypertension  Study,  629  individuals  from  207  families  were 
included  in  analyses.  These  included  207  hypertensive  probands  (57%  male; 
43%  female),  174  parents  (130  fathers;  144  mothers)  of  whom  53%  had  essential 
hypertension  and  148  siblings  (43%  male;  57%  female)  of  whom  32%  had 
essential  hypertension.  Demographic  and  clinical  characteristics  are  shown  in 
Table  3.3.1. 
The  MIDSPAN  Family  cohort  included  869  singletons  and  1,469  siblings  from  a 
total  of  1,477  families  of  whom  45%  were  male.  Of  the  2,338  individuals, 
22.3%  were  hypertensive  at  time  of  recruitment  and  26%  of  the  hypertensives 
(5.8%  of  the  cohort)  reported  being  on  anti-hypertensive  treatment.  Mean  blood 
pressures  were  normotensive  and  body  mass  index  was  within  normal  limits, 
specifically:  SBP  was  127  ±  15.9  mmHg;  DBP  was  74.6  ±  11.2  mmHg  and  BMI 
was  26.1  ±  4.53  kg  M-2  . 
Demographic  and  phenotypic  characteristics  are 
described  in  Table  3.3.2,  sub-categorised  by  size  of  sibship. 
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C14 Table  3.3.3:  Map  positions,  number  of  alleles  and  observed  heterozygosities 
of  5q3l.  l-qter  microsatellite  markers  in  the  study  populations. 
Silesian  Hypertension  Study 
Marker  Position  (cM)  Alleles  (N)  H 
MIDSPAN  Study 
Alleles  (N)  H 
D5s494  127.93  15  0.75  16  0.76 
D5s642  134.72  11  0.72  11  0.72 
D5s5OO  140.72  11  0.81  14  0.84 
D5sI480  147.49  9  0.82  9  0.82 
D5s636  153.17  12  0.76  15  0.80 
D5s820  159.77  8  0.77  9  0.80 
D5s2O93  164.19  9  0.66  10  0.69 
D5sI471  172.13  14  0.77  15  0.75 
D5sl456  174.80  9  0.78  11  0.80 
D5s462  178.75  8  0.58  8  0.62 
D5s2ll  182.89  8  0.74  13  0.75 
Map  positions  are  taken  from  the  Marshfield  sex-averaged  genetic  map  and  are 
quoted  as  distance  from  the  pter.  H=  observed  heterozygosity. 
123 3.3.2:  LINKAGE  STUDIES  OF  5q31.1-qter: 
Eight  microsatellite  markers  were  genotyped,  initially,  with  the  subsequent 
addition  of  three  markers.  Thus,  11  markers  across  55  cM  of  the  distal  portion  of 
chromosome  5q  were  ultimately  genotyped.  All  markers  had  high  observed 
heterozygosity  in  both  populations  studied.  Marshfield  map  positions,  numbers 
of  alleles  and  observed  heterozygosities  are  shown  for  both  Silesian  and 
MIDSPAN  study  populations  in  Table  3.3.3. 
Linkage  analysis  was  conducted,  initially,  in  the  Silesian  study  sample.  Two- 
point  linkage  results  are  shown  in  Table  3.3.4.  Two-point  analysis  of  the  8  distal 
microsatellite  markers  by  Haseman-Elston  regression  showed  significant  linkage 
of  D5sI480  to  hypertension  (P=0.001).  This  result  was  corroborated  by  SPLINK 
1131)  and  SIB-PAIR  IBS  two-point  analyses.  No  other  microsatellite  marker 
demonstrated  significant  linkage.  Results  of  linkage  to  hypertension  status  were 
supported  by  analyses  of  quantitative  phenotypes,  with  systolic  (SBP)  and 
diastolic  blood  pressure  (DBP)  both  adjusted  for  anti-hypertensive  treatment 
effect.  D5sI480  again  showed  significant  linkage  to  both  phenotypes  as  shown 
in  Table  3.3.4. 
Multipoint  linkage  testing  followed  two-point  analyses.  Results  of  two-point 
analyses  were  apparently  confirmed  by  the  multipoint  Z  scores,  maximal  at 
D5sl480,  with  the  Z  statistic  still  increasing  as  the  limit  of  the  marker  map  was 
reached.  D5sl480  marked  the  proximal  margin  of  the  marker  map  and  it  is 
possible  that  artefactual  multipoint  linkage  may  arise  at  the  edges  of  marker  sets. 
124 To  eliminate  this  possibility,  the  marker  set  was  extended  proximally  with  three 
additional  microsatellites  which  were  genotyped  and  analysed.  Two-point 
Haseman-Elston  analysis  of  linkage  to  essential  hypertension  implicated  the  two 
markers  closest  to  D5sl480.  Of  the  two,  D5s5OO  was  closest  and  most 
significant  with  t=2.45  (P=0.008)  whilst  for  D5s642  t=1.96  (P=0.03).  Two-point 
linkage  of  D5s5OO  also  reached  borderline  significance  for  SBP  (P=0.09)  and 
DBP  (P=0.06). 
Multipoint  linkage  results  of  SBP  using  the  extended  marker  map  are  shown  in 
Fig.  3.3.1.  Multipoint  analysis  showed  that  linkage  to  SBP  was  maximal 
proximal  to  D5sI480  (Z  =  2.3;  P=0.01).  This  implicated  a7  cM  region  between 
D5sl480  and  D5s5OO,  and  confirmed  that  the  previously  observed  multipoint 
linkage  had  not  been  an  artefactual  effect  due  to  the  marker  map.  Analysis  of 
DBP  showed  an  equivalent  linkage  peak  with  a  maximal  Z  score  of  1.8  (P  = 
0.03)  proximal  to  the  D5sI480  locus. 
Further  genotyping  and  linkage  analysis  were  subsequently  conducted  in  the 
MIDSPAN  cohort  with  a  view  to  following  up  the  results  in  the  Silesian  sample. 
All  analyses  were  conducted  using  SOLAR  with  age,  sex  and  BMI  as  covariates. 
Two-point  linkage  analysis  again  implicated  D5sI480,  with  linkage  to  all 
quantitative  phenotypes  greatest  at  this  locus.  The  highest  two-point  LOD  score 
was  obtained  for  mean  arterial  pressure  (MAP)  (Table  3.3-5).  Furthermore, 
when  multipoint  analyses  were  performed,  a  linkage  peak  maximal  at  the 
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-Tý  -0 Table  3.3.5:  Results  of  two-point  linkage  of  systolic,  diastolic  and 
mean  arterial  blood  pressures  to  microsatellite  markers  spanning 
the  5q31.1  to  5qter  region  of  human  chromosome  5  in  the 
MIDSPAN  study  group. 
Marker 
SBP 
LOD 
DBP 
LOD 
MAP 
LOD 
D5s494  0.00  0.13  0.03 
D5s642  0.90  1.05  0.90 
D5s5OO  0.71  0.63  1.02 
D5s1480  1.19  1.18  1.57 
D5s636  0.06  0.00  0.00 
D5s820  0.61  0.63  1.12 
D5s2O93  0.00  0.00  0.00 
D5sl471  0.28  0.05  0.13 
D5sl456  0.42  0.00  0.05 
D5s462  0.02  0.00  0.05 
D5s2lI  0.06  0.32  0.09 
SBP  =  systolic  blood  pressure;  DBP  diastolic 
blood  pressure;  MAP  =  mean  arterial  pressure;  LOD 
logarithm  of  odds  score. 
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Fig.  3.3-2:  Results  of  multipoint  linkage  analysis  of  quantitative  blood  pressure 
phenotypes  to  11  microsatellite  markers  across  the  5q3l.  l-qter  region  in  the 
MIDSPAN  study  group.  Covariates  of  age,  sex  and  BMI  were  included  in  the 
analyses  performed  with  SOLAR.  (A)  Comparison  of  multipoint  results  from  the 
MIDSPAN  and  Silesian  study  groups  shows  the  close  agreement  of  linkage  in  the 
two  populations.  Location  of  the  genes  FGFI,  NR3CI  and  ADRB2  are  shown. 
(B)  Maximal  linkage  to  DBP  and  (C)  MAP  was  also  seen  at  the  same  locus.  LOD 
=  logarithm  of  odds 
129 D5sl480  locus  was  present  whether  SBP,  DBP  or  MAP  was  assessed.  Maximal 
multipoint  LOD  was  1.65  for  MAP.  Both  location  and  morphology  of  the 
linkage  peaks  were  highly  comparable  between  the  Silesian  and  MIDSPAN 
study  groups.  Results  of  these  multipoint  analyses  are  shown  in  Fig.  3.3.2.  To 
confirm  that  inclusion  of  treated  MIDSPAN  individuals  did  not  materially  affect 
the  result,  a  second  two-point  analysis  was  performed  with  treated  individuals 
removed  from  the  dataset.  Two-point  LOD  scores  were  maximal  at  D5sI480  for 
MAP  and  DBP  (1.68  and  1.11,  respectively).  LOD  scores  for  SBP  were  1.26  at 
the  D5sl480  locus  but  maximal  at  the  flanking  D5s5OO  locus  (LOD  =  1.29). 
This  mirrors  the  broader  multipoint  peak  seen  for  SBP  (Fig.  3.3.2  A). 
3.4:  DISCUSSION: 
A  targeted  approach  has  been  used,  focusing  on  the  5q3  1.1  to  qter  chromosomal 
segment,  to  examine  linkage  to  blood  pressure  phenotypes  in  Caucasian  study 
samples.  The  decision  to  focus  on  this  small  chromosomal  region  was  based  on 
previous  linkage  studies,  which  have  implicated  this  chromosome  segment 
(Krushkal  et  al,  1998;  Krushkal  et  al,  1999),  and  the  presence  of  putative 
cardiovascular  candidate  genes  which  provide  scope  for  subsequent  positional 
analysis  if  appropriate.  Suggestive  linkage  of  a7  cM  region  to  blood  pressure 
and  hypertension  status  was  found  in  the  Silesian  Hypertension  Study 
(Tomaszewski  et  al,  2002).  A  peak  of  suggestive  linkage  to  quantitative  BP 
traits  was  also  seen  at  the  same  locus  in  the  MIDSPAN  Family  Study  cohort. 
130 The  Silesian  Hypertension  Study  comprised  nuclear  families  that  were  recruited 
based  on  their  family  history  of  essential  hypertension  from  the  Silesian  region 
of  Poland.  Consequently,  nearly  64%  of  individuals  were  hypertensive  and 
many  were  being  treated  for  their  hypertension.  Therefore,  an  adjustment  for 
treatment  was  applied  to  blood  pressures  (Tomaszewski  et  al,  2002).  The 
MIDSPAN  Family  Study  comprised  unselected  sibships  from  the  general 
population  in  the  west  of  Scotland.  Just  over  one  fifth  of  participants  were 
hypertensive  at  recruitment.  This  agrees  with  prevalence  of  hypertension 
reported  by  large  epidemiological  studies  in  Western  populations  (Burt  et  al, 
1995). 
Linkage  to  the  same  locus,  proximal  to  D5sI480,  was  demonstrated  for  both 
quantitative  blood  pressure  traits  and  hypertension  status  in  the  study  groups. 
The  idea  that  the  same  genes  underlie  both  normal  population  distribution  of 
blood  pressure  and  the  pathological  development  of  high  blood  pressure  and 
hypertension  is  often  tacitly  assumed  (Altmuller  et  al,  2001).  Indeed,  it  is  rare 
for  linkage  studies  to  analyse  linkage  to  hypertension  status  and  blood  pressure. 
This  is  probably  driven  by  two  factors.  Firstly,  general  population  samples 
suitable  for  blood  pressure  linkage  analysis  often  lack  sufficient  hypertensives  to 
contribute  power  to  such  an  endeavour;  secondly,  there  is  a  widely  held  opinion 
that  quantitative  traits  provide  more  power  than  qualitative  traits  which,  as  with 
hypertension,  may  be  somewhat  arbitrary  in  their  definition.  Interestingly,  a 
recent  review  of  101  genome-wide  scans  across  31  different  complex  diseases 
found  no  difference  in  rate  of  linkage  detection  between  quantitative  and 
qualitative  trait  scans  (Altmuller  et  al,  2001).  However,  statistical  studies  using 
11)  1 simulated  clatasets  have  suggested  that  quantitative  traits  are  more  informative 
(Duggirala  et  al,  1997). 
The  ideal  approach  to  analysis  of  complex  disorders  may  be  to  analyse  both 
qualitative  and  quantitative  traits  jointly,  if  study  samples  lend  themselves  to  this, 
since  this  may  increase  power  to  detect  effects  (Williams  et  al,  1999).  Since  the 
Silesian  study  sample  consists  of  a  high  percentage  of  hypertensive  individuals, 
this  provided  the  opportunity  to  analyse  both  blood  pressure  and  hypertensive 
status.  The  results  from  these  analyses  suggest  that,  at  least  in  the  QTL  proximal 
to  D5sI480,  the  same  genes  may  be  involved  in  blood  pressure  control  and 
hypertension  development.  However,  this  may  not  necessarily  be  the  case  for  all 
QTL.  Linkage  to  both  hypertension  and  blood  pressure  has  been  examined  in  the 
same  sample  in  at  least  one  genome-wide  scan.  In  this  case  the  separate  analyses 
gave  very  different  results  (Hunt  et  al,  2002). 
The  major  strength  of  this  study  is  that  the  two  study  groups  are  very  different 
yet  the  linkage  to  blood  pressure  at  D5sl480  is  present  in  both.  Consistency  of 
linkage  evidence  to  blood  pressure  or  hypertension  is  rare  across  the  many 
studies  now  published  (Samani,  2003;  Harrap,  2003).  A  few  studies  have 
replicated  their  initial  findings  in  an  independent  sample  (Xu  et  al,  1999;  Zhu  et 
al,  2001)  but  this  is  the  exception  rather  than  the  rule.  As  such  this  has  caused 
concern  and  raised  the  question  of  the  feasibility  of  finding  blood  pressure  and 
hypertension  genes  by  such  methods  (Harrap,  2003). 
132 Much  of  the  conjecture  surrounding  the  successfulness  of  linkage  approaches  in 
complex  diseases  has  been  based  around  the  lack  of  genome-wide  significant 
results.  This  concept,  first  proposed  by  Lander  and  Kruglyak  (Lander  & 
Kruglyak,  1995),  was  based  on  their  realisation  that  testing  of  hundreds  of 
markers  would  certainly  result  in  false  positive  results.  However,  in  their 
argument  for  stringency  these  authors  also  left  room  for  smaller  scale  studies 
which,  unlike  genome-wide  scans,  are  partly  hypothesis  -driven.  Given  that  such 
a  targeted  approach,  as  employed  here,  does  not  necessitate  the  use  of  many 
markers,  it  also  does  not  require  such  stringent  levels  of  significance. 
Since  Lander  and  Kruglyak's  guidelines  were  published,  the  practicality  of  their 
suggestions  has  been  tested  empirically.  Logarithm  of  odds  (LOD)  scores  of  3.6 
or  over  in  complex  disease  studies  are  now  felt  by  many  to  be  too  stringent  (Rao 
&  Province,  2000).  Thus  the  thin  red  line  of  significance  has  given  way  to  a 
broader,  interpretative  approach.  Often  this  involves  simulation  methods  to 
empirically  derive  significance  levels  (Cheng  et  al,  200  1;  Angius  et  al,  2002; 
Caulfield  et  al,,  2003).  Other  studies  use  lower  fixed  thresholds  of  significance 
(Rankinen  et  al,  200  1;  Rice  et  al,  2002;  Cooper  et  al,  2002).  No  approach  to 
significance  determination  represents  a  panacea,  and  interpretation  of  linkage 
results,  particularly  genome-wide  data,  is  still  very  much  a  grey  area.  Indeed,  it 
was  acknowledged  from  the  outset  that  such  interpretation  was  not  trivial  and 
that  high  LOD  scores  could  be  false  just  as  low  LOD  scores  could  be  genuine 
(Lander  &  Kruglyak,  1995). 
133 In  light  of  the  difficulties  with  interpreting  linkage  evidence,  combination  of 
evidence  from  multiple  samples  remains  essential  (Altmuller  et  al,  2001). 
Replication  is  one  of  the  few  ways  to  increase  confidence  in  a  linkage  result,  in 
the  absence  of  a  method  for  definitively  proving  the  existence  of  a  QTL.  It  also 
provides  some  evidence  for  broader  applicability  of  the  QTL  than  simply  to  the 
original  sample  studied.  With  respect  to  the  identification  of  genes  relevant  to 
hypertension  development  at  the  population  or  global  level,  this  is  obviously 
important.  Replication  of  our  5q  QTL  thus  provides  confidence  in  the  result  and 
may  indicate  a  broader  relevance  to  Caucasian  populations. 
The  expectation  from  simulation  studies  is  that  study  samples  with  more  extreme 
phenotypes  provide  greater  power  to  detect  genetic  effects  (Risch  &  Zhang, 
1995;  Gu  et  al,  1997).  This  philosophy  has  been  applied  in  some  hypertension 
scans  which  have  recruited  individuals  at  the  extremes  of  blood  pressure 
distribution  (Xu  et  al,  1999;  Caulfield  et  al,  2003).  From  this,  the  expectation 
with  our  study  samples  is  that  the  Silesian  group  should  provide  more  power  to 
detect  blood  pressure  linkage  given  the  majority  of  hypertensive  individuals. 
That  the  same  QTL  with  comparable  linkage  has  also  been  detected  in  the 
normal,  healthy  MIDSPAN  group  is  probably  a  consequence  of  the  much  greater 
size  of  this  population.  Certainly  sample  size  has  been  identified  as  a  major 
factor  for  success  in  linkage  studies  (Altmuller  et  al,  2001). 
The  QTL  described  in  our  two  populations  is  approximately  30  cM  from  that  of 
Krushkal  et  al  (Krushkal  et  al,  1999).  QTL  separated  by  such  a  distance  would 
normally  be  considered  to  indicate  different  linkage  effects.  It  is  interesting, 
134 however,  that  further  work  by  the  US  group  could  only  implicate  the  ADR132 
gene,  which  is  within  the  linkage  region  identified  in  our  study  (Bray  et  al, 
2000b).  Subsequent  studies  have  reported  linkage  in  the  region  proximal  to 
ADRB2.  A  US  genome-wide  scan  of  344  healthy,  white  sib  pairs  assessed  the 
effect  of  a  20  week  exercise  program  on  ADBP.  A  multipoint  LOD  score  of  1.38 
at  the  ADRI32  locus  was  reported  (Rankinen  et  al,  2001).  A  GWS  in  Icelandic 
families  reported  a  LOD  score  of  0.95  for  hypertension  close  to  the  ADRB2 
locus  (Kristjansson  et  al,  2002).  A  population-based  study  in  the  US  reported 
linkage  to  hypertension  but  not  to  SBP  or  DBP  at  the  qter  in  Caucasian  families 
(Hunt  et  al,  2002).  Between  these  previously  published  studies,  the  entire  5q3  1.1 
to  qter  region  has  been  implicated.  However,  with  the  reproducible  linkage 
found  in  our  populations,  and  in  light  of  the  findings  by  others  proximal  to  the 
ADRB2  locus,  the  region  around  5q3l.  1  to  q33  is  now  highlighted  as  a 
promising  region  (Tomaszewski  et  al,  2002). 
Classically,  QTL  may  be  tightened  by  addition  of  additional  microsatellite 
markers  to  increase  map  density.  We  chose  not  to  do  this  since  our  study  is  an 
amalgamation  of  linkage  study  and  candidate  gene  study  rationales.  Our  prior 
hypothesis  is  that  any  linkage  detected  within  the  5q  region  may  be  related  to 
variants  of  the  ADRB2  gene  encoding  the  P2-adrenergic  receptor  given  the 
findings  of  the  US  studies  (Bray  et  al,  2000b).  At  a5  cM  resolution,  we  are 
already  working  with  a  map  which  is  at  least  twice  as  dense  as  GWS  studies. 
The  observations  of  Krushkal  et  al  and  Bray  et  al  (Krushkal  et  al,  1999;  Bray  et 
al,  2000b)  also  indicate  that  linkage  maxima  may  not  coincide  with  the  gene 
locus  in  this  region.  Finally,  the  linkage  region  has  a  lower  gene  density  than  the 
135 genomic  average,  with  only  a  few  sensible  cardiovascular  candidates.  A 
candidate  gene  approach  from  this  point  therefore  seems  reasonable  although 
grid  tightening  is  a  future  option. 
Evidence  from  experimental  models  further  strengthens  the  case  for  the  linkage 
region  found  in  our  populations.  A  region  of  human  chromosome  5q  of 
approximately  13  Mbp  is  syntenic  with  rat  and  mouse  chromosome  18.  This 
syntenic  block  extends  from  the  centromeric  flank  of  D5s494  to  the  distal  flank 
of  D5s636,  thus  encompassing  our  entire  linkage  region.  Genome-wide  scanning 
of  a  stroke-prone  spontaneously  hypertensive  (SHRSP)  x  Wistar-Kyoto  (WKY) 
F2  cross  detected  a  QTL  for  baseline  and  salt-loaded  DBP  on  rat  chromosome  18 
(Jacob  et  al,  1991).  This  QTL,  denoted  BP2,  extended  distally  to  the  rat 
glucocorticoid  receptor  gene,  Grl,  the  human  homologue  of  which  (NR3CI)  is 
located  under  our  peak  of  linRage  on  human  chromosome  5q  (see  Fig.  3.3.2A). 
Linkage  in  this  region  of  rat  chromosome  18  has  since  been  reported  by  other 
genome-wide  scans  in  rat  models;  specifically,  SBP  in  a  cross  of  spontaneously 
hypertensive  rat  (SHR)  x  BioBreeding  OK  substrain  (BB/OK)  (Kovacs  et  al, 
1997)  and  salt-loaded  blood  pressures  in  Brown  Norway  (BN)  x  Dahl  salt- 
sensitive  (SS)  (Cowley  et  al,  2000).  This  QTL  is  absent  in  other  strains,  notably 
our  own  Glasgow  WKY  x  SHRSP  cross  (Clark  et  al,  1996).  In  mice,  a  QTL  for 
SBP  in  a  cross  of  hypotensive  BP/I  mice  with  normotensive  M  spretus  was  also 
reported  on  mouse  chromosome  18,  at  the  proximal  limit  of  the  region  syntenic 
to  human  chromosome  5q  (Wright  et  al,  1999). 
136 Our  QTL  in  the  5q31.1-q33  region  contains  several  promising  candidate  genes. 
The  previous  work  implicating  the  ADRB2  gene  (Bray  et  al,  2000b),  has 
implicated  this  as  a  prime  positional  candidate  and  physiological  candidate  with 
its  involvement  in  regulation  of  vascular  tone  and  dilatation  (Wood,  2003).  With 
regard  to  the  wider  cardiovascular  picture,  theP2-adrenergic  receptor  is  known  to 
mediate  thermogenesis  and  lipolysis  (Lowell  &  Bachman,  2003).  It  can  be 
hypothesised  to  connect  the  vascular  and  metabolic  abnormalities  often 
cosegregating  in  hypertensive  patients  (Reaven,  2003).  Functional  relevance  of 
ADRB2  polymorphisms  is  relatively  well  understood  due,  in  part,  to  the  interest 
of  asthma  researchers  in  ADRB2-mediated  bronchial  dilatation  (Drysdale  et  al, 
2000).  The  ADRB2  locus  has  been  studied,  quite  extensively,  as  a  candidate 
gene  in  blood  pressure  and  hypertension.  Some  studies  imply  an  effect  in 
Caucasian  (Gratze  et  al,  1999;  Busjahn  et  al,  2000;  Bengtsson  et  al,  2001)  and 
black  populations  (Kotanko  et  al,  1997),  whilst  others  show  no  association  (Jia  et 
al,  2000).  Our  own  findings  with  regard  to  ADRB2  (Tomaszewski  et  al,  2002) 
are  described  in  Chapter  4. 
A  novel  cardiovascular  candidate  gene,  which  is  located  within  the  middle  of  the 
linkage  region,  is  the  acidic  fibroblast  growth  factor  gene,  FGFI.  Following 
comparative  mapping  of  QTL  between  rat  and  the  human  5q3l-qter  region, 
FGF  I  was  suggested  as  a  positional  candidate  for  blood  pressure  (Stoll  et  al, 
2000).  Despite  this,  relatively  few  studies  have  assessed  the  potential  of  this 
gene  as  a  factor  in  blood  pressure  control  and  hypertension.  However,  as  a 
potent  endothelial  cell  proliferator  (Powers  et  al,  2000),  with  proven  effects  on 
blood  pressure  in  animal  models  (Cuevas  et  al,  1991;  Wu  et  al,  1996)  and  a 
137 possible  role  in  defence  against  oxidative  stress  (Yang  &  deBono,  1997),  FGF  I 
suggests  itself  as  a  biological  candidate  whose  involvement  in  the  pathogenesis 
of  hypertension  could  be  explained  by  a  number  of  mechanisms. 
The  glucocorticoid  receptor  (GR),  encoded  by  the  NR3CI  gene,  is  also  located 
within  the  linkage  region.  As  a  regulator  of  gene  transcription,  GR  affects 
immune,  metabolic,  behavioural,  cell-growth  and  vascular  processes  (De  Rijk  et 
al,  2002).  Mutations  affecting  ligand  binding  or  receptor  regulation  cause 
corticosteroid  resistance,,  one  feature  of  which  is  hypertension  (Ruiz  et  al,  2001). 
The  locus  has  been  implicated  in  hypertension  by  some  (Watt  et  al,  1992)  but 
excluded  by  others  (Lin  et  al,  1999;  Takami  et  al,  1999;  Dobson  et  al,  2001) 
using  both  association  and  linkage  methods. 
The  work  described  here,  then,  has  suggested  evidence  of  linkage  of  a7  cM 
region  of  human  chromosome  5q3l.  l-q33  to  blood  pressure  and  hypertension. 
The  linkage  evidence  to  blood  pressure  phenotypes  has  been  seen  in  two 
Caucasian  study  populations  despite  different  ascertainment  criteria.  Previous 
targeted  studies  and  genome-wide  scans  had,  between  them,  implicated  a  broad 
region  of  the  distal  5q  arm.  The  QTL  described  here  provides  a  more  focused 
area  for  further  efforts.  The  implication  of  the  proximal  segment  of  the  5  q3  1.1  - 
qter  region  is  also  reasonable  in  the  context  of  work  in  rat  and  mouse  models. 
Physiological  positional  candidates  for  cardiovascular  disease  exist  within  the 
QTL  and  will  provide  a  focus  for  further  work  to  dissect  this  locus. 
138 CHAPTER  4 
GENETIC  STUDIES  OF  THE  POSITIONAL  AND 
PHYSIOLOGICAL  CANDIDATE  GENES  ADRB2  AND  FGF1  IN 
THE  HUMAN  5q3l.  l-  q  33  BLOOD  PRESSURE  QTL 
139 4.1:  INTRODUCTION: 
The  role  of  essential  hypertension  as  a  risk  factor  for  stroke  and  coronary  heart 
disease,  and  its  30-60%  genetic  determination  (Ward,  1990),  have  made  it  the 
focus  of  Herculean  efforts  by  the  research  community  (Kannel,  2000). 
However,  its  complex,  multifactorial,  oligo-  or  polygenic  nature  (Lander  & 
Schork,  1994;  Caulfield  et  al,  2003)  combined  with  small  individual  gene 
effects  (Stoll  et  al,  2000)  has  consistently  hampered  advances  in  understanding. 
There  are,  inevitably,  inherent  difficulties  in  studying  heterogeneous  human 
populations  with  their  variation  in  environment  and  genetic  factors  (Lander  & 
Schork,  1994). 
Dissection  of  the  complex  genetics  of  essential  hypertension  necessitates 
combination  of  complementary  approaches  (Risch,  2000).  Thus  we  began  with 
a  targeted  linkage  study  concentrating  on  the  human  5q3l.  l  to  q33 
chromosomal  region.  We  confirmed  the  presence  of  linkage  to  blood  pressure 
in  this  region  in  two  independent  study  samples  (Tomaszewski  et  al,  2002).  Part 
of  the  rationale  for  focusing  on  the  distal  segment  of  chromosome  5q  was  the 
presence  of  a  number  of  good  candidate  genes  for  blood  pressure  control  and 
cardiovascular  disease.  In  addition,  this  region  had  been  implicated  by  other 
linkage  studies  of  blood  pressure  (Krushkal  et  al,  1999).  By  identifying  linkage 
to  a7  cM  region  we  were  able  to  narrow  the  field  of  candidate  genes  to  those 
which  were  both  physiological  and  positional  candidates.  The  natural 
progression  of  this  work,  then,  is  the  application  of  candidate  gene  strategies  to 
assess  the  contribution  of  such  genes  to  the  blood  pressure  linkage. 
140 Simulation  studies  suggest  that  association  approaches  should  be  more  powerful 
in  detecting  small  to  moderate  gene  effects  than  linkage  approaches  (Risch  & 
Merikangas,  1996).  Such  approaches  lend  themselves  to  interrogation  of 
candidate  genes  and  are,  potentially,  very  powerful  but  can  also  be  problematic. 
Analysis  of  candidate  genes  has  been  criticised  on  two  fronts:  firstly,  the 
significant  findings  of  association  in  many  candidate  genes  studies  have  not 
been  replicated  when  followed  by  subsequent  studies.  Secondly,  candidate  gene 
studies  are  based  on  the  ability  to  predict  ftinctional  genes  and  variants.  Some 
commentators  believe  that  current  knowledge  is  insufficient  to  allow  this  (Tabor 
et  al,  2002). 
Many  of  the  pitfalls  of  candidate  gene  studies  result  from  the  methodologies 
used.  The  most  commonly  used  paradigm,  the  case-control  study,  can  give  false 
positive  and  negative  results  due  to  population  stratification  (Cardon  &  Palmer, 
2003;  Ziv  &  Burchard,  2003).  This  has  led  to  the  development  of  family-based 
methods  in  an  effort  to  control  for  such  population  effects  (Spielman  &  Ewens, 
1996;  Rabinowitz  &  Laird,  2000).  In  addition,  studies  are  commonly  based  on 
the  genotyping  of  a  single  polymorphism  within  genes  which  may  span 
hundreds  of  kilobases.  The  polymorphism  genotyped  may  have  no  functional 
relevance  itself  in  which  case  it  must  be  in  linkage  disequilibrium  with  any 
functional  polymorphisms  for  association  with  disease  to  be  detected  (Sharma  & 
Jeunemaitre,  2000). 
141 Current  guidelines  recommend  a  hierarchical  selection  policy  for 
polymorphisms  based  on  their  potential  for  functional  effects  (Tabor  et  al, 
2002).  In  addition,  it  is  recommended  that  multiple  polymorphic  sites  within  a 
gene  are  genotyped  (Sharma  &  Jeunemaitre,  2000).  Here  these  policies  are 
applied,  in  conjunction  with  family-based  analysis  methods,  to  the  investigation 
of  two  candidate  genes  which  are  both  biological  and  positional  candidates 
following  the  previously  described  linkage  studies.  These  candidates  are  theP2- 
adrenergic  receptor  and  the  acidic  fibroblast  growth  factor  genes,  located  within 
the  5q3  1.1  -q33  blood  pressure  QTL. 
ADRB2,  encoding  theP2-adrenergic  receptor,  is  well  recognised  as  a  potentially 
important  cardiovascular  candidate  gene.  The  gene  has  a  simple  structure 
consisting  of  a  promoter  region  of  approximately  300-500  bp  followed  by  a 
single  coding  exon  (Emorine  et  al,  1987).  The  protein  is  a  413  residue  peptide 
with  7  transmembrane  domains  (Fig  4.1.1).  Expressed  by  multiple  tissues 
including  epithelial  cells,  adipose  tissue,  vascular  endothelium  and  bronchial 
smooth  muscle,  ADRB2  is  aG  protein-coupled  receptor  (GPCR)  which 
mediates  signalling  by  catecholamines  such  as  adrenaline  (Liggett,  1997). 
Binding  of  ligand  results  in  G,  -dependent  stimulation  of  adenylyl  cyclase  and 
production  of  cAMP.  In  the  context  of  blood  pressure  regulation,  this  signalling 
pathway  mediates  vasodilatory  responses  through  receptors  expressed  in  the 
vessel  wall,  but  the  role  of  the  ADRB2  receptor  may  be  considerably  more 
complex.  Recent  evidence  has  suggested  that  the  ADRB2  receptor  complexes 
with,  and  regulates  signalling  through,  other  GPCRs  including  the  angiotensin  11 
type  I  receptor  (ATIR).  Antagonism  of  ADRB2  in  mice  was  recently  shown  to 
142 also  reduce  signalling  via  the  ATIR  (Barki-Harrington  et  al,  2003).  ADRB2  is 
also  known  to  be  integral  to  metabolic  processes  in  vivo  and  the  P-adrenergic 
receptors,  generally,  mediate  sympathetically  driven  thermogenesis  as  well  as 
lipolysis  and  glucose  homeostasis  (Lowell  &  Bachman,  2003). 
ADRB2  has  received  much  interest  from  the  asthma  community  owing  to  its 
role  in  dilatation  of  the  bronchi  and  the  known  therapeutic  benefits  of  P- 
agonists.  Consequently,  polymorphisms  within  the  gene  are  well  known  and 
some  have  been  functionally  characterised  (Liggett,  1997).  This  prior 
knowledge  allows  the  selection  of  known  functional  polymorphisms.  Family- 
based  methods  were  used  to  investigate  association  of  three  functional  gene 
polymorphisms  as  single  loci  and  haplotypes  to  hypertension  in  the  nuclear 
families  of  the  Silesian  Hypertension  Study. 
FGFI,  encoding  the  acidic  fibroblast  growth  factor,  is  a  member  of  the  FGF 
gene  family  encoding  at  least  22  ligands.  These  mediate  a  variety  of  signalling 
events  via  four  widely  expressed  fibroblast  growth  factor  receptors  (FGFRs). 
FGFI  itself  has  kidney  and  brain-specific  promoters,  and  additional  promoters 
controlling  expression  in  various  tissues  including  vascular  smooth  muscle 
(VSM)  (Fig.  4.1.2).  It  is  unusual  in  that  it  binds  with  high  affinity  to  all  known 
FGFR  isoforms,  unlike  other  FGFs  (Chiu  et  al,  2001).  FGFI  is  released  from 
cells  to  bind  to  cell-surface  FGFRs  which  triggers  a  signalling  cascade  and 
stimulates  gene  expression.  It  has  wide-ranging  roles  in  development,  wound 
healing,  turnour  development  and  progression,  and  angiogenesis.  FGF  I  is  also  a 
potent  proliferator  of  endothelial  cells  (Powers  et  al,  2000).  Systemic 
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1:  A  schematic  of  the  ADRI32  gene  and  receptor.  The  ADRI32  receptor 
mediates  signalling  by  catecholamines  in  various  tissue  types.  Its  roles  in  cardiac, 
vascular  and  metabolic  regulation  make  it  an  important  cardiovascular  candidate  gene. 
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Fig.  4.1.2:  A  schematic  of  the  FGF  I  gene.  Its  diverse  expression  is  regulated  by  at 
least  four  promoters.  A  number  of  tissue-specific  roles  of  potential  relevance  to 
cardiovascular  disease  are  noted.  Untranslated  regulatory  exons  are  shown  in  blue. 
Translated  exons  are  shown  in  red.  3'  UTR  is denoted  by  the  red-boxed  area. 
NO  =  nitric  oxide;  HPA  =  Hypothalamic-pituitary-adrenal. 
145 administration  of  FGFI  into  rats  causes  a  dose-dependent  decrease  in  blood 
pressure,  arteriolar  dilatation  and  increased  vascular  flow.  Nitric  oxide  synthase 
inhibitors  or  endothelial  denudation  abolish  these  effects  (Cuevas  et  al,  1991; 
Wu  et  al,  1996).  FGH  may  also  increase  the  endothelium's  resistance  to 
oxidative  stress  by  increase  of  intracellular  reduced  glutathione  (Yang  & 
deBono,  1997).  Infusion  into  rats  has  also  been  shown  to  stimulate  the 
hypothalamic  pituitary  adrenal  (HPA)  axis,  leading  to  increased  plasma 
corticosterone  (Matsumoto  et  al,  1998b),  and  the  sympathetic  nervous  system, 
increasing  catecholamine  secretion  (Matsumoto  et  al,  1998a). 
FGH  has  received  little  attention  from  the  cardiovascular  community,  and  in 
this  context  is  a  novel  candidate  gene.  To  investigate  this  novel  locus,  FGH 
sequencing  and  SNP  locus  and  haplotype  studies  are  presented  as  first  steps  in 
assessing  its  contribution  to  blood  pressure  variation  and  hypertension  risk  in  the 
Silesian  families. 
4.2:  METHODS: 
4.2.1:  SILESIAN  HYPERTENSION  STUDY  DESIGN  AND  RECRUITMENT: 
The  Silesian  Hypertension  Study  was  used  in  linkage  studies  described  in 
Chapter  3.  A  detailed  description  of  the  ascertainment  strategy,  recruitment  and 
phenotyping  can  be  found  in  Sections  2.2.1  and  3.2.1.1. 
146 4.2.2:  P2-ADRENERGIC  RECEPTOR  CANDIDATE  LOCUS  STUDY: 
4.2.2.1:  GENOTYPING  OFfi2-ADRENERGIC  RECEPTOR  SNPS.  - 
Three  non-synonymous  functional  SNPs  were  genotyped  in  the  Silesian  sample: 
Argl6Gly,  Gln27GIu  and  Thr16411e.  PCR  for  each  was  performed  as  detailed 
in  Section  2.5.1  in  a  volume  of  20  ýtl  using  HotStar  Taq  (Qiagen  Ltd,  UK). 
Each  polymorphism  introduces  a  restriction  site  into  the  sequence.  Therefore, 
genotyping  was  done  by  restriction  enzyme  digest  as  described  in  Section  2.5.2. 
Argl6Gly  was  digested  with  BsrDl  (New  England  Biolabs  (UK)  Ltd,  UK); 
Gln27GIu  was  digested  with  Ital  (Roche,  Switzerland);  Thrl6411e  SNP  was 
digested  with  Mn1l  (New  England  Biolabs  (UK)  Ltd,  UK).  Digestion  products 
were  resolved  on  agarose  gels  and  genotypes  were  scored  visually  by  two 
individuals.  Digestion  products  have  been  described  previously  (Large  et  al, 
1997).  Examples  are  shown  in  Appendix  4.  Arg  I  6Gly  resulted  in  fragments  as 
follows:  14,56,  and  131  bp  for  Arg  homozygotes;  14,23,56  and  108  bp  for  Gly 
homozygotes.  Heterozygotes  were  distinguished  by  the  presence  of  108  and 
131  bp  fragments.  Gln27GIu  digestion  gave  the  following  fragments:  27,55,97 
and  174  bp  for  Gln  homozygotes;  27,97  and  229  bp  fragments  for  Glu 
homozygotes.  Heterozygotes  were  distinguished  by  the  presence  of  174  and 
229  bp  fragments.  Thr1641le  gave  38,114  and  206  bp  fragments  in  Thr 
homozygotes;  38  and  320  bp  fragments  in  Ile  homozygotes  and  38,114,206  and 
320  bp  fragments  in  heterozygotes. 
147 4.2.3:  FIBROBLAST  GROWTH  FACTOR  I  CANDIDATE  LOCUS  STUDY: 
4.2.3.1:  FIBROBLAST  GROWTH  FACTOR  I  SEQUENCING: 
Single  nucleotide  polymorphism  (SNP)  discovery  within  the  FGFI  locus  was 
performed  by  sequencing  coding,  flanking  intronic  and  3'  untranslated  regions 
(3'  UTR)  of  the  gene  as  described  in  Sections  2.6.1  and  2.6.2.  Three  coding 
exons  are  known  at  present,  as  detailed  in  Fig.  4.1.2.  PCR  primers  were 
designed  to  intronic  sequences  flanking  each  exon  based  on  genornic  sequences 
in  the  NCBI  database  (www.  ncbi.  nlm.  nih.  gov;  Accession  no:  NT_029289)  and 
FGF1  cDNA  sequences  from  the  same  database  and  the  literature  (Payson  et  al, 
1993).  Primer  sequences  are  given  in  Appendix  3. 
Twenty  unrelated  Polish  individuals  were  selected  for  sequencing.  A 
deliberately  heterogeneous  group  was  used.  Thus,  ten  individuals  were  male, 
ten  female.  Of  these  two  subgroups,  half  were  hypertensive  and  half 
normotensive.  HotStar  Taq  (Qiagen  Ltd,  UK)  was  used  to  amplify  intron/exon 
and  3'  UTR  sequences  as  described  in  Section  2.6.1.  PCR  products  were 
purified  by  Nucleofast-96  plates  (Macherey-Nagel,  Germany).  Direct 
sequencing  of  the  purified  PCR  products  from  the  20  individuals  was  done  by 
MWG  Biotech  using  the  forward  PCR  primers.  Data  from  MWG  were  aligned 
to  a  reference  sequence  using  Vector  NTI  A  (Informax  Inc,  US).  Putative 
polymorphic  sites  were  confinned  by  visual  inspection  of  the 
electrophero  grams. 
148 4.2.3.2:  FIBR  OBLA  ST  GR  0  WTH  FA  C  TOR  I  SNP  GENO  TYPING 
.- 
Genotyping  of  polymorphisms  within  the  FGFI  gene  was  done  by  the  MRC 
Gene  Service  (Cambridge,  UK).  Genomic  DNA  at  5  ng/ýtl  was  provided.  PCR 
primers  were  identical  to  those  used  during  sequencing  of  the  FGF  I  gene. 
Genotyping  was  performed  on  an  ABI  7900HT  (TaqMan)  instrument  platform 
(Applied  Biosystems,  UK).  Allelic  recognition  probes  were  labelled  with  the 
fluorescent  dyes  VIC  or  FAM.  Probe  sequences  are  provided  in  Appendix  3. 
4.2.4:  STATISTICAL  ANALYSES: 
Genotypic  data  were  checked  for  Mendelian  inconsistencies  using  the 
PEDCHECK  program  (O'Connell  &  Weeks,  1998).  Genotypes  were  confirmed 
for  individuals  flagged  by  the  software,  corrected  if  appropriate  or  individuals 
removed  from  the  dataset. 
Blood  pressure  measurements  were  corrected  for  the  effect  of  anti-hypertensive 
treatment  using  a  method  developed  by  the  Framingham  Study  (Levy  et  al, 
2000)  and  described  in  Section  3.2. 
4.2.4.1.  -  ANALYSIS  OF  THEP2-ADRENERGIC  RECEPTOR  LOCUS: 
A  detailed  description  of  analytical  methods  used  and  reasons  for  their  selection 
can  be  found  in  Section  2.7.2.1.  Briefly,  family-based  tests  of  association  and/or 
linkage  were  used  to  assess  the  SNPs  genotyped  in  the  ADRB2  gene  and 
149 hypertension  status.  Transmission  disequilibrium  testing  (TDT)  was  employed 
to  test  for  linkage  and  association  (Spielman  et  al,  1993).  This  was  originally 
devised  as  a  test  for  linkage  in  the  presence  of  association  and  uses  simplex 
families  consisting  of  parents  and  an  affected  child.  Transmission  of  alleles 
from  parent  to  child  at  a  polymorphic  locus  is  compared  to  non-transmitted 
alleles.  This  test  is  robust  to  the  effects  of  population  stratification  since  the 
non-transmitted  alleles  provide  the  control  genotype.  To  test  for  association 
with  hypertension,  assuming  linkage,  the  empirical  variance  option  of  FBAT 
(EV-FBAT)  was  used.  The  null  hypothesis  of  linkage  but  no  association  is 
tested  by  this  method  (Lake  et  al,  2000).  FBAT  is  robust  with  regard  to 
pedigree  structure,  population  admixture,  phenotype  distribution  and 
ascertainment  methods  and  uses  all  individuals  in  a  pedigree  unlike  TDT. 
ADRB2  SNP  haplotypes  were  assessed  using  a  modified  TDT  method 
implemented  in  TRANSMIT  (Clayton,  1999).  This  is  a  likelihood  method 
which  allows  for  missing  parental  data  and  haplotype  phase  uncertainty  and  uses 
genotype  data  from  available  parents  and  offspring  to  efficiently  determine 
phase.  The  method  is  robust  against  population  stratification. 
Binary  logistic  regression  analysis  was  performed  in  the  parental  generation  to 
test  for  increased  risk  of  hypertension  with  genotype  at  the  three  polymorphic 
loci.  Covariates  of  age,  sex,  and  body  mass  index  were  included. 
150 4.2.4.2.  -  A  NA  L  YSIS  OF  THE  FIBR  OBLA  ST  GR  0  WTH  FA  C  TOR  IL0C  US.  - 
Genotypes  derived  from  SNP  genotyping  of  the  FGFI  locus  in  the  Silesian 
Hypertension  Study  group  were  assessed  for  association  to  quantitative  and 
qualitative  blood  pressure  traits.  The  software  package  FBAT  was  used  to 
perform  a  family-based  association  test  of  SNPs  to  phenotypes  (Horvath  et  al, 
2001).  The  empirical  variance  option  (EV-FBAT)  was  used  to  investigate  the 
null  hypothesis  of  linkage  but  no  association  (Lake  et  al,  2000).  In  addition, 
haplotype  analyses  were  performed  using  Haplotype-FBAT  (H-FBAT)  in  which 
genotypes  at  all  polymorphic  loci  were  assessed  jointly.  The  method  handles 
missing  parental  genotypes  and  unknown  haplotype  phase. 
4.3:  RESULTS: 
4.3.1:  STUDIES  OF  THE  P2-ADRENERGIC  RECEPTOR  LOCUS: 
ADRB2  was  examined  as  a  positional  and  physiological  candidate  which  has 
been  implicated  by  other  studies  of  blood  pressure  and  hypertension.  Three 
non-synonymous,  functional  single  nucleotide  polymorphisms  within  the 
ADRB2  gene  were  genotyped  and  analysed.  These  were  Argl6Gly,  Gln27GIu 
and  Thr16411e.  TDT  analysis  was  used  to  assess  linkage  in  the  presence  of 
linkage  disequilibrium  to  essential  hypertension.  Analysis  was  performed  in 
trios  consisting  of  two  parents,  one  child  or  trios  of  one  parent,  one  affected 
child,  one  unaffected  child.  Argl6Gly  and  Gln27Glu  were  not  significantly 
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Fig.  4.3.1:  Odds  ratios  (OR)  and  95%  confidence  intervals  for  binary 
regression  modelling  of  essential  hypertension  risk.  Confounders  of  age,  sex 
and  BMI  were  included.  OR  was  calculated  for  heterozygous  or  homozygous 
variant  individuals  with  respect  to  wild  type  homozygotes. 
ND  =  not  done  due  to  the  rarity  of  the  Ile  allele. 
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012345 linked  to  hypertension  with  P  values  greater  than  0.05.  The  allele  frequencies  of 
1641le  wer  einsufficient  to  allow  a  vlid  test  of  this  locus  (Table  4.3.1). 
The  EV-FBAT  method  confirmed  the  TDT  results.  No  test  could  be  performed 
for  the  Thr1641le  polymorphism  due  to  the  rarity  of  the  Ile  allele  with  only  17 
occurrences  in  the  study  group.  However,  tests  for  Argl6GIy  and  Gln27GIu 
agreed  with  the  findings  of  the  TDT  analysis.  Neither  polymorphism  was 
significantly  associated  with  essential  hypertension  (Table  4.3.1). 
Of  8  possible  haplotypes,  7  were  observed  in  our  population.  These  were 
designated  A  to  G.  Haplotypes  B,  D  and  F  were  most  common  and  accounted 
for  97.4%  of  observations  (Table  4.3.2).  Transmissions  of  each  haplotype  were 
compared  with  expected  number  of  transmissions  using  TRANSMIT.  The 
observed  transmissions  from  heterozygous  parents  to  hypertensive  offspring 
were  not  significantly  different  from  the  expected.  Haplotype  analysis  therefore 
supported  the  single  locus  analyses,  indicating  no  association  of  the 
polymorphisms  to  essential  hypertension  (Table  4.3.2). 
Binary  regression  modelling,  including  confounders  of  age,  sex  and  BMI,  also 
confirmed  the  single  locus  and  haplotype  TDT  analyses.  Presence  of  one  or  two 
variant  alleles  at  any  SNP  locus  did  not  significantly  increase  risk  of 
hypertension  when  compared  to  common  individuals.  Odds  ratios  for 
heterozygotes  and  variant  homozygotes  were:  0.85  (95%  Cl,  0.3  to  2.2);  P=0.74) 
and  1.46  (95%  Cl,  0.5  to  4.2;  P=0.49)  for  Argl6GIy;  1.33  (95%  Cl,  0.6  to  3.1; 
155 P=0.5)  and  1.54  (95%  Cl,  0.5  to  4.4;  P=0.43)  for  Gln27GIu;  and  0.7  (95%  Cl, 
0.1  to  4.9;  P=0.72)  for  Thr1641le  respectively  (Fig.  4.3.1). 
4.3.2:  STUDIES  OF  THE  FIBROBLAST  GROWTH  FACTOR  I  LOCUS: 
FGF  I  was  investigated  next  as  a  second  putative  physiological  candidate  which 
lay  under  the  maximal  multipoint  linkage  region.  SNP  hunting  and  association 
analyses  were  performed  in  the  Silesian  hypertensive  family  resource. 
4.3.2.1.  -  FIBROBLAST  GROWTH  FACTIOR  I  SEQUENCING  AND  SNP 
DETECTION: 
No  SNPs  within  coding  exons  were  listed  in  on-line  databases  such  as  NCBI 
(http:  //www.  ncbi.  nlm.  nih.  gov/)  so  coding  exons,  flanking  intronic  regions  and 
the  3'  UTR  of  the  gene  were  sequenced  to  allow  identification  of 
polymorphisms  in  the  Silesian  population.  Sequencing  was  performed  with 
genomic  DNA  from  20  unrelated  individuals,  half  of  whom  were  hypertensive. 
This  sample  of  40  chromosomes  gave  an  87%  probability  of  finding 
polymorphisms  with  minor  allele  frequencies  of  5%  and  99%  probability  of 
finding  polymorphisms  with  10%  minor  allele  frequency. 
Regions  covered,  and  results  obtained  by  sequencing,  are  shown  in  Fig.  4.3.1. 
Sequence  data  obtained  were  aligned  to  reference  sequences  from  the  NCBI 
database.  Polymorphic  sites  were  identified  which  differed  from  the  reference 
sequence.  These  xxere  confirmed  by  a  visual  check  of  the  sequencing 
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S electrophero  grams.  The  majority  of  polymorphisms  were  eliminated  as 
sequencing  errors.  In  agreement  with  available  information,  no  SNPs  or  other 
polymorphisms  in  coding  regions  were  found  in  the  20  Polish  individuals 
sequenced.  However,  an  intron  2  SNP  (SNP  1,  T->G)  was  found  19  basepairs 
from  the  start  of  exon  3  and  three  further  SNPs  were  identified  in  the  3'  UTR  of 
the  gene.  These  were  located  284  bp  (SNP  2,  C->A),  323  bp  (SNP  3,  G->A) 
and  774  bp  (SNP  4,  G-+C)  into  the  3'  UTR.  In  total,  then,  4  SNPs  were  found 
spanning  987  bp.  SNPs  2  and  4  were  listed  in  public  databases;  dbSNP 
accession  numbers  were  34002  and  2278688,  respectively.  SNPs  I  and  3  were 
not  listed. 
4.3.2.2.  -  FGFI  SNP  GENOTYPE  ANALYSIS: 
Allele  frequency  estimates  based  on  sequencing  40  chromosomes  suggested  that 
all  four  SNPs  were  common  (Fig.  4.3.1).  Given  this,  heterozygotes  were 
expected  to  be  common  and  each  SNP  was  expected  to  be  informative  for 
family-based  association  studies.  Therefore,  all  four  SNPs  were  genotyped. 
SNP  I  in  intron  2  proved  intractable  to  the  hybridisation  method  used,  and  so 
data  were  not  obtained.  However,  genotypes  were  obtained  for  SNPs  2  to  4  in 
the  3'  UTR.  These  were  analysed  by  family-based  association  testing 
procedures  implemented  in  the  software  FBAT. 
Association  in  the  presence  of  linkage  of  each  individual  SNP  and  hypertension 
was  tested  using  the  empirical  variance  FBAT  (EV-FBAT)  test.  This  method 
was  also  used  to  test  for  association  to  SBP,  DBP  and  pulse  pressure  (PP).  EV- 
158 FBAT  was  preferred  over  TDT  for  FGF  I  analyses  since  it  makes  more  thorough 
use  of  available  genotyped  individuals,  whilst  TDT  is  restrictive  in  its  use  of 
simplex  families.  Use  of  TDT  as  the  primary  method  for  ADRB2  analyses  had 
been  prescribed  by  our  desire  to  follow-up  the  ADRB2  studies  of  Bray  et  al 
(2000b).  This  decision  meant  we  concentrated  on  analysis  of  hypertension 
status  for  ADRB2.  However,  because  we  subsequently  adopted  FBAT  as  our 
primary  analysis  for  FGF  1,  we  were  able  to  assess  SBP,  DBP  and  pulse  pressure 
and  compare  them  directly.  In  FGFI,  SNP  2  proved  to  be  associated  with 
hypertensive  status,  pulse  pressure  and  systolic  blood  pressure  at  the  95% 
confidence  level.  SNPs  3  and  4  showed  no  evidence  of  such  association  (P  > 
0.05).  No  loci  were  associated  with  DBP. 
Association  of  haplotypes  across  the  three  SNP  loci  and  hypertension  status  was 
considered  using  the  haplotype  extension  of  FBAT  (H-FBAT).  This 
methodology  had  not  been  developed  when  ADRB2  was  studied.  However,  its 
availability  for  FGFI  allowed  us  to  examine  single  loci  and  haplotypes  in  a 
concerted  manner.  Of  a  possible  8  haplotypes,  7  were  observed,  denoted  A  to 
G.  Three  of  these,  haplotypes  A,  B  and  C,  accounted  for  96.9%  of  all 
observations  (Table  4.3.4).  These  were  common  enough  to  be  informative  in 
the  study  group.  Haplotype  A,  consisting  of  the  alleles  C,  G  and  G  at  SNPs  2,3 
and  4,  respectively,  was  significantly  associated  with  hypertension  status  in  the 
Silesian  study  sample.  Neither  haplotype  B  nor  C  was  significantly  associated. 
It  appears  that  association  of  haplotype  is  dependent  on  the  allele  at  SNP  2.  All 
other  haplotypes  having  allele  C  at  SNP  2  had  frequencies  of  0.5%  so  were 
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>) uninformative.  However,  the  particular  importance  of  this  SNP  supports  the 
findings  of  the  single  locus  analyses. 
4.4:  DISCUSSION: 
Previous  linkage  analyses  focused  our  attention  on  positional  and  physiological 
candidate  genes  in  a7  cM  region  of  human  chromosome  5q  (Tomaszewski  et  al, 
2002).  Association  studies  of  two  genes  were  performed  in  the  Silesian 
Hypertension  Study  sample,  using  family-based  analysis  methods.  Work  by 
others  had  previously  implicated  the  ADRB2  gene  encoding  the  02-adrenergic 
receptor,  and  this  was  investigated  first.  Single  locus  and  haplotype  analysis  of 
three  non-synonymous,  functionally  relevant  SNPs  within  the  ADRB2  gene  did 
not  support  its  involvement  in  the  development  of  essential  hypertension  in  our 
study  sample  (Tomaszewski  et  al,  2002).  This  was  despite  86%  power  to  detect 
association  (P<0.05)  with  an  odd  ratio  of  1.6  at  the  two  common  ADRB2  loci. 
Attention  turned  to  the  FGF  I  gene  encoding  the  acidic  fibroblast  growth  factor,  a 
cardiovascular  candidate  gene  which,  to  our  knowledge,  has  not  been  studied 
previously.  Single  locus  and  haplotype  analyses  demonstrated  association  of 
polymorphisms  within  the  3'  UTR  of  the  gene.  In  particular,  a  single  locus, 
denoted  SNP  2  and  located  284  bp  into  the  3'  UTR,  appears  to  determine 
presence  or  absence  of  association. 
The  association  analyses  of  both  ADRB2  and  FGH  used  family-based 
approaches.  The  compact  nuclear  family  structure  of  the  Silesian  Hypertension 
Study  sample  lends  itself  to  such  methodologies.  Concerns  have  been  raised  by 
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association  studies  (Ziv  &  Burchard,  2003)  and  family-based  studies  have  been 
developed  to  address  this  (Spielman  &  Ewens,  1996).  In  increasing  robustness 
to  stratification,  however,  there  is  generally  a  loss  of  power  of  family-based 
methods  over  the  case-control  method  (Risch  &  Teng,  1998).  Simulations  have 
shown  that  this  is  particularly  acute  if  parental  genotyping  is  incomplete  or 
absent  (Risch  &  Teng,  1998).  Power  can  be  improved,  however,  by  the  inclusion 
of  at  least  one  affected  parent  and  additional  offspring,  particularly  if  they  are 
also  affected  (Whittaker  &  Lewis,  1998).  In  the  Silesian  sample,  parents  were 
present  and  genotyped.  In  addition,  owing  to  the  recruitment  strategy, 
prevalence  of  essential  hypertension  was  high  in  the  group  resulting  in  a  high 
percentage  of  affected  parents  and  siblings.  Thus,  whilst  controlling  for  the 
effects  of  population  stratification,  the  power  of  the  family-based  methods  used 
is  potentially  maximised.  In  addition,  use  of  multiple  polymorphic  loci  and 
consideration  of  haplotypes  results  in  a  more  robust  analysis  (Sharma  & 
Jeunernaitre,  2000).  These  candidate  genes  were  not  studied  in  the  MIDSPAN 
sample,  partly  due  to  unavailability  of  funding  to  accomplish  this.  However,  it 
was  also  felt  that  such  studies  were  more  usefully  pursued  in  samples  with  a 
significant  disease  burden,  such  as  the  Silesian  sample,  rather  than  a  normal, 
nominally  healthy  population  sample  such  as  MIDSPAN  since  allele  frequencies 
of  genuine  susceptibility  loci  would  be  greater. 
The  ADRB2  gene,  encoding  the  P2-adrenergic  receptor  has  received  much 
attention  from  cardiovascular  researchers  owing  to  its  role  in  maintenance  of 
vascular  tone,  heart  rate,  salt  and  water  excretion  and  lipolysis  (Bray  & 
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well-characterised  functional  polymorphisms.  This  knowledge  allowed  us  to 
select  SNPs  with  known  functional  significance  in  line  with  current  thinking 
(Risch,  2000;  Tabor  et  al,  2002).  These  were  Argl6GIy,  Gln27GIu  and 
Thr16411e.  Argl6GIy  and  Gln27GIu  affect  receptor  downregulation.  The  Gly16 
allele  promotes  agonist-induced  receptor  downregulation,  decreasing  numbers  of 
receptors  at  the  cell  surface.  The  Glu27  allele  has  been  shown  to  result  in 
resistance  to  agonist-induced  downregulation.  Where  both  variant  alleles  are 
present,  the  receptor  downregulates  at  an  increased  rate  comparable  to  the 
presence  of  Gly16  alone  (Green  et  al,  1994).  The  Thrl6411e  variant  receptor  is 
less  common  but  most  functionally  altered.  The  Ile  allele  causes  a  slight  decease 
in  agonist  binding  affinity  but  a  substantial  decrease  in  basal  and  agonist- 
stimulated  adenylyl  cyclase  activity  due  to  defective  G,  protein  coupling  (Green 
et  al,  1993). 
Haplotype  studies  of  ADRB2  gene  polymorphisms  are  rare,  despite  the  potential 
for  interactions  between  the  functional  polymorphisms  described.  A  case-control 
study  including  707  French  hypertensives  found  no  evidence  of  increased  risk  of 
hypertension  from  haplotypes  across  four  ADRB2  polymorphisms,  including 
Arg  I  6GIy  and  Gln27GIu  (He=ann  et  al,  2002).  This  agrees  with  our  findings 
in  the  hypertensive  Silesian  sample.  Conversely,  two  reports  of  normotensive 
study  groups  from  Europe  reported  association  of  haplotypes  of  Argl6GIy  and 
Gln27GIu  with  SBP.  A  population  sample  from  Italy  showed  association  of  SBP 
with  the  haplotype  Argl6-Glu27  as  well  as  association  of  the  Arg16  allele  alone 
(Castellano  et  al,  2003).  A  Norwegian  case-control  study  compared 
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parents.  It  showed  association  of  a4  locus  haplotype  with  blood  pressure.  It  was 
again  found  that  Arg  16  was  the  critical  allele  (Timmermann  et  al,  1998). 
The  vast  majority  of  studies  of  the  ADRB2  locus  examine  polymorphisms  as 
single  loci.  European,  American,  Japanese  and  African  Caribbean  populations 
have  been  investigated.  Ethnic  differences  may  explain  some  of  the  variability  in 
findings.  For  example,  a  case-control  study  in  African  Caribbean  individuals 
demonstrated  association  of  the  pro-downregulatory  Gly16  allele  with 
hypertension  (Kotanko  et  al,  1997).  Association  of  the  Gln27GIu  polymorphism 
and  hypertension  was  demonstrated  in  a  Japanese  case-control  study  with  Gln27 
more  common  in  hypertensives  (Kato  et  al,  2001).  However,  in  agreement  with 
our  findings  and  those  of  He=ann  et  al,  studies  in  white  European  hypertensive 
samples  from  Sweden  and  the  UK  show  no  association  of  ADRB2 
polymorphisms  to  hypertension  (Jia  et  al,  2000;  Bengtsson  et  al,  2001).  In 
contrast,  positive  association  of  ADRB2  polymorphisms  with  blood  pressure  has 
been  reported  in  normotensive  samples  from  Germany  (Busjahn  et  al,  2000), 
Austria  (Gratze  et  al,  1999)  and  Finland  (Bengtsson  et  al,  2001).  Association  of 
SBP  to  ADRB2  has  also  been  reported  in  white  normotensive  US  sibs  (Bray  et 
al,  2000b).  Studies  of  intermediate  phenotypes  in  normotensives  also  suggest 
association  of  ADRB2.  These  include  forearm  blood  flow,  response  to 
isoproterenol  infusion  in  individuals  from  the  UK  (Cockcroft  et  al,  2000)  and 
salbutamol-induced  vasodilatation  in  Austrian  men  (Gratze  et  al,  1999).  It  is 
notable,  then,  that  association  of  ADRB2  is  negative  in  hypertensive  European 
populations  whereas  studies  in  normotensive  groups  suggest  association. 
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hypertension  risk  versus  normal  blood  pressure  distribution  may  lie  in  interaction 
of  other  metabolic  and  cardiovascular  phenotypes.  ADRB2  influences  insulin 
resistance,  obesity  and  heart  failure  (Bray  &  Boerwinkle,  2000).  These  in  turn 
are  known  to  have  very  different  prevalence  in  hypertensive  and  nonnotensive 
individuals  (Reaven,  2003).  They  cannot,  therefore,  be  excluded  as  potential 
factors  confounding  the  relationship  between  ADRB2  variants  and  blood 
pressure.  This  possibility  is  supported  by  studies  of  subsets  of  European 
hypertensives,  for  example  those  with  type  11  diabetes,  for  whom  positive 
association  of  ADRB2  to  hypertension  has  been  reported  (Bengtsson  et  al,  200  1). 
Alternatively,  the  different  contribution  of  ADRB2  in  normotensive  and 
hypertensive  individuals  may  indicate  differences  in  the  genetic  basis  of  high  and 
low  blood  pressure.  This  remains  to  be  clarified.  However,  in  our  hypertensive 
population  there  is  no  evidence  to  suggest  that  ADRB2  contributes  to 
hypertension  risk  across  the  sample. 
The  fibroblast  growth  factor  I  (FGFI)  gene,  unlike  ADRB2,  has  received  little 
attention  from  the  cardiovascular  research  community  making  it  an  exciting  and 
novel  candidate.  Studies  in  animal  models  have  suggested  a  possible  role  in 
blood  pressure  regulation  and,  potentially,  hypertensive  disease.  Direct  effects  of 
FGF  I  on  blood  pressure  have  been  demonstrated.  Infusion  into  rats  causes  a 
dose-dependent  hypotensive  effect  which  is  blocked  by  nitric  oxide  synthase 
(NOS)  inhibitors  (Cuevas  et  al,  1991).  FGFI  has  been  shown  to  stimulate 
increase  in  intracellular  Ca  2+  concentrations,  and  it  is  possible  that  FGH 
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(Cuevas  et  al,  1991).  Others  showed  that  infusion  of  FGFI  into  rats  at 
physiological  concentrations  resulted  in  vasodilatation  of  resistance  arteries  and 
arterioles.  Vascular  flow  also  increased  and  all  effects  were  again  blocked  by 
NOS  inhibition  or  endothelial  denudation  (Wu  et  al,  1996).  Systemic  infusion 
into  rats  has  also  been  demonstrated  to  induce  adrenomedullary  secretion,  raising 
plasma  adrenaline  and  noradrenaline  via  a  corticotropin  releasing  factor- 
dependent  mechanism  (Matsumoto  et  al,  1998a).  Cerebroventricular  or  intra- 
atrial  delivery  of  FGF  I  increased  plasma  corticosterone  and  adrenocorticotrophic 
hormone  (ACTH)  (Matsumoto  et  al,  1998b).  This  suggests  possible  roles  in 
metabolic  processes  and  energy  expenditure  for  a  molecule  which  is  known  to 
act  as  an  appetite  suppressant,  via  glucose-sensitive  neurons  in  the  hypothalamus 
(Matsumoto  et  al,  1998a). 
FGF  I  is  important  in  development  and  causes  proliferation  of  fibroblasts  and 
endothelial  cells  (Powers  et  al,  2000)  -  hence  its  designation  as  a  growth  factor. 
However,  on  binding  to  FGF  receptors,  it  also  triggers  expression  of  a  variety  of 
genes.  Evidence  from  studies  in  cultured  endothelial  cells  suggests  that  one 
effect  of  this  may  be  to  upregulate  glutathione  peroxidase-dependent  oxidative 
stress  defence.  Studies  in  cultured  human  endothelial  cells  showed  that 
application  of  FGF  I  or  the  closely  related  FGF2  increased  intracellular  reduced 
glutathione  concentrations,  and  accelerated  the  removal  of  hydrogen  peroxide 
applied  to  the  cells  (Yang  &  deBono,  1997). 
167 Although  the  FGF  I  gene  has  been  suggested  as  a  cardiovascular  candidate  gene 
previously  (Stoll  et  al,  2000),  genetic  studies  have  yet  to  be  published.  There  are 
presently  no  known  polymorphisms  within  the  coding  region  of  FGF.  Consistent 
with  this,  we  also  did  not  find  any  coding  polymorphisms  despite  good  power  to 
find  alleles  of  5%  frequency  or  over.  In  the  absence  of  polymorphic  loci  in 
coding  regions  it  has  been  suggested  that  5'  and  3'  regulatory  regions  take 
precedence  since  they  may  affect  the  timing,  location  or  level  of  gene  expression 
(Tabor  et  al,  2002).  Our  analysis  of  three  polymorphic  loci  in  the  3'  UTR  of  the 
FGF  I  gene  showed  association  of  the  locus  to  hypertension  status  and  blood 
pressure  phenotypes.  This  is  consistent  with  our  linkage  studies  which  were 
positive  for  both  disease  status  and  quantitative  trait  in  the  Silesian  group 
(Tomaszewski  et  al,  2002).  Our  results  implicate  SNP  2,  primarily,  since  it  was 
associated  both  as  a  single  locus  and  within  a  haplotype  across  three  loci. 
The  frequencies  of  the  haplotypes  indicate  linkage  disequilibrium  between  the 
three  loci.  However,  LD  is  not  total  since  the  allele  at  SNP  2  does  not 
definitively  predict  the  allele  at  SNPs  3  or  4.  This  may  explain  why  SNPs  3  and 
4.  as  individual  loci,  are  not  associated.  It  is  known  that  LD  is  not  proportional 
to  distance  below  60  Kb  separation  (Wright  et  al,  1999).  Complexity  in  LD  over 
very  short  distances  -  in  this  case,  490  bp  -  may  be  expected  and  has  been 
reported  by  others  in  studies  of  complex  diseases  such  as  asthma  (Allen  et  al, 
2003).  Equally,  the  possibility  exists  that  strong  LD  may  be  present  between 
polymorphic  loci  separated  by  quite  large  distances,  perhaps  as  much  as  100  Kb 
(Daly  et  al,  2001).  Therefore,  association  of  SNP  2  with  hypertension  and  blood 
168 pressure  traits  serves  to  implicate  a  smaller  segment  of  the  original  7  cM  linkage 
region,  essentially  fine  mapping  an  area  of  interest. 
SNP  2,  itself,  may  be  the  functional  locus  but  in  the  absence  of  functional 
characterisation  it  is  not  possible  to  conclude  this.  It  may  also  be  in  LD  with  the 
causative  locus.  Determination  of  the  strength  of  LD  in  the  region  requires  a  fine 
mapping  strategy  as  used  by  others  to  describe  haplotype  block  structures  (Rioux 
et  al,  200  1).  At  present,  then,  the  association  at  the  3'  end  of  the  FGF  1  gene  may 
implicate  a  region  of  perhaps  200  Kb.  Fine  mapping  within  this  region  will 
identify  the  critical  haplotype  tag  associated  with  the  phenotypes  of  interest. 
This  may  result  in  a  number  of  genetically  equivalent  loci  which  cannot  be 
separated  based  on  strength  of  association,  a  limitation  which  has  been  reported 
by  others  (Rioux  et  al,  2001).  In  this  case,  study  of  the  functional  effects  of 
polymorphisms  may  be  required  to  determine  their  relative  importance. 
Within  the  local  region  around  the  associated  SNP  loci,  density  of  known  genes 
is  relatively  low,  compared  to  the  genomic  average  of  approximately  10  per 
million  bases  (Cartegni  et  al,  2002).  The  100  Kb  proximal  of  SNP  2  contains  the 
FGF  I  gene  including  regulatory  regions  (Chiu  et  al,  200  1).  In  the  distal  100  Kb, 
no  other  genes  are  known  except  for  GRAF  (GTPase  regulator  associated  with 
focal  adhesion  kinase)  which  is  located  85  Kb  distal  of  the  FGF  I  gene.  GRAF  is 
a  GTPase-activating  protein  which  interacts  with  focal  adhesion  kinase  (FAK). 
FAK  provides  a  link  between  integrins  and  the  signalling  cascades  that  are 
activated  by  them  (Hildebrand  et  al,  1996).  Integrin  signalling  plays  a  part  in 
regulation  of  vascular  tone,  perhaps  partly  through  regulation  of  ion  channels. 
169 Signalling  through  (xvP3  integrins  results  in  NO  production  by  endothelial  cells 
and  there  is  evidence  to  suggest  that  extracellular  matrix  deposition  and  integrin 
expression  in  hypertension  are  altered  (Martinez-Lemus  et  al,  2003).  The  GRAF 
gene  cannot  be  dismissed  out  of  hand  as  a  candidate,  therefore.  However,  its 
distance  from  the  locus  of  association  weakens  the  case  in  favour  whilst 
strengthening  that  of  FGF  I.  Given  that  FGF  I  has  plausible  biological  merit  and 
is  the  only  known  gene  within  180  Kb,  FGFI  is  a  logical  focus  for  further 
mapping  and  functional  studies. 
In  summary,  haplotype  and  single  locus  association  analyses,  using  family-based 
methods,  were  applied  to  the  investigation  of  two  candidate  genes,  ADRB2  and 
FGF  1,  in  the  5q3  1.1  -q33  linkage  region  previously  described.  Analysis  of  three 
common,  functional  polymorphisms  probably  excludes  an  effect  of  these 
polymorphisms  as  hypertension  susceptibility  loci  in  our  Silesian  Hypertension 
Study  group.  However,  such  analyses  are  unlikely  to  describe  all  haplotype 
structure  within  the  gene  and  must  have  lower  power  to  exclude  other  loci, 
particularly  those  in  low  LD.  Analysis  of  polymorphisms  in  the  3'  UTR  of 
FGFI,  however,  revealed  association  to  both  hypertension  and  blood  pressure 
phenotypes  and  implicated,  particularly,  a  SNP  locus  284  bp  into  the  3'  UTR. 
No  other  known  genes  exist  within  85  Kb  of  the  associated  loci.  Thus,  FGF  I  has 
been  confirmed  as  a  positional  candidate  as  well  as  being  a  physiological 
candidate.  Further  mapping  and  functional  studies  of  this  gene  are  required  to 
confirm  its  contribution  to  hypertension  risk. 
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CANDIDATE  GENE  ANALYSES  OF  FAMILIAL  INTRACRANIAL 
ANEURYSMS 
171 5.1:  INTRODUCTION: 
Familial  intracranial  aneurysms  (FIAs)  form  as  a  result  of  complex  processes 
involving  genetic  and  acquired  risk  factors  (Alberts,  1999).  Whilst  as  many  as 
95%  remain  asymptomatic  (Schievink  et  al,  1994),  the  minority  that  rupture  do 
so  with  devastating  effect.  Aneurysmal  subarachnoid  haemorrhage  is  associated 
with  50%  mortality  and  about  a  third  of  survivors  have  serious  neurological 
deficits  (Schievink,  1997).  Prognosis  for  those  patients  who  undergo  elective 
surgery  for  intracranial  aneurysms  (lAs)  is  considerably  better.  Mortality  of  1% 
and  morbidity  of  4%  underline  the  benefit  of  detecting  and  treating  intracranial 
aneurysms  early  (King  et  al,  1994). 
At  present  the  aetiology  of  FlAs  is  poorly  understood.  Mechanical  factors  such 
as  haemodynamic  stress  are  involved  and  may  account  for  the  common  siting  of 
aneurysms  at  arterial  bifurcations,  particularly  around  the  circle  of  Willis.  Other 
factors  such  as  inflammatory  responses  are  thought  to  act  on  regions  of  the 
arterial  wall  weakened  by  other  processes.  However,  the  underlying  weakness 
may  be  genetically  determined  (Zhang  et  al,  2003).  Presently,  no  biochemical 
markers  of  aneurysm  formation  are  known  and,  without  an  understanding  of  the 
genetic  basis,  it  is  difficult  to  effectively  identify  at-risk  individuals  in  families 
with  a  history  of  FIA  (van  Gijn  &  Rinkel,  2001). 
Studies  of  the  pattern  of  inheritance  in  intracranial  aneurysm  families  have 
identified  autosomal  dominant,  autosomal  recessive  and  multifactorial 
inheritance  patterns  (Bromberg  et  al,  1995) 
. 
This  indicates  the  possibility  of 
172 major  gene  effects,  but  also  the  probability  of  genetic  heterogeneity  (Schievink, 
1997).  However,  in  the  event  that  major  gene  effects  exist  they  may  be 
detectable  by  linkage  analysis  or  association-based  methods.  Such  studies  in  FIA 
patients  are  presently  rare  (Zhang  et  al,  2003).  Here  a  candidate  gene  approach 
is  used  to  examine  the  contribution  of  four  genes  to  the  formation  of  intracranial 
aneurysms  in  families  from  the  west  of  Scotland  who  have  a  history  of  FIA. 
A  present  hypothesis  suggests  that  the  underlying  defect,  which  leads  to 
intracranial  aneurysm  (IA)  formation,  involves  an  imbalance  in  extracellular 
matrix  formation  and/  or  degradation  (Zhang  et  al,  2003).  It  may  be  this  that 
amplifies  the  long-term  effects  of  ageing  and  haemodynamic  stress.  Rare 
Mendelian  connective  tissue  disorders  such  as  autosomal  dominant  polycystic 
kidney  disease,  Marfan  syndrome  and  Ehlers-Danlos  syndrome  type  IV  arise 
from  mutations  in  genes  encoding  structural  proteins.  Features  of  these 
pathologies  include  vascular  catastrophes  such  as  arterial  dissections  and 
ruptures  as  well  as  aneurysm  formation  on  both  systemic  and  cerebral  arteries 
(Schievink,  1997).  It  is  reasoned  that  mutations  in  genes  underlying  these 
Mendelian  disorders  or  other  components  of  matrix  fon-nation  and  decomposition 
may  lead  to  the  formation  of  IAs  seen  in  families.  Selection  of  the  candidate 
genes  studied  has  been  based  on  this  hypothesis.  Consequently,  genes  encoding 
collagen  type  111,  fibrillin  1,  polycystin  1,  and  serine  protease  inhibitor  Al  have 
been  studied. 
Collagen  type  III  is  a  major  component  of  the  arterial  wall  and  is  encoded  by  the 
COL3AI  gene  on  chromosome  2q32.2.  Three  collagen  al(III)  chains  form  the 
173 finished  homotrimeric  collagen  III  fibre  (Fig.  5.1.1)  and  provide  tensile  strength 
to  the  arterial  wall  (van  Vlijmen-van  Keulen  et  al,  2002). 
Mutations  in  COUAI  are  responsible  for  Ehlers  Danlos  syndrome  type  IV  (EDS 
IV).  The  majority  of  deaths  in  EDS  IV  patients  are  due  to  spontaneous  rupture, 
dissection  and  aneurysm  formation  of  large  to  medium-sized  arteries  (Schievink, 
1997).  The  COUAI  gene  has  therefore  attracted  considerable  interest  as  a 
candidate  for  aneurysmal  disorders.  Studies  of  collagen  type  III  levels  in  skin 
fibroblasts  from  abdominal  aortic  aneurysm  (AAA)  patients  suggest  that  10%  of 
AAA  patients  may  have  reduced  collagen  III  levels  (van  Keulen  et  al,  1999). 
Reduced  collagen  type  III  production  has  also  been  reported  in  IA  patients  (van 
den  Berg  et  al,  1997).  Some  IA  patients  may  have  impaired  secretion  of  collagen 
type  111,  as  low  as  50%,  in  the  absence  of  differences  in  initial  production.  This 
may  be  due  to  structural  defects  affecting  thermal  stability  (Majamaa  &  Myllyla, 
1993).  Crosslinking  of  collagen  fibres,  essential  to  the  integrity  of  the  tissue, 
may  also  be  reduced  (Gaetani  et  al,  1996). 
Despite  the  biochemical  data,  sequencing  or  single  strand  conformational 
analyses  (SSCP)  of  the  coding  regions  of  COUAI  have  failed  to  reveal  relevant 
mutations  in  IA  patients  (Kuivaniemi  et  al,  1993;  van  den  Berg  et  al,  1999). 
However,  such  mutations  affecting  the  triple  helical  domain  of  the  gene  have 
been  reported  in  AAA  families  (Tromp  et  al,  1993).  Linkage  studies  have  not 
been  performed  in  IA  families.  However,  a  single  case-control  study  of  19  IA 
patients  and  15  controls  showed  a  significant  association  of  an  Avall  restriction 
polymorphism  to  IA  (Brega  et  al,  1996). 
174 FBNI  on  chromosome  15q2l.  l  encodes  fibrillin  1,  the  principal  structural 
component  of  elastic-  fibre-associated  microfibrils  (Fig.  5.1.1).  It  is  crucial  to  the 
elasticity  and  resilience  of  blood  vessels  (Kielty  et  al,  2002).  The  consequences 
of  disruption  of  this  role  are  seen  in  Marfan  syndrome  where  mutations  in  FBNl 
cause  aortic  ruptures  and  dissections.  Case  reports  of  intracranial  aneurysms  in 
Marfan  patients  also  exist  (Schievink,  1997).  Its  significance  in  at  least  a  subset 
of  AAA  families  has  been  suggested  by  linkage  of  intragenic  markers  (Vaughan 
et  al,  2001),  and  mutations  have  been  described  in  thoracic  aortic  aneurysm 
patients  (Milewicz  et  al,  1996)  and  AAA  patients  (Francke  et  al,  1995).  Studies 
of  FBNI  in  IA  patients  have  yet  to  be  published.  However,  some  groups  are  at 
present  studying  this  gene  in  families  having  isolated  features  of  Marfan 
syndrome  including  arteriopathies  and,  specifically,  intracranial  aneurysms 
(Zhang  et  al,  2003). 
The  PKDI  gene  encodes  polycystin  I  and  is  located  on  chromosome  16pI3.3. 
The  putative  functions  of  polycystin  I  include  cell-cell  adhesion  and  cell 
signalling,  but  its  function  is  not  precisely  known  at  present  (Weston  et  al,  2003). 
Mutations  in  the  gene  result  in  autosomal  dominant  polycystic  kidney  disease 
(ADPKD).  A  primary  characteristic  of  this  disorder  is  the  formation  of  renal 
cysts  which  affect  nephrons  and  collecting  ducts.  However,  aortic  aneurysms 
and  dissections  are  also  common  and  there  is  a  firm  link  with  increased  risk  of 
lAs  (Schievink,  1997).  As  might  be  expected  from  the  vascular  aspect  of 
ADPKD,  polycystin  I  is  expressed  in  medial  layers  of  arterial  walls  (Griffin  et 
al,  1997)  (Fig.  5.1.1). 
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"ý  r.  r- Studies  to  correlate  site  of  mutation  with  phenotype  suggest  that  more  5'  PKD  I 
mutations  result  in  a  more  cerebrovascular  phenotype  (Rossetti  et  al,  2003). 
Families  with  more  marked  cerebrovascular  but  less  severe  renal  manifestations 
are  known  (McConnell  et  al,  2001).  However,  despite  the  arterial  expression  of 
polycystin  1,  the  vascular  defects  in  ADPKD  and  the  confirmed  risk  of  IA  from 
this  disorder,  no  studies  of  PKD  I  in  IA  families  or  aortic  aneurysm  families  have 
been  reported.  It  is,  nevertheless,  considered  a  candidate  gene  worthy  of  study 
(Zhang  et  al,  2003). 
The  fourth  gene  studied  is  SERPINAI  which  encodes  a  serine  or  cysteine 
protease  inhibitor  known  variously  as  'protease  inhibitor'  (PI)  or  'a  I  -antitrypsin' 
(Fig.  5.1.1).  The  gene  is  located  on  chromosome  14q32.13.  Its  product,  PI,  is 
the  most  abundant  and  important  inhibitor  of  elastase  which,  itself,  is  a  key 
enzyme  in  processing  of  elastic  tissues  (Zhang  et  al,  2003).  The  balance  between 
PI  and  elastase  determines  elastin  catabolism  (Baker  et  al,  1995).  Deficiency 
phenotypes  of  Protease  Inhibitor  (PI)  exist  within  the  general  population.  The 
wild  type  phenotype  is  denoted  PiMM  and  has  a  95%  frequency.  Of  the 
deficiency  phenotypes,  the  most  severe  is  PiZZ  which  has  only  10-  15%  activity, 
but  is  also  the  most  rare  at  2-3%  (Cohen  et  al,  1990).  Homozygosity  for  the  'T 
phenotype  leads  to  pulmonary  emphysema  and  liver  disease  (Zhang  et  al,  2003). 
However,  the  effect  of  less  severe  deficiencies  is  unclear. 
Deficiency  phenotypes  of  PI  have  been  reported  as  more  common  in  aortic 
aneurysm  patients  (Cohen  et  al,  1990)  and  small  studies  of  IA  patients  have 
reported  similar  observations.  Schievink  et  al  (Schievink  et  al,  1996)  showed  a 
177 2-fold  prevalence  of  such  deficiency  phenotypes  in  100  consecutive  IA  patients 
compared  with  the  general  population  and  others  have  reported  as  high  as  8-fold 
over-representation  in  London  IA  patients,  although  this  was  not  significant  after 
multiple  testing  correction  (StJean  et  al,  1996).  PI  activity  may  also  be  reduced 
in  intracranial  (Tartara  et  al,  1996)  and  aortic  aneurysm  patients  (Cohen  et  al, 
1987). 
Investigation  of  the  candidate  genes  described  was  conducted  in  Scottish  families 
with  history  of  FIA  and  SAH.  Further  analysis  of  PI  was  performed  using  DNA 
samples  obtained  from  FIA  families  recruited  in  the  south  of  England.  To  assess 
the  association  and  linkage  of  IA  formation  to  these  candidate  genes,  an 
intragenic  or  proximal  microsatellite  was  genotyped  for  each  gene. 
5.2:  METHODS: 
5.2.1:  STUDY  RECRUITMENT: 
Recruitment  of  Scottish  individuals  to  this  pilot  study  took  place  during  1998  to 
1999  following  the  strategy  described  in  Section  2.2.1.  It  was  conducted  by  a 
single  research  nurse  from  the  case  files  of  one  neurosurgeon,  Mr  K.  W.  Lindsay, 
who  has  a  special  interest  in  FIA.  The  original  study  design  specified 
recruitment  of  affected  sibling  pairs,  a  design  since  used  by  others  in  recently 
published  FIA  genome-wide  scans.  However,  in  the  absence  of  suitable  families 
or  due  to  unwillingness  on  the  part  of  individuals  to  participate,  focus  turned  to 
recruiting  with  the  following  priority:  1)  any  affected  family  members;  2)  parents 
178 of  affected  persons;  3)  any  other  family  members.  Affected  status  was  based  on 
history  of  aneurysmal  SAH  or  angiographic  screening  for  IA  by  Mr  Lindsay's 
team.  Data  on  IA  and  SAH  risk  factors  such  as  age,  sex,  hypertension  and 
smoking  history  were  recorded.  Eighty  individuals  from  21  families  were 
recruited,  including  28  affected  by  IA. 
DNA  from  Southampton  FIA  families  was  the  generous  gift  of  Prof.  1.  N.  M. 
Day  at  the  University  of  Southampton.  DNA  was  derived  from  12  extended 
pedigrees  with  history  of  FIA  and/or  SAH.  A  total  of  143  individuals  was 
available  of  which  16  individuals  were  known  to  be  affected. 
5.2.2:  CANDIDATE  MARKER  GENOTYPING: 
For  each  candidate  gene,  a  search  of  on-line  databases  and  the  literature  was 
made  to  find  an  intragenic  microsatellite  marker,  if  known,  or  a  marker  as 
proximal  to  the  gene  as  possible.  From  the  Genome  Database  (GDB, 
http:  //gdbwww.  gdb.  orgo,  intragenic  markers  were  available  within  intron  26  of 
COUAI  and  the  3'  UTR  of  PKDI,  and  7  Kb  upstream  from  SERPINAL 
Primer  sequences  for  these  were  taken  directly  from  GDB.  A  literature  search 
revealed  a  microsatellite  in  intron  43  of  FBNI  (Miller  et  al,  1996). 
5.2.2.1.  -  GENOTYPING  OF  SCOTTISH  FIA  SAMPLES: 
Fluorescently  labelled  PCR  of  the  four  microsatellite  markers  was  conducted  as 
detailed  in  Section  2.4.1  using  HotStar  Taq  (Qiagen  Ltd,  UK).  Primer  sequences 
and  annealing  temperatures  are  given  in  Appendix  3.  Following  PCR,  markers 
179 were  pooled  together  and  diluted  to  enable  resolution  on  the  ABI  377  semi- 
automated  DNA  analyser  (Applied  Biosystems,  UK).  PCR  products  were 
resolved  on  the  ABI  377  as  detailed  in  Section  2.4.2.1.  Data  were  extracted  and 
analysed  with  GeneScan  v3.1.  Genotypes  were  assigned  and  checked  using 
Genotyper  Q.  I.  Data  were  checked  by  two  independent  individuals  who  were 
blind  to  phenotype. 
5.2.2.2:  GENOTYPING  OF  SOUTHAMPTON  FIA  SAMPLES: 
Only  the  marker  for  SERPINAI  was  genotyped  in  the  Southampton  families. 
PCR  for  this  marker  was  performed  exactly  as  for  Scottish  samples.  Resolution 
and  genotyping  was  accomplished  with  an  ABI  3730  DNA  analyser  as  detailed 
in  Section  2.4.2.2.  Data  were  analysed  and  genotyped  using  GeneMapper  v3.0. 
Parity  of  binning  between  Genotyper  software  and  GeneMapper  software  was 
assured  by  the  use  of  identical  control  DNA  samples  in  all  runs  and  genotyping 
of  a  subset  of  Southampton  samples  on  an  ABI  377.  Genotypic  data  from  377 
and  3730  platforms  were  compared  in  this  subset  using  an  Excel  spreadsheet  to 
ensure  agreement. 
5.2.3:  STATISTICAL  ANALYSES: 
Genotypic  data  were  held  in  an  anonymised  Access  database  to  aid  analysis. 
PEDCHECK  (O'Connell  &  Weeks,  1998)  was  used  to  check  for  and  resolve 
Mendelian  errors  within  families. 
180 Initial  analyses  of  the  Glasgow  data  are  described  in  detail  in  Section  2.7.3  and 
were  as  follows:  two-point  linkage  between  each  microsatellite  marker  and  the 
trait  was  assessed  using  Affected  Pedigree  Member  (APM)  linkage  analysis 
(Weeks  &  Lange,  1988).  This  tests  for  an  excess  of  identity-by-state  (IBS)  allele 
sharing  between  affected  relatives,  conditional  on  the  degree  of  relatedness  and 
allele  frequencies  at  the  marker  locus.  Although  the  IBS  method  is  not  as 
powerful  as  IBD  methods,  the  small  numbers  suitable  for  the  APM  analysis  and 
lack  of  parents  meant  that  IBD  estimations  would  have  likely  been  unreliable. 
This  IBS  method  compromised  power  for  pragmatism.  Empirical  P  values  were 
determined  by  simulation,  over  1000  replicates,  using  SIM  and  HIST  (Weeks & 
Lange,  1988). 
Linkage  was  also  assessed  using  the  combined  Transmission  Disequilibrium  Test 
JDT)  (Spielman  et  al,  1993)  and  sibling  TDT  (S-TDT)  (Spielman  &  Ewens, 
1998)  in  multiplex  families.  In  this  context,  TDT/S-TDT  is  valid  as  a  test  for 
linkage  only.  Transmission  of  alleles  from  heterozygous  parents  to  affected 
offspring  is  assessed  by  TDT.  In  families  having  only  one  parent,  the  S-TDT 
uses  the  unaffected  offspring  to  provide  an  untransmitted  genotype  to  replace  the 
missing  parent.  Analyses  were  performed  twice,  specifying  those  with  unknown 
affection  status  as  unknown  and  then  as  unaffected. 
Linkage  in  the  presence  of  linkage  disequilibrium  was  tested  by  use  of  TDT  and 
S-TDT  in  simplex  families.  Two  analyses  specifying  unknown  and  unaffected 
status  were  performed,  as  for  the  multiplex  family  analyses. 
181 The  Family-Based  Association  Test  (FBAT)  (Horvath  et  al,  2001)  tests  the  null 
hypothesis  of  no  linkage  and  no  association  It  allows  the  analysis  of  complex 
pedigree  data  by  decomposing  complex  structures  into  individual  nuclear 
families.  This  was  used  to  test  for  linkage  and  association  within  the  complete 
pedigrees,  allowing  inclusion  of  all  genotyped  individuals.  The  null  hypothesis 
of  no  association  can  also  be  tested  using  the  empirical  variance  option  within 
FBAT  (EV-FBAT).  Markers  were  therefore  analysed  for  association  to  the  trait 
with  this  method. 
Finally,  a  case-control  design  was  used  to  test  for  association  between  markers 
and  trait.  Eighteen  affected,  unrelated  individuals  were  ethnicity,  age  and  sex- 
matched  to  18  controls.  Obviously,  these  are  very  small  groups  for  the  study  of  a 
complex  trait.  Realistically,  the  power  of  such  small  samples  is  negligible, 
particularly  in  the  face  of  probably  heterogeneity.  It  is  unlikely  that  a  single  gene 
disorder  could  be  detected,  particularly  if  allelic  heterogeneity  were  present. 
Such  heterogeneity  has  been  reported  for  Mendelian  disorders  caused  by  some  of 
the  genes  selected.  To  use  the  available  patients  as  efficiently  as  possible, 
controls  were  carefully  selected  from  families  originating  from  the  same  locality 
as  the  FIA  families,  having  no  known  history  of  cerebrovascular  catastrophes, 
nor  connective  tissue  disorders.  The  existence  of  Hardy-Weinberg  equilibrium 
(HWE)  was  confirmed  in  controls  using  Fisher's  exact  test  with  1000  simulations 
as  implemented  in  GDA  vl.  O  (Lewis,  P.  0.  and  Zaykin,  D.  2001; 
http:  //lewis.  eeb.  uconn.  edu/lewishome/software.  html).  Genotype  frequencies  in 
case  and  control  groups  were  compared  by  an  exact  X2  test  using  STATXACT- 
TURBO  v2.1  (Cytel  Software  Corporation,  USA). 
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00 Genotypes  obtained  for  the  SERPINAI  marker  in  Southampton  families  were 
combined  with  data  from  Glasgow  families.  This  combined  data  set  was 
analysed  with  APM,  TDT/S-TDT,  FBAT  and  EV-FBAT. 
5.3:  RESULTS: 
A  total  of  80  individuals,  including  28  known  to  have  lAs,  were  recruited  from 
21  families  in  the  Glasgow  area  of  Scotland.  Demographic  data  are  shown  in 
Table  5.3.1.  In  five  of  the  21  families,  only  one  family  member  was  willing  to 
participate.  Of  these  five  singletons,  two  were  not  known  to  be  affected. 
Individuals  recruited  from  the  other  16  families  are  shown  in  Fig.  5.3.1.  Family 
18  contained  a  single  affected  individual  for  whom  no  genotypes  could  be 
obtained  due  to  PCR  failure.  This  family  and  the  two  unaffected  singletons  were 
not  used  in  analyses.  In  addition,  PCR  failed  for  the  affected  child  in  family  5 
restricting  the  usefulness  of  this  pedigree.  Thus,  76  individuals  from  18  families 
were  included  in  the  final  Scottish  study  group.  Of  these,  26  were  known  to  be 
affected. 
Individuals  from  Southampton  were  derived  from  12  families.  Of  143 
individuals,  16  were  known  to  be  affected.  Mendelian  errors  in  a  branch  of  one 
family  resulted  in  28  individuals  being  excluded  from  analysis.  None  of  these 
were  known  to  be  affected  nor  had  affected  siblings,  parents  or  children.  Thus, 
the  combined  data  set  consisted  of  191  individuals  including  42  known  affected 
subjects  from  30  pedigrees  of  variable  structure. 
184 Table  5.3.1:  Demographic  and  phenotypic  data  for  Scottish  FIA  study 
participants. 
Affection 
Affected 
status 
Unknown 
N  28  52 
Screened  for  IAs  (N)  28  5 
%  multiple  aneurysms  39  - 
%  SAH  60.7 
%  sex  (m:  f)  21  :  79  46  :  54 
Mean  age  ±  SE  /  yrs  51.1±  2.0  42.4  ±  2.3 
Mean  SBP  SE  mmHg  136.8  ±  4.3  131.0  ±  2.5 
Mean  DBP  SE  mmHg  84.5  ±  2.4  79.4  ±  1.7 
%  on  HTN  treatment  35.7  11.5 
%  history  of  smoking  68  52 
Details  are  shown  for  patients  with  a  positive  affection  status  for  IA 
and/or  SAH  versus  individuals  not  known  to  be  affected. 
185 Genotypes  for  four  markers  were  obtained  in  Scottish  individuals.  Locations  of 
these  markers  relative  to  candidate  genes  are  shown  in  Figure  5.3.2.  Names, 
published  and  observed  heterozygosities  are  shown  in  Table  5.3.2.  Each 
candidate  marker  was  assessed  using  linkage  and  association  methods.  Results 
of  these  analyses  are  presented  in  Table  5.3.3. 
Linkage  of  each  candidate  marker  to  presence  of  intracranial  aneurysms  in  the 
Scottish  cohort  was  assessed  by  both  APM  linkage  analysis  and  TDT/S-TDT 
multiplex-family  analysis.  No  marker  was  significantly  linked  to  intracranial 
aneurysm  status  as  assessed  by  APM.  This  was  the  case  for  the  TDT/S-TDT 
analyses  also,  whether  unknowns  were  treated  as  'unknown'  (Analysis  1)  or 
'unaffected'  (Analysis  II).  The  lowest  P  value  obtained  for  each  multi-allelic 
marker  is  presented.  In  such  small  numbers  of  individuals,  trends  of  significance 
may  be  of  relevance.  Given  this,  it  is  noted  that  the  COUAI  VNTR  had  the 
lowest  P  value  in  all  three  linkage  analyses.  However,  it  was  not  affected  by  the 
status  of  unknowns/unaffecteds  in  the  TDT/S-TDT  analyses. 
P  values  obtained  for  TDT/S-TDT  in  simplex  families  are  also  presented.  No 
significant  linkage  in  the  presence  of  association  was  seen  in  these  analyses  but, 
again,  COUAI  produced  the  lowest  P  value.  In  analyses  of  both  multiplex  and 
simplex  families,  the  specification  of  status  of  unknowns  had  the  greatest  impact 
on  the  P  value  of  the  SERPINA  I  locus. 
186 COUA1 
VNTF,  intron  26 
FBNI 
234  Kb 
Microsatellite,  intron  43 
PKD1 
46  Kb 
Microsatellite,  3'  UTR 
SERPINAl  10  Kb 
Microsatellite,  7.3  Kb  upstream 
Fig.  5.3.2:  A  schematic  representation  of  marker  positions  relative  to  genes.  An 
intragenic  or  proximal  microsatellite  or  'variable  number  of  tandem  repeats' 
(VNTR)  marker  was  genotyped  for  each  candidate  gene.  Positions  of  markers 
relative  to  gene  coding  regions  are  represented  schematically.  Size  of  regions 
spanned  by  genes  are  presented. 
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(7-1 Results  from  multi-allelic  FBAT,  multi-allelic  EV-FBAT  and  ý  analyses  showed 
a  different  trend.  In  all  of  these  analyses,  SERPINAI  produced  the  lowest  P 
values.  The  case-control  )?  test  for  SERPINAI  gave  the  strongest  indication  of 
association  (P=0.028).  This  was  not  significant  if  corrected  for  multiple  testing. 
Tests  of  association  are  more  powerful  than  linkage  analyses,  requiring  fewer 
individuals  to  detect  the  same  magnitude  of  genotype  risk  (Risch  &  Merikangas, 
1996).  Thus,  they  may  be  more  useful  in  studies  containing  small  numbers  of 
individuals  as  in  this  case.  In  this  study,  use  of  FBAT  also  allowed  inclusion  of  a 
greater  number  of  participants  in  analysis  than  IBD  linkage  or  TDT  approaches. 
The  Z  analysis  has,  in  its  favour,  the  correct  specification  of  affection  status  of 
both  cases  and  controls,  with  little  or  no  ambiguity.  Total  number  of  people 
included  in  the  Xý  analysis  also  exceeded  that  of  the  APM  or  TDT/S-TDT 
analyses.  Since  the  SERPINAI  marker  gave  the  greatest  suggestion  of 
significance  in  these  analyses,  it  was  further  genotyped  in  the  Southampton 
family  samples  and  the  data  combined  with  the  Glasgow  genotypes  to  assess  the 
effect  of  increased  numbers  on  significance. 
Results  for  analyses  of  the  combined  data  set  are  presented  in  Table  5.3.3.  Since 
matched  controls  were  not  available  for  the  Southampton  samples,  aX2  analysis 
could  not  be  done.  Poorly-matched  controls  may  result  in  type  I  error  in  case- 
control  studies  due  to  population  stratification  (Rabinowitz  &  Laird,  2000).  This 
is  particularly  important  given  the  small  numbers  of  individuals  studied  here.  All 
other  analyses  were  performed  using  the  combined  data.  AP  value  of  0.024  was 
obtained  for  the  157  bp  allele  ftom  TDT/S-TDT  analysis  in  multiplex  families 
190 when  unknowns  were  set  as  unaffected.  TDT/S-TDT  in  simplex  families 
resulted  in  P=0.077  for  the  157  bp  allele,  again  with  unaffected  status  specified. 
P  values  bordering  on  0.05  were  obtained  for  the  multi-allelic  FBAT  and  EV- 
FBAT  analyses  (Table  5.3.3).  Bi-allelic  FBAT  analysis  was  also  run  on  the 
combined  dataset.  This  gave  P=0.02  from  10  informative  families  for  allele 
157.  This  reflects  findings  of  the  TDT  tests. 
5.4:  DISCUSSION: 
This  study  provides  case-control  study  evidence  to  suggest  that  association  of  a 
marker  proximal  to  the  SERPINAl  gene  and  intracranial  aneurysm  status  may 
exist  in  Scottish  individuals  from  FIA  families.  In  a  larger  cohort  consisting  of 
families  from  Scotland  and  the  south  of  England,  combined  TDT  and  S-TDT 
analyses  suggested  that  the  SERPINAI  marker  may  be  both  linked  to  and 
associated  with  intracranial  aneurysm  status.  A  case-control  design  was  not 
possible  in  this  larger  data  set.  However,  P  values  from  other  family-based 
analyses  support  this  trend.  Linkage  and  association  analyses  of  markers  within 
the  COUAI,  FBNI  and  PKDI  genes  did  not  provide  any  suggestion  that  these 
markers  are  linked  to  or  associated  with  intracranial  aneurysm  status. 
Clearly,  it  is  not  possible  to  draw  firm  conclusions  from  this  pilot  study 
including,  as  it  does,  small  numbers  of  individuals  from  families  with  highly 
variable  structures.  P  values  obtained  are  not  significant  if  corrected  for  multiple 
testing.  Any  suggestions  of  linkage  or  association  require  investigation  in  a 
much  larger  study.  However,  it  is  notable  that  a  number  of  different  analytical 
191 methods,  all  using  the  data  in  different  ways,  display  the  same  trend  towards 
significance.  It  is  interesting  to  note  that  most  P  values  decreased  on  adding  the 
additional  Southampton  families.  The  largest  effect  was  seen  for  TDT/S-TDT 
tests  when  unknowns  were  specified  as  unaffected.  It  is  almost  inevitable  that 
some  of  those  unknowns  will  either  be  harbouring  lAs  now  or  will  develop  them 
later.  This  therefore  introduces  misclassification  and  must  weaken  the  power  of 
the  S-TDT  tests.  However,  the  bias  in  this  case  would  be  towards  type  11  error 
since  some  affected  individuals  would  be  misclassified  as  unaffected.  It  would 
be  expected  that  this  should  decrease  significance  as  a  result.  The  fact  that 
significance  increases  is  therefore  interesting. 
No  other  studies  specifically  examining  linkage  or  association  of  the  SERPINA  I 
locus  to  aneurysmal  disease  in  families  have  been  published.  Two  recently 
published  genome-wide  scans  of  FIA  patients  both  report  linkage  on 
chromosome  l4q.  Onda  et  al  (Onda  et  al,  2001)  showed  linkage  to  marker 
D14s74,20  cM  centromeric  of  the  SERPINAI  locus  in  Japanese  affected  sib 
pairs.  Olson  et  al  (Olson  et  al,  2002)  demonstrated  linkage  in  Finnish  affected 
sib  pairs  at  DI  4s  1426,12  cM  telomeric  of  SERPINA  1.  Prevalence  of  deficiency 
phenotypes  has  been  reported  to  be  increased  in  series  of  IA  patients  (Schievink 
et  al,  1996).  However,  a  causative  role  has  not  been  confirmed. 
Since  SERPINAI  expresses  protease  inhibitor  (PI),  the  most  important  inhibitor 
of  elastase,  the  prevailing  hypothesis  is  that  a  reduction  in  PI  may  result  in  an 
offset  of  the  balance  governing  vessel  wall  turnover.  Damaged  or  absent  elastic 
skeleton  is  a  common  feature  observed  by  histological  studies  of  experimental 
192 aneurysms  (Yamazoe  et  al,  1990;  Kondo  et  al,  1997).  Generalised  elastic  fibre 
abnormalities  have  been  described  in  skin  biopsies  from  IA  patients,  raising  the 
possibility  that  not  only  increased  degradative  proteins  but  increased 
suscepti  ility  to  their  action  may  exist  in  some  IA  patients  (Grond-Ginsbach  et 
al,  2002).  However,  the  possibility  also  exists  that  increased  levels  of 
SERPINAI  may  result  in  FIA  formation.  It  has  been  shown  that  elastase  also 
fulfils  a  protective  role,  cleaving  other  proteases  such  as  plasmin  (Moir  et  al, 
2002).  If  elastase  is  inhibited,  the  net  result  will  be  increased  degradation  of 
glycoprotein  elements  of  the  extracellular  matrix  (ECM)  by  plasmin.  This  in 
turn  leaves  the  fibrillar  components  of  the  ECM  more  vulnerable  to  matrix 
metalloproteinases  (MMPs)  (DeClerck  &  Laug,  1996).  Plasmin  also  activates 
various  members  of  the  MMP  family  and  is  expressed  at  higher  levels  in 
aneurysmal  tissue  compared  with  normal  cerebral  arteries,  although  whether  this 
is  cause  or  effect  is  not  clear  (Bruno  et  al,  1998). 
This  study  serves  to  highlight  some  of  the  obstacles  which  have  seen  genetic 
studies  of  FIA  published  so  rarely.  The  inability  to  detennine  the  affection  status 
of  anyone  not  known  to  be  affected  is  clearly  a  major  difficulty.  Linkage 
analyses  solely  using  affected  individuals  are  one  way  to  minimise 
misclassification.  Such  strategies  have  been  used  recently  in  the  genome-wide 
scans  mentioned  above  (Onda  et  al,  2001;  Olson  et  al,  2002).  However,  linkage 
analyses  are  inherently  less  powerful  than  association  strategies  (Risch  & 
Merikangas,  1996)  and,  of  course,  rely  on  the  availability  of  affected  individuals 
willing  to  participate.  Herein  lies  another  difficulty  in  a  disorder  which  affects 
only  1%  to  4%  of  the  population  (Rinkel  et  al,  1998)  and  may  carry  50% 
193 mortality  and  30%  morbidity  from  SAH  (Schievink,  1997).  This  combined  with 
the  difficulty  in  identifying  affected  patients  by  screening  (van  Gijn  &  Rinkel, 
2001)  means  recruiting  affected  individuals  is  not  trivial.  This  is  reflected  in  the 
relatively  small  number  of  individuals  included  in  the  recent  GWS  studies. 
Association  studies  are  more  powerful  but  often  rely  on  the  presence  of 
unaffected  controls.  The  case-control  paradigm  largely  avoids  the  problem  of 
misclassification.  Families  with  a  risk  for  a  disorder  with  consequences  as 
catastrophic  as  SAH  will  be  aware  of  this.  Thus,  controls  can  be  picked  with 
some  confidence.  However,  the  problems  of  admixture  and  population  structure 
in  case-control  studies  have  resulted  in  their  criticism  (Tabor  et  al,  2002). 
Methods  such  as  TDT  (Spielman  &  Ewens,  1996)  have  been  developed  to  negate 
these  problems  by  using  relatives  to  derive  control  genotypes.  However,  a 
reliance  on  the  availability  of  parental  data  is  a  drawback  in  a  late  onset  disorder. 
This  has  been  partially  addressed  by  S-TDT  (Spielman  &  Ewens,  1998)  but  one 
parent  is  still  required  and  both  TDT  tests  can  only  use  nuclear  family  data.  This 
presumes  that  suitable  family  structures  can  be  recruited  and,  further,  that  parents 
are  heterozygous  and  so  informative.  This  was  not  the  case  with  the  present 
study  in  which  TDT  or  S-TDT  trios  were  unusual.  FBAT  and  the  general  class 
of  family-based  association  tests  allow  the  use  of  complex  pedigrees.  However, 
they  again  also  use  data  from  unaffected  individuals.  It  is,  then,  a  problem  of 
circular  logic:  identifying  patients  is  difficult  and  to  recruit  and  correctly 
phenotype  sufficient  for  robust  genetic  studies  requires  an  effective  screening 
protocol;  but  to  develop  screening  we  must  have  a  better  understanding  of 
aetiologY,  which  requires  genetic  studies.  Prospective  recruitment  may  soll,,,,  e 
194 some  difficulties,  but  requires  long-term  follow-up  of  participants  to  establish 
affection  status. 
This  pilot  study  has  provided  preliminary  evidence  that  association  and  linkage 
of  IA  status  and  a  marker  proximal  to  SERPINAI  may  exist  in  UK  families. 
Study  of  this  locus  in  a  much  larger  resource  is  necessary  to  determine  if 
SERPfNAl  is  involved  in  FIA  aetiology.  However,  as  this  pilot  study  has  also 
demonstrated,  such  a  large  resource  will  require  a  collaborative,  multi-centre 
recruitment  program  due  to  the  paucity  of  suitable  families  at  the  single  centre 
level  and  the  resulting  lack  of  power.  There  is  also  potential  for  classical  linkage 
studies  in  extended  pedigrees  having  simple  modes  of  inheritance  of  IA  and/or 
SAH.  However,  the  high  mortality  makes  it  unlikely  that  such  families  will  be 
easily  obtained.  Recruitment  for  this  pilot  study  is,  at  present,  complete. 
Considerable  funding  would  be  required  to  expand  recruitment  to  other  centres, 
and  to  allow  a  realistic  chance  of  achieving  sufficient  power  given  that  multiple 
families  must  be  approached  to  find  one  that  is  suitable. 
195 CHAPTER  6 
GENERAL  DISCUSSION 
196 In  1990  the  World  Health  Organisation  (WHO)  stated  that  coronary  heart  disease 
(CHD)  and  cerebrovascular  disease  would  rank  first  and  fourth,  respectively,  as 
causes  of  global  disease  by  the  year  2020  (Murray  &  Lopez,  1990).  Despite 
significant  technological  advances  in  the  intervening  14  years,  complex  disease 
genetics  still  represent  a  considerable  challenge. 
Essential  hypertension  and  familial  intracranial  aneurysms  are  complex  disorders 
sharing  common  features  such  as  genetic  heterogeneity,  gene-gene  and  gene- 
envirom-nent  interactions,  small  individual  gene  effects,  pleiotropy  and  low 
penetrance.  These  features  reduce  the  statistical  power  of  genetic  studies  of  all 
complex  disorders  (Glazier  et  al,  2002).  Hypertension  and  intracranial 
aneurysms  also  differ  in  fundamental  respects  including  the  quantitative  nature  of 
blood  pressure  versus  the  dichotomous  IA  trait;  the  relative  ease  of  phenotyping 
for  hypertension  versus  the  difficulties  of  identifying  occult,  dynamic  aneurysmal 
lesions;  and  the  prevalence  in  the  general  population.  Genetic  study  of 
intracranial  aneurysms  is  at  least  ten  years  behind  that  of  essential  hypertension 
and  is  made  more  difficult  by  the  lack  of  confirmed  Mendelian  disorders,  animal 
models  and  measurable  phenotypes. 
6.1:  ESSENTIAL  HYPERTENSION: 
Essential  hypertension  is  a  classic  example  of  a  complex  oligogenic  or  polygenic 
disorder,  with  an  estimated  30%  to  60%  of  inter-  individual  variation  due  to 
genetic  factors  (Ward.  1990).  There  is  wide  scope  for  interaction  of  multiple 
physiological  systems  and  environmental  factors  (Soubrier,  1998).  In  the  realm 
197 of  genetics,  greatest  success  has  been  had  in  the  dissection  of  Mendelian  traits 
with  the  application  of  classical  linkage  approaches  (Lifton  et  al,  2001). 
However,  the  application  of  these  strategies  in  essential  hypertension  has  met 
with  far  less  success,  and  has  necessitated  the  evolution  and  adoption  of  other 
complementary  approaches  (Lander  &  Schork,  1994). 
We  examined  the  distal  region  of  human  chromosome  5q  by  a  combination  of 
complementary  strategies.  The  selection  of  this  specific  chromosomal  segment 
was  based  on  the  presence  of  good  cardiovascular  candidate  genes  and  genetic 
evidence  including  previous  work  in  humans  (Krushkal  et  al,  1998;  Krushkal  et 
al,  1999),  rat  models  (Jacob  et  al,  1991)  and  mice  (Wright  et  al,  1999). 
Beginning  with  a  linkage  study,  we  detected  a7  cM  blood  pressure/  hypertension 
QTL  in  a  Polish  hypertensive  family  resource  (Tomaszewski  et  al,  2002),  and 
confirmed  the  blood  pressure  linkage  in  a  normotensive  Scottish  population 
sample.  The  use  of  independent  study  groups  to  confirm  linkage  has  been  used 
before  (Zhu  et  al,  2001),  but  relatively  rarely  in  hypertension  linkage  studies. 
Such  independent  confirmation  goes  some  way  toward  negating  the  concerns 
regarding  significance  of  linkage.  The  focus  on  a  small  chromosomal  region  also 
reduces  marker  number  and  type  I  error  (Lander  &  Kruglyak,  1995).  The  use  of 
both  dichotomous  trait  and  quantitative  trait  analyses  again  is  not  unique  (Hunt  et 
al,  2002),  but  is  not  often  employed.  However,  such  dual  analysis  is  believed  to 
be  more  informative  (Williams  et  al,  1999). 
Evidence  of  linkage  in  the  5q3l.  l-q33  region  was  followed  by  candidate  gene 
studies.  ADRB2  was  selected,  again  based  on  the  existence  of  previous  evidence 
198 (Bray  et  al,  2000;  Bengtsson  et  al,  2001),  the  plausible  physiological  role  of  the 
P2-adrenergic  receptor  in  hypertension  (Bray  &  Boerwinkle,  2000)  and  its 
positional  candidacy  within  our  linkage  region.  This  selection  policy  was  driven 
by  concerns  that  have  been  voiced  regarding  candidate  gene  selection  and, 
specifically,  the  lack  of  reproducibility  in  candidate  gene  studies  (Tabor  et  al, 
2002). 
Selection  of  ADRB2  polymorphisms  for  study  was  based  on  desire  to  test  loci 
known  to  affect  receptor  function.  We  aimed  to  directly  assess  the  role  of  these 
in  hypertension  as  has  been  recommended  (Risch,  2000).  The  consideration  of 
haplotypes  therefore  allowed  us  to  examine  the  interaction  of  these  functional 
effects  and  provided  a  more  meaningful  analysis  (Sharma  &  Jeunemaitre,  2000). 
Further  to  this,  we  employed  family-based  approaches  to  test  for  association  of 
gene  and  phenotype  (Tomaszewski  et  al,  2002).  This  allowed  us  to  side-step 
some  of  the  pitfalls  which  are  believed  to  affect  the  more  popular,  and 
genotypically  efficient,  case-control  paradigm  (Spielman  &  Ewens,  1996).  By 
also  recruiting  carefully  selected  families  with  a  confirmed  history  of  essential 
hypertension,  we  maximised  our  power  to  detect  association  (Whittaker  & 
Lewis,  1998).  Exclusion  of  the  ADRB2  locus  in  our  Silesian  population  does 
not,  of  course,  imply  any  exclusion  in  black  or  Asian  populations.  However, 
taken  in  context  with  other  studies  in  white  Europeans  (Jia  et  al,  2000;  Bengtsson 
et  al,  2001;  Herrmann  et  al,  2002),  it  does  demonstrate  that  this  locus  does  not 
have  a  detectable  effect  on  hypertension  risk  in  such  populations  (Tomaszewski 
et  al,  2002). 
199 Our  subsequent  selection  and  analysis  of  FGF  I  was  based  upon  the  same  criteria 
of  physiological  and  positional  candidacy  as  ADRB2.  Owing  to  a  lack  of  coding 
region  variants,  selection  of  polymorphic  loci  for  genotyping  was  necessarily  less 
directed.  However,  in  the  absence  of  coding  polymorphisms,  those  in  the 
untranslated  regions  have  been  suggested  to  assume  precedence  (Tabor  et  al, 
2002).  Our  demonstration  of  association  of  a  polymorphism  in  the  3'  UTR  of 
FGH  represents  the  first  known  data  suggesting  that  this  locus  might  have 
relevance  in  human  hypertension.  Further  work  will  concentrate  on  mapping  the 
association  more  finely  to  localise  the  functional  variant.  In  the  absence  of 
coding  polymorphisms,  3'  UTR  and  promoter  regions  are  obvious  targets. 
Intronic  polymorphisms  may  also  be  relevant  given  their  potential  for  affecting 
splicing  and  RNA  stability  (Cartegni  et  al,  2002).  Intronic  polymorphisms  are 
known  within  FGF  I  and  these  must  also  remain  under  consideration. 
Genetic  studies  alone  will  not  yield  a  definitive  answer  on  the  importance  of 
FGF  I  or  any  other  gene  in  essential  hypertension.  For  example,  the  possibility 
exists  that  several  associated  polymorphic  loci  may  be  statistically  equivalent. 
Examples  of  this  already  exist  in  a  study  of  Crohn's  disease  (Rioux  et  al,  2001). 
Dense  mapping  with  SNPs  across  a  region  of  5q3l  resulted  in  strong  association 
of  a  250  kb  haplotype  with  Crohn's  disease.  However,  eleven  of  301 
polymorphic  loci  were  unique  to  the  risk  haplotype  and  their  relative  importance 
could  not  be  dissected  by  genetic  methods.  Recently,  working  criteria  have  been 
proposed  for  gene  discovery  in  complex  traits,  taking  into  account  the  need  for 
functional  studies  (Glazier  et  al,  2002).  The  need  for  such  rigour  has  been 
demonstrated  by  studies  such  as  that  implicating  phosphodiesterase  4D  (PDE4D) 
200 in  ischaemic  stroke  (Gretarsdottir  et  al,  2003).  Detailed  genetic  and  gene 
expression  studies  have  suggested  PDE4D  as  a  putative  candidate.  However, 
with  no  association  to  either  of  two  coding  polymorphisms  found,  in  vitro 
functional  testing  of  regulatory  regions  has  yet  to  be  done  to  support  the 
association  data.  This  is  essential  if  the  role  of  PDE4D  is  to  be  confirmed 
(Dominiczak  &  McBride,  2003).  Similarly,  successful  haplotype  tagging  of  the 
FGH  gene  would  need  to  be  followed  by  expression  and,  most  importantly, 
functional  studies  to  confirm  its  role.  The  lack  of  coding  polymorphisms,  which 
we  have  already  demonstrated,  suggests  that  we  too  would  need  to  examine 
regulatory  regions. 
Several  pathways  could  mediate  a  contribution  by  FGH  to  development  of 
hypertension.  These  could  involve  the  endothelium  and  nitric  oxide,  oxidative 
stress,  the  sympathetic  nervous  system  or  the  hypothalamic  -pituitary  adrenal 
axis,  based  on  observations  in  animal  models.  Thus,  there  are  many  potential 
gene-gene  interactions.  There  is  an  increasing  acknowledgement  that 
interactions  between  genes  may  need  to  be  incorporated  into  analysis  before 
complex  disease  genes  can  be  detected  (Cordell,  2002).  Statistical  methods  are 
under  development  to  model  QTL  interactions  in  genome-wide  linkage  (Cordell 
et  al.  2000;  Cordell,  2002)  and  linkage  disequilibrium  analysis  (Ott  &  Hoh, 
2001).  Such  approaches  have  been  explored,  for  example,  in  type  11  diabetes 
(Cox  et  al,  1999)  and  asthma  (Zandi  et  al,  2001).  At  the  level  of  candidate 
genes,  analysis  of  interactions  has  suggested  that  gene-gene  synergy  is 
detectable.  Staessen  et  al  (Staessen  et  al,  2001)  studied  hypertension  gene-gene 
interactions  by  genotyping  polymorphisms  in  the  a-adducin  (ADDL 
201 Gly460Trp),  angiotensin  I  converting  enzyme  (ACE,  I/D)  and  aldosterone 
synthase  (AS,  -344C/T)  genes.  Prospective  analysis  of  678  initially 
normotensive  Caucasian  individuals,  who  were  followed  up  for  a  median  9.1 
years,  showed  that  the  ACE/DD  genotype  was  associated  with  31%  increased 
incidence  of  hypertension.  Incidence  increased  by  59%  if  in  combination  with 
the  ADDl/Trp  allele,  and  122%  in  AS/CC  subjects.  Among  subjects  having 
ADD/Trp,  AS/CC  and  ACE/DD  there  was  252%  higher  incidence  of 
hypertension.  AS/CC  genotype  was  associated  with  decreased  aldosterone 
secretion  in  the  same  population.  It  was  suggested  that  this  could  result  in  over- 
compensation,  by  the  renin-angiotensin  system,  in  patients  already  more  prone  to 
sodium  retention  due  to  ACE  and  ADDI  variants  (Staessen  et  al,  2001).  The 
synergistic  effect  between  the  ACE/DD  genotype  and  ADD/Trp  allele  had  been 
shown  previously  (Barlassina  et  al,  2000).  Hypertensive  individuals  having  both 
DD  and  Trp  were  most  responsive  to  sodium  loading  and  both  alleles  were 
associated  with  reduced  plasma  renin  activity. 
Interaction  of  the  M235T  locus  in  angiotensinogen  (AGT)  and  I/D  in  ACE  has 
been  examined  in  a  Caucasian  case-control  study  (Vasku  et  al,  1998).  Of  interest 
is  the  fact  that  neither  AGT  nor  ACE,  alone,  was  associated  with  hypertension. 
However,  in  202  normotensives  compared  with  163  hypertensives,  consideration 
of  double  homozygotes  showed  an  increased  frequency  of  DD/MM  subjects  in 
the  hypertensive  group  (Vasku  et  al,  1998).  The  implication  of  the  M235  allele 
is  contrary  to  meta-analyses  of  AGT  (Staessen  et  al,  1999).  This  suggests  that 
data  from  gene-gene  interaction  studies  may  be  as  difficult  to  interpret  as  single 
gene  candidate  studies.  However,  many  lessons  have  already  been  learnt  with 
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now  appreciated  although  a  recent  review  suggests  that  there  are,  in  fact,  few 
clear  examples  where  population  structure  has  compromised  case-control  studies; 
lack  of  power  is  perhaps  a  far  greater  problem  (Cardon  &  Palmer,  2003).  Power 
will  be  as  important  an  issue  with  gene-gene  interaction  studies  as  single  gene 
studies. 
Available  strategies  in  hypertension  research  have,  to  date,  failed  to  consistently 
identify  susceptibility  genes  for  hypertension.  Candidate  gene  studies  have  been 
confusing,  whilst  linkage  studies  have  not  lived  up  to  expectations.  In  the 
context  of  the  popular  genome-wide  linkage  paradigm,  the  recent  BRIGHT 
Study  genome-wide  scan  represents  the  cutting-edge  of  study  design  (Caulfield 
et  al,  2003).  Despite  this,  it  has  not  eased  the  concerns  of  many  that  GWS 
studies  have  failed  to  provide  a  consensus  on  hypertension  QTL  (Harrap,  2003). 
However,  the  recent  description  of  haplotype  blocks  and  the  potential  for  linkage 
disequilibrium  mapping  of  complex  disease  genes  is  now  offering  new  hope  for 
gene  mapping  in  complex  disorders  such  as  essential  hypertension  (Kruglyak, 
1999).  Already,  some  mapping  success  using  LD  approaches  has  been  reported, 
for  example,  with  Crohn's  disease  (Rioux  et  al,  2001),  asthma  (Allen  et  al,  2003) 
and  ischaernic  stroke  (Gretarsdottir  et  al,  2003).  The  approach  has  yet  to  be 
extended  to  a  genome-wide  study,  and  already  debate  rages  as  to  the  number  and 
nature  of  SNPs  to  use  (Daly  et  al,  2001;  Maniatis  et  al,  2002;  Dawson  et  al, 
2002).  However,  characterisation  of  LD  across  the  genome  is  underway  and  may 
provide  some  answers  (Gibbs  et  al,  2003).  In  addition,  there  is  unprecedented 
availability  of  data  following  immense  advances  in  sequencing,  genotyping 
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the  human  (Lander  et  al,  2001),  mouse  (Waterston  et  al,  2002)  and  ongoing  rat 
genome  sequences  (http:  //www.  hgsc.  bcm.  tmc.  edu  /projects/rat/)  is  an  invaluable 
asset.  In  combination,  novel  strategies,  wealth  of  data  and  application  of 
technology  provide  the  best  opportunity  for  future  dissection  of  the  genetic  basis 
of  essential  hypertension. 
6.2:  FAMILIAL  INTRACRANIAL  ANEURYSM: 
The  work  on  candidate  genes  of  familial  intracranial  aneurysms  considers  a 
disorder  which  has  yet  to  see  the  sort  of  detailed  investigation  directed  at 
hypertension.  The  aetiology  of  FIA  formation,  like  hypertension,  is  complex, 
most  likely  involving  genetic  heterogeneity  and  certainly  affected  by 
enviromnental  factors  (Zhang  et  al,  2003).  Therefore,  the  study  of  genetics  of 
familial  intracranial  aneurysms  is  similarly  challenging.  However,  our  work  here 
highlights  a  specific  set  of  obstacles  for  this  disorder.  Primary  among  these  is 
the  difficulty  experienced  in  trying  to  recruit  sufficient  numbers  for  study  due  to 
high  mortality  and  morbidity.  This  is  reflected  in  recent  genome-wide  scans  of 
FIA  (Onda  et  al,  2001;  Olson  et  al,  2002)  which  are  small  in  comparison  with 
hypertension  scans.  To  compound  this  problem,  in  the  absence  of  biological 
markers  and  intermediate  phenotypes,  analysis  can  only  consider  a  dichotomous 
affection  status.  The  expected  benefit  of  quantitative  trait  analyses  is  not  an 
option  (Duggirala  et  al,  1997).  Finally,  the  occult  nature  of  the  lesions  means 
that  classification  relies  on  complex  screening,  the  efficiency  of  which  is  a  matter 
of  debate  (Kirkpatrick  &  McConnell,  1999).  In  many  instances,  screening  has 
204 not  been  performed  as  there  is  an  associated  risk  and  apparently  healthy 
individuals  are  understandably  reticent. 
Choice  of  the  FIA  candidate  genes  studied  relied  solely  on  plausible  physiology, 
particularly  derived  from  Mendelian  disorders  (Schievink,  1997).  In  the  absence 
of  genetic  animal  models  (Dobrin,  1999)  and,  until  recently,  human  genome- 
wide  studies,  comparative  and  positional  mapping  data  were  unavailable.  With 
the  small  size  of  this  study,  mapping  of  large  numbers  of  polymorphisms  across 
the  genes  would  have  increased  chances  of  false  positives.  In  light  of  this, 
genotyping  of  a  single  microsatellite  was  a  sensible  option,  and  one  that  has  been 
used  in  many  studies  before  (Caulfield  et  al,  1994).  Microsatellite  markers  may 
also  be  more  informative  than  single  SNPs  owing  to  their  multiallelic  nature 
(Xiong  &  Jin,  1999). 
The  preliminary  results,  suggesting  association  of  a  marker  near  the  SERPINAl 
locus  and  intracranial  aneurysm,  suggest  the  value  of  further  analysis  of  this 
locus.  The  most  pressing  requirement  is  for  increased  numbers  of  families  to 
allow  a  more  detailed  investigation.  Non-synonymous  polymorphisms  resulting 
in  deficiency  phenotypes  are  known  (Crystal,  1989)  and  these  would  provide  a 
starting  point  for  haplotype  analyses,  were  sufficient  individuals  available.  It  is 
also  possible  that  the  microsatellite  tested  may  be  functional.  Located  in  the 
upstream  region,  it  may  affect  promoter  elements  of  the  SERPINAl  gene. 
Others  have  demonstrated  such  functional  effects  of  microsatellites.  For 
example,  a  microsatellite  in  the  promoter  region  of  MMP9  was  shown  to  be 
associated  with  intracranial  aneurysm.  Reporter  gene  assays  also  showed  that  it 
205 affected  expression,  lying  between  two  transcription  factor  binding  sites  and 
perhaps  modifying  their  interaction  (Peters  et  al,  1999). 
SERPINAI  is  of  interest  in  terms  of  the  potential  interactions  with  other 
components  of  extracellular  matrix  remodelling.  As  has  been  discussed,  recent 
genome-wide  scans  have  been  followed  by  candidate  gene  studies  which 
implicated  elastin  and  collagen  type  I  a2  (Onda  et  al,  200  1;  Yoneyama  et  al, 
2004).  Some  in  vitro  functional  studies  have  been  performed  in  the  latter  case. 
However,  further  work  is  required  for  both  genes,  including  detailed  functional 
studies  and  confirmation  in  other  populations,  if  presently  accepted  standards  are 
to  be  adhered  to  (Dominiczak  &  McBride,  2003).  Regardless,  SERPINAI  fits 
neatly  into  the  pathology  suggested  by  these  genes.  With  its  inhibition  of 
elastase  (Zhang  et  al,  2003)  there  is  potential  for  interaction  with  variants  of 
elastin.  Elastase  also  protects  some  components  of  the  extracellular  matrix  by 
degrading  MMPs  (Moir  et  al,  2002).  Thus,  plausible  interactions  may  be 
hypothesised  with  unstable  collagen  variants  or  high  activity  MMPs,  both  of 
which  have  been  implicated  (Peters  et  al,  1999;  Yoneyama  et  al,  2004)  as 
mentioned  above. 
Studies  of  inheritance  pattern  of  FIA  have  shown  that  some  families  exhibit  an 
autosomal  dominant  mode.  Others  are  recessive  whilst  still  others  are  more 
complex  (Bromberg  et  al,  1995).  One  conclusion  from  this  may  be  that  there  are 
Mendelian  IA  disorders  yet  to  be  discovered  which  might  shed  light  on  the  more 
complex  fonns  of  IA  formation.  These  should  be  accessible  to  linkage  studies  in 
large  pedigrees  if  enough  survivors  can  be  found,  and  families  phenotyped 
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to  potential  aetiology  of  more  complex  forms.  It  would  also  offer  further 
confirmation  of  the  role  of  genes,  as  has  been  the  case  with  the  report  of 
NOTCH3  mutations  in  cerebral  autosomal  dominant  arteriopathy  with 
subcortical  infarcts  and  leukoencephalopathy  (CADASIL)  in  ischaemic  stroke 
(Joutel  et  al,  1997;  Dominiczak  &  McBride,  2003).  There  may  also  be  IA 
subtypes  which  are  highly  complex  and  offer  as  great  a  challenge  to  researchers 
as  essential  hypertension,  or  some  that  are  oligogenic  and  tractable  to  genome- 
wide  linkage  study.  However,  no  animal  models  are  available  to  give  a 
perspective  on  this.  The  recent  genome-wide  scans  may  be  the  first  of  many  as 
this  approach  is  tested  empirically,  although  the  lack  of  consensus  between  them 
is  a  familiar  story  (Harrap,  2003).  Alternatively,  LD  mapping  methods,  as  used 
recently  in  ischaemic  stroke  (Gretarsdottir  et  al,  2003),  may  prove  of  worth  in 
aneurysmal  haernorrhagic  stroke.  At  a  genome-wide  level,  this  will  require  a 
major  undertaking  to  recruit  enough  individuals  to  provide  power.  Alternatively, 
QTL  suggested  by  GWS  linkage  studies  could  provide  more  focused  targets  for 
LD  mapping.  However,  a  far  clearer  picture  of  pathophysiology,  subtypes  of  IA 
and  potential  mechanisms  is  needed  before  full  advantage  can  be  taken  of 
developments  in  genetic  strategies. 
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Suppliers  of  chemicals  and  reagents  used: 
Reagent  Supplier 
Agarose-  1000  Life  Technologies 
Ammonium  persulphate  BDH 
BigDye  Terminator  Sequencing  kit  Applied  Biosystems 
Bromophenol  blue  Sigma 
BsrDI  restriction  enzyme  New  England  Biolabs 
Chloroform  Fisher  Scientific 
Decon  75  Decon  Laboratories  Ltd. 
Dextran-EDTA  loading  buffer  Applied  Biosystems 
dNTPs/deoxynucleoside  triphosphates  Promega 
EDTA  Fisher  Scientific 
Ethanol  Sigma 
Ethidium  bromide  Sigma 
Formamide  Amresco 
GENESCAN-500  Rox  Applied  Biosystems 
GENESCAN-500  Tamra  Applied  Biosystems 
Hi-Di  formamide  Applied  Biosystems 
HotStarTaq  DNA  polymerase  Qiagen 
Ital  restriction  enzyme  Roche 
Long  Ranger  5%  acrylamide  solution  FMC 
MasturePure  DNA  Purification  kt  Epicentre  Technologies 
209 MgC12  Fisher  Scientific 
MnlI  restriction  enzyme  New  England  Biolabs 
Nucleofast-96  PCR  purification  plates  Macherey-Nagal 
PCR  buffer  (I  OX)  Qiagen 
Phenol  Fisher  Scientific 
Picogreen  dsDNA  Quantitation  kit  Molecular  Probes 
Proteinase  K  Sigma 
SDS  (sodium  dodecyl  suphate)  BioRad 
Sodium  Acetate  Sigma 
Sodium  chloride  Fisher  Scientific 
Sucrose  Fisher  Scientific 
TBE  (1  OX)  National  Diagnostics 
TEMED  Amresco 
Tris  Fisher  Scientific 
Triton  X-  100  Sigma 
Ultra  Pure  agarose  Life  Technologies 
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List  of  formulations  for  preparation  of  solutions. 
ABI  377  sample  loading  cocktail  for  genotyping  (for  96  samples): 
106  ýtl  formamide  combined  with  40  ýfl  ROX  or  TAMRA  standard,  and  40  gl  of 
Dextran-EDTA  buffer  (Applied  Biosystems). 
ABI  377  genotyping  sample: 
2  ýd  of  ABI  377  loading  cocktail  and  1.5  ýtl  of  pooled  PCR  products. 
ABI  377  sequencing  loading  cocktail  (96  samples): 
435  ýtl  of  formamide  combined  with  115  ýfl  of  Dextran-EDTA  buffer. 
ABI  377  sequencing  sample: 
Precipitated  sequencing  products  plus  5  ýtl  of  ABI  377  sequencing  loading 
cocktail. 
ABI  3730  loading  cocktail  for  genotyping  (96  samples): 
1000  ýfl  of  Hi-Di  formamide  and  1.2  ýd  of  ROX  or  TAMRA  standard. 
ABI  3730  genotyping  sample: 
10  ýtl  of  3  73  0  loading  cocktail  and  2  ýd  pooled  PCR  products. 
211 ABI  3730  sequencing  sample: 
Precipitated  sequencing  products  resuspended  in  15  ýd  Hi-Di  formamide. 
10%  ammonium  persulphate  (10  ml): 
Ig  APS  in  10  ml  sterile  deionised  water.  Store  at  4'C. 
BigDye  Terminator  sequencing  mastermixes: 
For  the  ABI  377  (1:  4  reaction,  20  ILI): 
2  ýtl  of  Ready  Reaction  Mix  (Applied  Biosystems),  3  ýtl  5X  sequencing  buffer 
(Applied  Biosystems),  3.2  [tl  sequencing  primer  (I  [M),  2  ýtl  template  DNA,  9.8 
ýtl  autoclaved  deionised  water. 
For  the  ABI  3730  (1:  16  reaction,  20  Ftl): 
0.5  ýfl  of  Ready  Reaction  Mix  (Applied  Biosystems),  3.75  ýtl  5X  sequencing 
buffer  (Applied  Biosystems),  3.2  ýd  sequencing  primer  (I  ýM),  2  ýtl  template 
DNA,  10.55  ýtl  autoclaved  deionised  water. 
6X  DNA  loading  buffer  (50  ml): 
25  ml  glycerol,  25  ml  deionised  water,  0.05  g  xylene  cyanol  FF,  0.05  g 
bromophenol  blue. 
dNTPs  (40  ml,  1  mM): 
400  ýtl  each  of  dGTP,  dATP,  dCTP  and  dTTP  (provided  as  100  mM  stocks) 
added  to  38.4  ml  autoclaved  deionised  water. 
212 70%  ethanol  (100  ml): 
70  ml  of  analar  100%  ethanol  combined  with  30  ml  of  deionised  water. 
95%  ethanol  (100  ml): 
95  ml  of  analar  100%  ethanol  combined  with  5  ml  of  deionised  water. 
PCR  master  mix  for  Qiagen  HotStarTaq  (20  pl): 
2  [tl  Qiagen  IOX  PCR  buffer,  4  ýtl  dNTPs  (I  mM),  I  gl  primers  (20  gM),  5  gl 
genomic  DNA  template  (5  ng/ýtl),  7.96  ýd  autoclaved  deionised  water,  0.04  VI 
Qiagen  HotStarTaq  (5  U/ýtl). 
Primer  stocks: 
Diluted  to  100  ýM  with  appropriate  volume  of  autoclaved  deionised  water. 
PCR  primer  working  solutions  (20  pM,  100  pl): 
10  ýd  of  forward  and  10  ýtl  of  reverse  primer  stocks  with  80  ýtl  of  autoclaved 
deionised  water. 
10%  SDS  (500  ml): 
500  ml  20%  SDS  with  500  ml  autoclaved  deionised  water. 
Sequencing  primer  working  solutions  (1  pM,  200  Itl): 
2  ý11  of  primer  working  solution  and  198  [il  of  autoclaved  deionised  water. 
213 3M  sodium  acetate,  pH  6.0  (11): 
408.1  g  sodium  acetate  dissolved  in  II  of  sterile  deionised  water.  pH  adjusted 
with  glacial  acetic  acid. 
1%  sodium  chloride  (11): 
10  g  sodium  chloride  dissolved  in  11  of  autoclaved  deionised  water. 
1X  TBE  buffer  (11): 
100  ml  of  I  OX  TBE  combined  with  900  ml  deionised  water. 
IM  Tris,  pH  8.0  (11): 
121.1  g  Tris  base  dissolved  in  II  deionised  water.  pH  adjusted  with 
concentrated  hydrochloric  acid. 
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Primer  and  probe  sequences: 
1,  forward;  2,  reverse  primer. 
#  indicates  presence  of  a  5'  GTT  TCTT  tail  to  aid  microsatellite  genotyping. 
Primer  sequence  Fluor  T.  Mg  2+ 
Label  ('C)  (mM) 
Chr  5q  linkage 
D5s494 
I  -GCT  TTC  ACG  AAG  GTA  GAT  ATT  GCT  FAM  53.9  1.5 
2-#CCA  GGC  TAG  GCA  GAT  TAC  AGA  T  54.8  1.5 
D5s642 
I  -AGC  TCT  TTA  CTT  CTG  GAC  TTA  CAA  A  HEX  5  2.7  1.5 
2-#CTA  GAC  CAT  AGA  TAA  CCC  TGT  GAT  53.9  1.5 
D5s5OO 
1  -ACC  TAT  TCG  ACC  TAA  TGA  CTA  AAG  A  FAM  52.7  1.5 
24ATC  GGT  GAA  ATG  CAA  CTA  CTT  48.5  1.5 
D5sI480 
I  -TTG  GGA  AGA  ATA  GCT  TTC  CC  FAM  49.7  1.5 
2-#TTC  TAG  CTT  CCC  CCT  ATG  CT  51.7  1.5 
D5s636 
1  -AAG  GCA  TAT  GGG  AAA  TAT  CTG  T  HEX  49.2  1.5 
24CCA  CAC  CAT  TAT  GAC  ATT  TTC  T  49.2  1.5 
D5s820 
I  -ATT  GCA  TGG  CAA  CTC  TTC  TC  NED  49.7  1.5 
2-#GTT  CTT  CAG  GGA  AAC  AGA  ACC  52.4  1.5 
D5s2O93 
I  -TTG  CAG  TGA  GTC  AAG  TTC  G  FAM  48.9  1.5 
2-#CTC  GGC  ATC  ATA  TAG  AGG  C  51.0  1.5 
D5sl471 
I  -TAT  ACA  TGT  GAA  ATT  AGA  AAG  CAC  C  FAM  51.1  1.5 
2-#TGA  GCT  ATG  TTT  GTG  GCA  GA  49.7  1.5 
215 D5sl456 
I  -TAT  CGA  ATT  GTA  ACC  CCG  TT  HEX  47.6  1.5 
2-#TCT  GGA  AAA  CCC  TAA  TTC  TCC  50.4  1.5 
D5s462 
1-TTC  ATT  CAT  CCA  CTC  AAA  CA  NED  45.6  1.5 
2-#AGC  TAA  TAC  AGT  CTT  TCA  AGC  AG  51.7  1.5 
D5s2ll 
I  -ACT  TTG  AAA  ACC  ACT  GGC  CT  FAM  49.7  1.5 
2-#ATG  TAT  CTA  GCC  ATG  GTA  GC  49.7  1.5 
ADRB2SNP 
genotyping 
Argl6GIy 
1-CTT  CTT  GCT  GGC  ACG  CAA  T  51.0  1.5 
2-CCA  GTG  AAG  TGA  TGA  AGT  AGT  TGG  55.6  1.5 
Gln27GIu 
I  -GGC  CCA  TGA  CCA  GAT  CAG  CA  55.8  1.5 
2-GAA  TGA  GGC  TTC  CAG  GCG  TC  55.8  1.5 
Thr1641le 
I  -GGA  CTT  TTG  GCA  ACT  TCT  GG  51.7  1.5 
2-ACG  AAG  ACC  ATG  ATC  ACC  AG  51.7  1.5 
FGFI 
PCR  and  sequencing 
FGF1  exon  I 
I  -GGT  CCA  AAG  CTG  TGT  CCA  AT  51.7  1.5 
2-ACC  TTC  CTC  CCA  CCT  TGA  CT  53.8  1.5 
FGF1  exon  2 
I-CCG  TGA  AAT  GAA  TGA  GCA  GA  49.7  1.5 
2-CTG  GAA  ACC  TCA  AAC  CTT  GG  51.7  1.5 
FGF1  exon  3 
I-ACC  ATG  ACC  CCA  ATT  TTC  CT  49.7  1.5 
2-ATT  TTT  GGG  TCA  ACC  AGG  TG  49.7  1.5 
FGFI  YUTR 
I  -AAC  AGA  GGG  ACC  AAA  TTG  CTT  50.4  1.5 
2-CTC  AGC  CAG  TTT  CCC  TTT  CTT  52.4  1.5 
216 FGFI  SNP 
genotyping 
SNP  2  primers 
I  -GAT  CTC  CAA  TTG  CCT  CTT  GCA 
2-GAC  CCC  TTA  ACA  CAC  TTC  ATT  TAG  C 
SNP  2  probes 
I  -CCC  TCC  ATG  CAA  AA 
2-CCC  TCA  ATG  CAA  AAG 
SNP  3  primers 
I  -GAT  CTC  CAA  TTG  CCT  CTT  GCA 
2-CTC  AGT  AGA  GGG  AAA  TAG  TGT  GCA  GTT 
SNP  3  probes 
I  -CAC  TTA  GCT  GAC  CCC 
ACT  TAG  CCG  ACC  CC 
SNP  4  primers 
I  -GAA  GTG  GTT  TCC  TGA  TAA  CAA  GCA  A 
2-TCT  CTG  CAC  TCC  CAC  ACT  CAG  T 
SNP  4  probes 
I  -TTC  ATG  TGC  ATC  TGG 
2-CAT  GTG  GAT  CTG  GGG 
FIA  genes 
COL3A1  VNTR 
1  -CCA  TTC  TTA  CCA  GGA  GAC  CCC  TAA  AG 
2-9GGG  GGG  CAG  AGG  CTA  CAG  TGA  G 
FBN1  MTS-4 
I  -GAT  GTC  CCT  ATT  GCC  ATC  ACC  AC 
2-#CCT  GTG  CAG  GGT  AAG  ACA  AG 
PKID1  BPI 
I  -CAC  AGC  CAG  CTC  CGA  GGG 
2-#TCC  TCC  TGG  GGG  CTG  GCT  C 
SERPINAl  D14sll42 
I  -TTG  CAG  GGA  GTC  AGG  TGT  ATG 
2-#GCA  TCA  CAC  AGA  GAC  ACG  GAT 
52.4  1.5 
56.0  1.5 
VIC  37.3 
FAM  3  9.2 
52.4  1.5 
58.2  1.5 
VIC  44.6 
FAM  43.2 
54.4  1.5 
56.7  1.5 
VIC  39.2 
FAM  44.6 
TET  5  9.5  1.5 
62.2  1.5 
HEX  5  7.0  1.5 
53.8  1.5 
TET  57.1  1.5 
59.7  1.5 
FAM  54.3  1.5 
54.3  1.5 
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Examples  of  resolved  restriction  digest  products  for  ADRB2  SNP  genotyping. 
Argl6GIy 
131  bp 
108  bp 
Gln27GIu 
229  bp 
174  bp 
218 
Arg/Arg  Glv/Glv 
Gln/Gln  Glu/Gln Thr1641le 
320  bp 
206  bp 
114  bp 
Expected  band 
pattern  for  rare 
219 
Ile/Thr  Thr/  Thr  Ile/  Ile APPENDIX  5 
Fibroblast  growth  factor  I  sequence  and  positions  of  SNPs  1.2,3,  and  4  found. 
Intron  2  (black), 
Exon  3  (blue) 
3'  UTR  (red) 
Underlined  text  denotes  primer  annealing  sites. 
..... 
CCATGACCCCAATTTTCCTGAAAAGGAGACTGAGGCATGGAGAGC 
TTTAGTATTTTGCCCAATGTCACACAGCTAGTAAATGGGGACCCCCAT 
GTGAAACTACTCACTGATTGTCCTACTCTCTVTGGTTTTATCTTTTTA 
GCAGACACCAAATGAGGAATGTTTGTTCCTGGAAAGGCTGGAGGAGA 
ACCATTACAACACCTATATATCCAAGAAGCATGCAGAGAAGAATTGG 
TTTGTTGGCCTCAAGAAGAATGGGAGCTGCAAACGCGGTCCTCGGAC 
TCACTATGGCCAGAAAGCAATCTTGTTTCTCCCCCTGCCAGTCTCTTC 
TGATTAAAGAGATCTGTTCTGGGTGTTGACCACTCCAGAGAAGTTTCG 
AGGGGTCCTCACCTGGTTGACCCAAAAATGTTCCCTTGACCATTGGCT 
GCGCTAACCCCCAGCCCACAGAGCCTGAATTTGTAAGCAACTTGCTTC 
TAAATGCCCAGTTCACTTCTTTGCAGAGCCTTTTACCCCTGCACAGTT 
TAGAACAGAGGGACCAAATTGCTTCTAGGAGTCAACTGGCTGGCCAG 
TCTGGGTCTGGGTTTGGATCTCCAATTGCCTCTTGCAGGCTGAGTCCC 
'I'C§A'I'(j('AAAAGTGGGGCTAAATGAAGTGTGTTAAGGGGTCICj('TA,  /\ 
Ci'I-CiGGACA'I"I'AGTAAC'FGCACACTATTTCCCTCTAC-f'GAGTAAACCC'I' 
ATCTGTGATTCCCCCAAACATCTGGCATGGCTCCCTTTTGTCCTTCCTG 
220 TGCCCTGCAAATATTAGCAAAGAAGCTTCATGCCAGGTTAGGAAGGC 
AGCATTCCATGACCAGAAACAGGGACAAAGAAATCCCCCCTTCAGAA 
CAGAGGCATTTAAAATGGAAAAGAGAGATTGGATTTTGGTGGGTAAC 
TTAGAAGGATGGCATCTCCATGTAGAATAAATGAAGAAAGGGAGGCC 
CAGCCGCAGGAAGGCAGAATAAATCCTTGGGAGTCATTACCACGCCT 
TGACCTTCCCAAGGTTACTCAGCAGCAGAGAGCCCTGGGTGACTTCA 
GGTGGAGAGCACTAGAAGTGGTTTCCTGATAACAAGCAAGGATATCA 
GAGCTGGGAAATTCATGTGJATCTGGGGACTGAGTGTGGGAGTGCAG 
AGAAAGAAAGGGAAACTGGCTGAG 
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